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ABSTRACT 
 
A QUALITATIVE DESCRIPTIVE ANALYSIS OF THE EXPERIENCES OF BLACKS 
IN CANCER CLINICAL TRIALS 
Terease S. Waite 
 Connie M. Ulrich 
Participation in cancer clinical trials (CCTs) is an effective means of reducing cancer 
disparities among Black cancer patients because they provide an opportunity to receive 
high quality health care from leading healthcare providers and researchers.  Yet, Black 
cancer patients remain underrepresented in CCTs.  The purpose of this study was to 
understand the patient, family member, physician, and protocol factors that influence 
Black cancer patients to participate and to remain in CCTs and the day-to-day 
experiences of Black cancer patients as they navigate their way through the clinical trial 
process.  Albrecht’s model of treatment decision making was used as a theoretical guide. 
A multimethod approach was used and included a qualitative descriptive design with 
semi-structured face-to-face interviews with 21 Black cancer patients involved in CCTs 
and a descriptive statistical analysis of the sample’s sociodemographics and a quantitative 
measure of symptom burden (the Memorial Symptom Assessment Scale-Short Form).  
Participants reported mild levels of symptom burden based on the mean values of the 
assessment scale.  Elements of real-time data capture were also used to facilitate 
collection of four semi-structured cell phone participant interviews over a two month 
period, in order to understand patient-participants’ everyday experiences in CCTs.  The 
majority of participants self-identified as Black-African American (80%) and attended 
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college or had a college degree (55%). A majority had comorbid conditions (70%) and 
40% were diagnosed with Stage 4 cancer.  The findings suggest that patient, family 
member, physician, and protocol factors in Albrecht’s model are important in decision 
making related to cancer clinical trial participation and retention, but in varying degrees.  
Patient-participants identified getting a second opinion, helping themselves, and helping 
others as important factors to their decisions to seek treatment at the Cancer Center and to 
enroll in CCTs.  The support of family members was identified primarily in CCT 
retention, and the qualities of the cancer physician motivated participant enrollment and 
retention.  These qualities included trust, attentiveness, timely referrals, and willingness 
to provide detailed explanations of treatment options.  Protocol features, such as 
provision of targeted therapy, randomization, and additional diagnostic surveillance, 
attracted participants to enroll in such trials.  Finally, elements of real-time data capture 
highlighted patient-participants’ everyday qualitative experiences, that included 
interactions with their clinical care team, events surrounding their outpatient cancer 
clinical trial appointments, and information shared at their appointments; and, the 
symptom burden issues that arose as patient-participants progressed in their trials.  
Patient-participants provided vivid descriptions of their CCT treatment, expectations and 
events surrounding CCT participation, their symptom experience, personal thoughts and 
feelings of the effect of CCT participation on their daily lives, and their relationships with 
family members, the CCT Team, and others during CCT participation.      
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CHAPTER 1:  INTRODUCTION 
 
The Problem 
Introduction 
  In 2016, approximately 70,000 Blacks are expected to die from cancer 
(American Cancer Society, 2016).  While Blacks comprise 12% of the U.S. population, 
they have the highest incidence and mortality rates for more types of cancer than any 
other population in the U.S. (American Cancer Society, 2016).  This group also has the 
shortest cancer survival from most cancer types (American Cancer Society, 2016).  
Unfortunately, stark differences continue to exist between Whites and Blacks in cancer 
incidence, prevalence, mortality, burden, and survivorship (DeSantis et al., 2016). 
Researchers acknowledge that Blacks suffer cancer health disparities; however, they 
differ on how these cancer health disparities can be eliminated (Flowers et al., 2007; 
Halpern & Holden, 2012; Howerton et al., 2007; Kauh, Brawley, & Berger, 2007; 
Nurgalieva et al., 2013).  
Although cancer mortality rates for Blacks and Whites actually declined between 
2008 and 2012, Black men continue to have higher incidence rates and mortality rates 
than White men for all cancers sites (American Cancer Society, 2016; DeSantis et al., 
2016).  In fact, Black men have higher mortality rates for gastrointestinal cancers (i.e., 
colorectal, pancreas, gastric, and liver), oral cancers (i.e., oral cavity, larynx, and 
pharynx), prostate cancer, multiple myeloma, and lung cancer (American Cancer Society, 
2016; DeSantis et al. 2016).  During this same time frame, Black women had higher 
mortality rates than White women for gastrointestinal cancers (i.e., colorectal, gastric, 
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liver, and pancreas), gynecologic cancers (i.e., uterine corpus, and uterine cervix), 
multiple myeloma, breast, esophagus, and urinary/bladder (American Cancer Society, 
2016; DeSantis et al. 2016).   For the same years, Black women also had higher incidence 
rates for selected types of cancer:  Kaposi’s sarcoma, multiple myeloma, gastrointestinal 
(e.g., stomach, pancreas, liver, and colorectal), uterine cervix, esophagus, kidney, and 
breast (American Cancer Society, 2016; DeSantis et al., 2016).  This dismal picture of 
cancer in the Black population statistics calls for further research that addresses the 
continuing cancer burden borne by this population group and ways to mitigate this 
burden.    
Cancer Health Disparities in the Black Population 
The bases for the existence of cancer health disparities among Blacks are multi-
factorial and include commonly reported factors such as reduced access to healthcare, 
lower socioeconomic status (SES), lack of access to quality healthcare, differences in 
treatment modalities, distrust of the healthcare system, stigma associated with cancer and 
death, differences in individual treatment decision-making, and refusal of standard 
therapeutic treatment (Brawley, 2007; Fedewa et al. 2010; Flowers et al., 2007; Howerton 
et al., 2007; Rizzo et al., 2009; Ward et al. 2008).  However, recent research has 
articulated other factors which impact cancer disparities among Black cancer patients, 
such as delay in treatment and advanced cancer stage at presentation for treatment—both 
of which may make standard cancer treatment inadequate and favor the use of novel 
treatment available in CCTs to promote positive treatment outcomes (Halpern & Holden, 
2012; Nurgalieva et al., 2013).   
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The benefits of cancer clinical trial (CCT) participation are well-known.  Many 
CCTs significantly extend the overall survival of cancer patients and offer considerable 
clinical benefit (Attal et al. 2012; Brufsky, et al., 2012; O’Shaughnessy et al., 2011).  
CCT participation offers cutting edge advances in cancer prevention and therapy, 
improves therapeutic outcomes, promotes progress in the treatment of cancer, and 
predicts over-all and cancer-specific survival (Baquet, Commiskey, Mullins, & Mishra 
2006; Chow et al., 2013; Held, Wedel, & Wilhelmsen, 2003). Further, certain cancers 
(e.g., triple negative breast cancer which has a poor response rate to standard treatment) 
affect Blacks in disproportionately higher rates, such that therapeutic CCTs are the only 
option to promote positive therapeutic outcomes and improve survival (Carey et al., 
2006; Santana-Davila & Perez, 2010). More significantly, research indicates that 
participation in a CCT, in fact, does improve survival and positive outcomes for lung, 
breast, and colo-rectal cancer—three of the four cancers with the highest incidence and 
mortality rates among Black cancer patients (Chow et al., 2013; Howlader et al., 2012).  
Blacks’ participation in CCTs is exceptionally poor when compared to their cancer 
incidence, mortality, and burden.  In this way, lack of CCT participation can translate into 
survival disparities for Black cancer patients. 
Rates of Research Participation in Cancer Research  
 Of the approximately 3-5% of adults with cancer who participate in CCTs, 
Whites represent the majority of participants at 85.6% and Blacks account for less than 
9.2% (Murthy, Krumholz, Ellison, & Gross, 2004).  Under-representation of Blacks in 
CCTs continues, despite efforts by the federal government in 1993 and amended in 2001 
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to establish guidelines mandating greater numbers of under-represented minority 
populations in NIH supported clinical trial research (Brawley, 2004; Hayat et al.,2007; 
Howlader et al., 2012).  The 1993 Guidelines required inclusion of minorities (as well as 
women) in research supported by the National Institutes of Health (NIH) and mandated 
that the NIH must ensure (a) inclusion of minorities in all human research projects, (b) 
inclusion of minorities/subpopulations of minorities in all phase III clinical trials in order 
to accomplish valid analyses of intervention effect differences, (c) preclusion of cost as a 
reason to exclude minorities/subpopulations of minorities, and (d) establishment of 
outreach efforts to encourage recruitment of minorities/subpopulations of minorities in 
clinical research studies.  (59 Federal Register Sections 11146-11151, 1994; 42 U.S. 
Code section 289a-2; National Institutes of Health, 2001).   
Researchers continue to struggle to meet the NIH’s mandate.  In a recent review 
of 304 peer-reviewed articles concerning 227 phase three cancer treatment and 27 
prevention trials with more than 100 participants, Kwiatkowski et al. (2013) reported that 
diversity of participants in therapeutic CCTs has improved only slightly, since 
publication of the 1993 Guidelines.  However, increases in Asian and Hispanic 
participants were countered by decreases in Black participants.  For the years 2001-2010 
and 1990-2000, Black participation in treatment CCTs decreased to 6.1% from 10.5%, 
respectively (Kwiatkowski et al., 2013). In contrast, White participants continued to 
represent more than 80% of participants in cancer trials.    
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Recruitment Methods 
Researchers have not agreed on a method to achieve the goal of improving 
participation of Black cancer patients in CCTs.   Frequently utilized methods include 
instituting patient navigation, addressing organizational and provider-mediated barriers, 
and initiating community-based participatory research (Adams et al., 2014; Anwuri et al., 
2013; Blakeney et al., 2014; Ghebre et al., 2014, Holmes et al., 2012; Wujcik & Wolff, 
2010).  All of these CCT recruitment methods seek to engage Black cancer patients by 
forging linkages between the Black cancer patient and the healthcare institution.    
Changing the research infrastructure and organizational culture at the provider 
and institutional levels has been implemented by some cancer centers as a means of 
increasing Black CCT enrollment (Anwuri et al., 2013; Joseph, & Dohan, 2009b).  This 
approach addresses perceived or potential institutional barriers to CCT recruitment and 
participation, such as provider coordination of patients involved in research studies, 
institutional standards and accrual targets for minority recruitment, and efficient 
monitoring and assessment of minority CCT participation and retention (Anwuri et al., 
2013, Joseph, & Dohan, 2009b). Inherent in this approach is the necessity of 
administrative leadership and oncology physicians to commit to increasing Black accrual 
to CCTs, to set enrollment benchmarks, and to accept changes to established clinical 
practices (Anwuri et al., 2013).  However well-intended, a limitation of these approaches 
is their focus on increasing the quota of enrolled Blacks in CCTs, instead of providing 
Black cancer patients with the necessary resources and time to process the requisite 
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information to make informed decisions for themselves and for their families (Denicoff et 
al., 2013).   
Utilization of community-based participatory research (CBPR) as a 
methodological approach to address the informational needs of Black cancer patients 
involves the members of a Black community in the planning, development, 
implementation, and evaluation of CCT recruitment strategies and CCTs (Adams et al., 
2014; Blakeney et al., 2014; Seifer, Michaels, & Collins, 2010).  CBPR involves the 
formation of genuine partnerships between researchers and community members, as 
represented by shared decision-making on the type and dimensions of the research 
undertaken in the community, sharing of data produced from the research, and 
involvement of community members in the research process (Greiner et al, 2014).  
However, CBPR is most useful if Black cancer patients are represented among the key 
community leaders/informants and are integral members of the stakeholder community 
groups, the research planning committees, and the research team.      
Finally, patient navigation has been employed increasingly and successfully as a 
means of providing access and identifying barriers to cancer care and cancer screening 
for Blacks (Freund et al., 2014; Halbert et al., 2014; Jandorf et al., 2013; Sly et al., 2013).    
Recently, patient navigation has been employed to ascertain and to surmount the barriers 
to CCT accrual and continued enrollment among Black cancer patients (Holmes et al., 
2012; Wujcik & Wolff, 2010). Patient navigators are utilized as vital connections 
between the healthcare institution, the community, and the Black cancer patient.  They 
interact more directly with prospective and actual CCT participants by providing 
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information and access to CCTs, enrolling community members onto appropriate CCTs, 
and monitoring research participants as they proceed along the CCT trajectory (Fouad, et 
al., 2014; Holmes et al. 2012; Schapira & Schutt, 2011).    
Addressing organizational and provider-mediated barriers, CPBR, and patient 
navigation seek to ameliorate ineffectual CCT accrual processes by influencing the 
cancer health behaviors, health beliefs, and health decision-making of the Black cancer 
patient at institutional, community, and interpersonal levels.  However, central to all of 
these recruitment interventions are Black cancer patients.  Only they can discuss their 
reasons for accruing to, continuing to participate in, and withdrawing from CCTs, as well 
as address the factors which figure most prominently in their on-going treatment 
decision-making process.  In addition, only they can describe the dynamic processes of 
symptom burden prior to and incident to CCT participation and establishing and 
maintaining relationships with members of the CCT team.  Very few studies have utilized 
Black cancer patients as the sole members of a study sample or requested their individual 
perspectives on CCT participation.  This study is one of the first studies specifically to 
enroll Black cancer patients actively involved in a cancer clinical trial, in order to 
determine the factors influencing their enrollment and continued participation.  This 
study also explores and captures the daily experiences of Black CCT participants.  
CCT participation encompasses much more than enrollment; it is the totality of 
each participant’s day-to-day experience.  During the course of CCT treatment, 
participants in CCTs contend with a plethora of daily challenges which maynot be 
adequately captured by even the most well-crafted, valid, and reliable research tools.  
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Daily challenges such as differential access to CCT trial treatment based upon insurance, 
caregiving responsibilities for parents and children, the deleterious and life-changing 
effects of symptom burden, dwindling financial resources, and receipt of CCT treatment 
while homeless cannot be encompassed in one study by surveys and questionnaires 
without obscuring the ardent, rarely heard voice of each Black cancer patient.  The 
relevant literature lacks a focused consideration of the experiences of Black cancer 
patients during the CCT process and the personal decisional factors which motivate Black 
cancer patients to accrue and to remain in CCTs.  There is emerging literature regarding 
CCT decision-making from the perspective of the Black cancer patient, which will be 
discussed in Chapter 2.  However, there is no literature regarding the experiences of 
Black cancer patients during CCTs.  This literature would be useful in informing 
decision-making interventions and more effective recruitment practices.             
Purpose of the Study 
  The purpose of this study is two-fold: (1) to identify and describe the patient, 
protocol, physician, and family member factors that Black cancer patients consider 
important in their decision to participate and remain in CCTs; and (2) to use real-time 
data capture methods to understand the daily experiences of patient-participants who are 
participating in CCTs.  The following research objectives will be addressed: 
1. To understand how patient, family member, physician, and protocol factors 
are expressed by patient-participants in their decisions to participate and 
remain in CCTs; 
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2. To understand the daily experiences of Black patient-participants as they 
navigate through their CCTs.  
Significance of the Study 
 This study is an important first step in giving voice to Black adults living with 
cancer who are participating in clinical research, by examining how their life events and 
real-time daily experiences positively or negatively influenced their participation and 
retention in cancer clinical research.  This study is unique in its use of real-time data 
capture (RTDC) using qualitative methods to capture the experiences of Black cancer 
patients as they occurred in real-time.  Typically, RTDC is used to acquire quantitative 
data for producing analytic models to examine within-person and between-person 
variations in experience, behavior, or physiological state (Shiffman, Stone, & Hufford, 
2008).   However, surveys and questionnaires are prone to retrospective bias and, 
therefore, may fail to capture the dynamic processes of the real world and how an 
individual negotiates his way through it.  Real-time insights from Black participants on 
their experiences of CCT participation will inform possible strategies at the individual, 
family, and community levels to enhance future CCT recruitment and retention by 
providing Black cancer patients with the information and resources necessary to make 
informed CCT treatment decisions.   Further, the findings will serve as the basis for the 
long-term goals of developing and testing culturally relevant, theoretically based 
behavioral change interventions designed to increase recruitment and retention of eligible 
Blacks in CCTs. 
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Significance of the Study to Nursing 
 This study is significant to nursing for three reasons.  First, it will enhance nursing 
research knowledge by explicating factors influencing CCT enrollment and retention for 
Black cancer patients.  In so doing, it may be a first step in reducing disparities in cancer 
outcomes and developing interventions for the Black population.  Understanding the 
patient, family member, physician, and protocol, factors that are important to cancer trial 
participation and retention is integral to further conceptual development and refinement 
of models.  This understanding can lead to dialogue about CCTs with the Black 
community and to culturally competent care that advances our knowledge of fears or 
other misperceptions of CCTs.  Second, it will advance nursing’s knowledge of 
methodological techniques, such as using real-time data capture.   
 Last, this study will approach the issue of Black CCT participation with a nursing 
lens (i.e., with a perspective reflecting the inherent strengths of nursing practice and 
research).  Foremost among a nurse’s commitments is a focus on providing care to the 
patient in the larger context of his psychosocial environment—ever mindful of the 
individuals who support and provide resources for the patient (Disch, 2012).  In a similar 
way, the nurse researcher must respect and uphold the ethical principles of conducting 
research with human participants by understanding the preferences and goals of patient-
participants.  Therefore, examining the relationships forged by the Black cancer patient 
with his family (however, the family is defined) and the cancer clinical trial team is 
integral to understanding his CCT participation (including recruitment and retention) 
(Disch, 2012).  This focus is a fulfillment of the “nursing lens” which seeks to know each 
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Black cancer patient within the confines of his daily experience in order to understand 
why he has chosen to be, and why he remains, a CCT participant (Gardner, 1995).  For 
this reason, this study was significant to nursing in its emphasis on the individual 
experience of each Black participant as he was impacted by his family, the CCT in which 
he was enrolled, and the oncology physician and CCT team who supervised his research 
treatment.            
The Definitions of Terms 
 Following is a list of terms used in this study: 
 Accrual is a term that is often used interchangeably with enrollment or 
recruitment to CCTs. 
 Cancer clinical trial (CCT) is synonymous with therapeutic CCT, or a CCT with 
curative intent that uses drugs, radiation, surgery, other biological agents, or behavioral or 
other interventions (V. Sallee, personal communication, July 8, 2011). 
 “Black,” is a term used instead of African American and signifies an individual 
who is identified as a domestic or foreign-born descendant of Africans, as well as an 
individual through acculturation who identifies as Black (Nelson et al., 2011).   
 Symptom burden is the totality of the severity and impact of observations of an 
individual which evidence disease or physical disturbance and can only be learned by 
patient self-report (Cleeland, 2007).   
 Real time data capture (RTDC) is defined as the acquisition of self-reported 
health information as it occurs in an individual’s immediate environment in real-time 
(Stone et al., 2007). 
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 Research participation is a broad term; and, for the purposes of this study may 
include recruitment, enrollment, and retention in CCTs.   
Summary 
 The primary purpose of this study is to examine the factors influencing CCT 
participation among Black cancer patients by adding the individual voices of Black 
cancer patients currently accrued to CCTs.  In addition, this study seeks to understand the 
influence of patient, family member, physician, and protocol factors on Black cancer 
patients’ CCT accrual and continued enrollment.  By describing factors influencing CCT 
enrollment from the patient-participants’ perspective in real-time, this study achieves 
some measure of ecological validity—that is, reflects the behaviors of other Black CCT 
participants in the real world as they progress through CCTs.   Further, this study 
ascertains the daily challenges and experiences of Black patients during their CCT 
participation as devoid as possible of retrospective bias.  The statement of the problem, 
purpose, and significance to nursing, as well as specific aims were presented  
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CHAPTER II 
 
REVIEW OF THE LITERATURE   
Introduction 
 The purposes of this study were to identify and to describe the influence of 
patient, family member, physician, and protocol factors on Black cancer patient CCT 
accrual and continued participation, as well as to understand the daily experiences of 
Black cancer patients enrolled in CCTs.  The literature reviewed for this chapter includes 
four main areas.  First, the chapter begins with an overview of the research on Black 
cancer patient CCT participation.  Second, there will be a discussion of Albrecht’s 
theoretical framework and its application to this study.  Third, research that focuses on 
the four main factors of Albrecht’s model will be discussed.  This includes patient, family 
member, physician, and protocol factors.  Fourth, in order to describe the phenomenon of 
CCT participation by Black cancer patients in the everyday language of the patient-
participants (Sandelowski, 2000), the relevant literature underpinning the use of elements 
of real-time data collection (RTDC) method used in this study will be discussed.  Finally, 
a summary of the gaps in the literature will be provided. 
Black Cancer Patients and Barriers to Cancer Care and Clinical Trials 
 Three systematic reviews encompassing the period 1960 through 2011 
enumerated barriers to cancer care and CCTs and reflected the influential role of patient, 
family member, physician, and protocol factors.  Shavers and Brown (2002) published 
one of the earliest reviews of the literature—from 1960 through 1997—addressing cancer 
health disparities among racial and ethnic minorities.  Their review identified racial and 
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ethnic gaps
1
 in cancer treatment for several types of cancer (i.e., breast, lung, colo-rectal, 
prostate, and cervical cancer) that decreased disease-free survival and that increased 
mortality and disease recurrence rates.  They also identified three broad factors that 
potentially affected receipt of cancer treatment:  structural, physician/clinical, and patient 
barriers (Shavers & Brown, 2002). Structural barrier factors included insurance status, 
insurance type, geographic region where care was received, and the type of institution 
where treatment was received.  Physician/clinical factors centered on factors that 
influence physician recommendations for cancer treatment, such as the presence of 
comorbidities, physician preference or bias, and physician perception of patient 
willingness to adherence to treatment.  Patient factors addressed patient preferences and 
biases, ability to access medical treatment, and attitudes and beliefs surrounding 
recommended treatment.  These three broad factors, along with family members (as 
broadly or narrowly defined by the participant), have come to be viewed as barriers and 
facilitators to CCT participation among Black cancer patients (Ford et al., 2008; Heller et 
al., 2015; Langford et al., 2013; Rivers et al. 2013; Sheppard et al., 2011; Royak-Schaler 
et al., 2008).      
 In their review of barriers to recruitment of under-represented populations from 
quantitative and qualitative studies for the period 1996 to 2005, Ford et al. (2007) found 
that reduced recruitment was influenced by barriers to awareness, opportunity, and 
acceptance of CCTs.  Barriers to CCT recruitment included physician awareness of 
                                                          
1
 The researchers evaluated racial/ethnic gaps in cancer treatment among Black, Hispanic, Native 
American, and Asia/Pacific Islander populations (Shavers & Brown, 2002).  The study focused 
predominantly on treatment care disparities among Blacks.   
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CCTs, lack of education about cancer, and the presence of culturally-relevant 
information.  The opportunity to participate in CCTs was affected by such factors as 
provider attitudes and characteristics, CCT design barriers (comorbid conditions and age-
based exclusions), sociodemographic factors (e.g., age, member of a racial/ethnic group, 
and socioeconomic status), provider communication, and CCT-associated costs.  Barriers 
to acceptance of CCTs included family influences, fear, direct and indirect costs, time 
commitment, transportation, and distrust of physicians and the healthcare system.      
 Rivers et al. (2013) synthesized the existing studies over a ten year period 
(from 2002 to 2011) to better understand the key factors that influence the participation 
of Blacks to CCTs.  In this review, five elements were found to influence the 
participation of CCTs:  negative attitudes towards CCTs, the importance of faith, 
knowledge deficits related to CCTs, the role of healthcare providers, and the 
recommendations of friends and family members.  Blacks were more likely to enroll in 
CCTs, if family and friends had enrolled or had knowledge of CCTs, promoted CCT 
enrollment, and provided support.  Knowledge of CCTs, and certain sociodemographic 
factors such as higher income and education which increase the likelihood of CCT 
awareness, influenced the prospect of CCT accrual. The presence of negative beliefs and 
attitudes, such as fear of experimentation, decreased the likelihood of Blacks enrolling in 
CCTs.  Religious faith was likely to discourage CCT participation among Blacks, 
secondary to beliefs that God controlled the outcome of their disease progression or cure 
and on reliance on religious intervention.  Finally, the role of healthcare providers was 
found to both encourage and discourage CCT participation among Blacks.      
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 Although the three systematic reviews lacked a focused consideration of the 
experiences of Black cancer patients during the CCT process and the personal decisional 
factors which motivate Black cancer patients to accrue and continue to participate in 
CCTs, they still enabled an examination of the four major factors which influence CCT 
participation among Black cancer patients:  patient, family member, physician, and 
protocol.  Further, the three systematic reviews showed a temporal movement (from 1960 
to 2011) from a consideration of the factors required for CCT enrollment (insurance, the 
healthcare institution, physicians/clinical settings, and cancer patients), to the recruitment 
process and its effect on CCT recruitment, and, finally, to a focus on factors influencing 
Blacks to enroll in CCTs (Ford et al., 2008; Rivers et al. 2013; Shavers & Brown, 2002).   
Albrecht’s Theoretical Model of CCT Decision-making 
 Albrecht’s Model (see Figure 2-1) served as the analytic starting point for this 
dissertation study (Albrecht et al., 2003).  Albrecht et al (2003) reported that cancer 
clinical trial decision-making is influenced by four factors:  patient, family member, 
physician, and protocol.  Albrecht et al. (2003) posited that patient decisions surrounding 
cancer treatment, including patient decision-making regarding CCT enrollment, generally 
were physician-dominated and the “patient and family member are primarily in response-
based roles where they react to the behavior of the physician (Albrecht, p. 41, 2003).”  
Albrecht et al. (2003) did not explicate specifically, or define the four factors, nor did the 
researchers delineate the particular patient, family member, physician, and protocol 
factors that influence treatment decision-making.  However, the researchers 
acknowledged that the four factors have socio-demographic and attitudinal features that 
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influenced patients’ decision-making when choosing CCT participation (Albrecht et al., 
2003).  Moreover, the researchers stated that aspects of the protocol which impacted 
patient treatment decisions included trial phase and composition of the CCT study arms 
(Albrecht et al., 2003).   
 Albrecht’s Model provided information regarding the role of the physician in the 
cancer treatment enrollment process.  Successful patient enrollment to CCTs was 
ascribed to the relevant physician’s support and responsiveness to a patient’s concerns, 
barriers to accepting treatment, and uncertainty (Albrecht et al., 2003).  Further, 
communication, which included a mediating role in CCT decision-making in Albrecht’s 
Model, was specifically defined as physician communication.  It provided the nexus for 
the patient, family, physician, and protocol factors to influence decision-making.  
Physicians were considered 
integral in referring cancer 
patients to CCTs, influencing 
decision-making by cancer 
patients, and discussing 
informed consent (Albrecht et al. 
1999; Albrecht et al., 2003; Albrecht 
et al. 2008).     
 Although the four factors and their attributes were not clearly defined in 
Albrecht’s Model, research literature has pointed to some of these attributes.    Several 
researchers, for example, identified factors influencing CCT treatment decisions.  These 
Figure 2-1:  Albrecht's Theoretical Model of Cancer 
Clinical Trial Decision-making 
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included patient factors such as altruism, an expectation of personal benefit, improvement 
of cancer-related symptoms, the absence of other treatment, and maintenance of hope 
(Agrawal et al., 2006; Kvale et al., 2010; Todd et al., 2009; Truong, Weeks, Cook, & 
Joffe, 2011; Ulrich et al., 2012; Wright et al., 2004). Protocol-related factors also 
influenced CCT enrollment.  Wujcik and Wolff (2010) identified eligibility requirements 
related to the protocol as problematic.  Indeed, from 2001-2007, of the 1,125 individuals 
screened for a clinical trial during this time period, only 30% had an available trial and 
21% enrolled.  Initial barriers included issues such as lack of transportation, missed 
appointments, insurance constraints, miscommunication, and concerns surrounding 
informed understanding of patients.  Other protocol-related factors that have been 
discussed in the literature included loss of relationship with a primary oncology 
physician, compensation for participation, lack of insurance coverage for CCTs, complex 
study protocols and informed consent documents, and increasing CCT requirements 
(Basche et al., 2008; Joseph & Dohan, 2009a; Klamerus et al., 2010).   
 Albrecht et al. (2003) freely acknowledged the influence of the behaviors of 
family members and significant others on CCT decision-making. However, again, 
Albrecht’s Model did not delineate the elements or the nature of the family member 
factors, yet research suggested that family member-related factors directly influence CCT 
enrollment, since cancer patients rely heavily on the tangible support and caregiving of 
family members and friends (Sheppard et al. 2011; Ulrich et al. 2012; Wootten et al., 
2011).  Family issues positively and negatively influenced CCT enrollment as some 
cancer patients felt compelled to enroll to appease family members, while others did not 
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participate because of concern for burdening family members with additional 
responsibilities or depriving them of care (Quinn et al., 2011; Ulrich et al 2012; Wootten 
et al. 2011).       
 Additionally, other factors beyond Albrecht’s Model were important in CCT 
treatment decision-making for CCT enrollment.  Concerns about treatment side effects 
and resultant symptom burden figured prominently among participants in CCTs in 
several research studies (Ulrich et al. 2012; Wootten et al. 2011).   Albrecht’s Model did 
not consider the impact of symptom burden on continued participation in cancer research, 
nor did it consider the effect of symptom burden on treatment decision-making on Black 
cancer patients with a history of prior cancer treatment.  Albrecht’s Model was physician-
centered, and, therefore, discussed the integral role that physicians play in the care and 
treatment of cancer patients.  Therefore, significantly, Albrecht’s Model overlooked the 
influence of nurses in their various roles during the CCT process (Grady & Edgerly, 
2009; Ulrich et al., 2012; Wootten et al., 2011). Ulrich et al. (2012) clearly illustrated the 
pivotal presence of nurses in the CCT process.  Further, nurses function as clinical 
research coordinators and nurse navigators who interact directly with potential 
participants prior to enrollment in CCTs and have a significant impact on CCT decision-
making and participation.     
 Albrecht’s Model provided a starting point for exploring decisional components 
that impact the clinical research decisions of Black adults living with cancer, since it 
acknowledged the complex factors that might influence Black cancer patients’ decision-
making related to CCT treatment options, i.e., the influences of patient, family member, 
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physician, and protocol-related factors, as well as the mediating role of physician 
communication (Basche et al., 2008; Lara et al., 2005; Ulrich et al. 2012; Wootten et al., 
2011).  Although it outlined these important variables in treatment decisions, Albrecht’s 
Model was silent on the role of nurses and other members of the CCT team, as well as the 
potentially negative effects of symptom burden on CCT treatment decision-making and 
on continued CCT participation. More significantly, it listed the patient as a factor, rather 
than focusing on the perspective of the patient and his or her preferences and goals 
related to research participation.   
Patient Factors 
   The willingness of Blacks to participate in medical research frequently has been 
referenced to a general distrust of physicians and medical research, with some of the 
distrust stemming from the ethical and human rights abuses perpetrated on rural Southern 
Blacks in the Tuskegee syphilis experiments (Tuskegee Study) (Linden et al., 2007; 
Shavers, Lynch & Burmeister, 2002).  Researchers have posited that knowledge of 
Tuskegee and its abuses have deterred Black participation in medical research, such as 
CCTs.  In a national telephone survey from a sample of the 527 Black and 328 White 
respondents, Corbie-Smith, Thomas, and St George (2002) found significant levels of 
distrust among Blacks regarding physicians and differences in trust among Blacks and 
Whites.  Overall, Blacks had significantly higher distrust scores than Whites, as well as 
more distrust of physicians than Whites.  In this study, Blacks as compared to Whites 
were more likely not to trust physicians to explain research to participants (41.7% vs. 
23.4%, p < .01), , to state that their physician sometimes exposed them to unnecessary 
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risks (45.5% vs. 34.8%, p < .01), to believe that someone like them would be treated as 
“guinea pigs” without their consent (79.2% vs. 51.9%, p < .01), and to believe that 
physicians often prescribed medication as a means of experimentation without consent 
(62.8% vs. 38.4%, p < .01).  After controlling for sociodemographic factors such as 
education, employment, and income, race continued to be significantly associated with 
distrust—which in turn, could affect willingness of Blacks to participate in CCTs.     
 Shavers, Lynch, and Burmeister (2002) affirmed this stance in their mail and 
telephone survey data collected in Detroit, Michigan, from predominantly White and 
Black Detroit residents (Blacks (N = 91), Whites (N = 88), and individuals of other racial 
and ethnic groups (N = 19)).  They found that knowledge of the Tuskegee Study was a 
factor deterring willingness of more Black respondents, than White respondents, to 
participate in medical research.  Eighty-one percent of Blacks and 28% of Whites stated 
awareness of the Tuskegee Study.  Fifty-one percent of the Black respondents reported 
that the Tuskegee Study resulted in less trust of medical researchers, 41% reported that 
their trust in medical researchers had not changed, and one percent reported feeling more 
trust.  Of the Whites who had knowledge of the Tuskegee Study, 17% percent stated that 
this knowledge resulted in less trust in medical researchers, and 83% reported no change 
in their trust of medical researchers.  Further, 49% of Blacks and 17% of Whites stated 
that their knowledge of the Tuskegee Study was a barrier to future participation in 
medical research studies.  Knowledge of the Tuskegee Study and its negative effect on 
CCT participation was found in participant samples in later studies concerning Blacks 
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and CCT participation (Evans, Lewis, & Hudson, 2012; Robinson, Newman, Wallington, 
& Swain, 2016).   
 Other studies found conflicting information regarding the willingness of Blacks to 
participate in CCTs.  Meng, McLaughlin, Pariera, and Murphy (2016) compared the 
effect of distrust on the willingness of Blacks and Whites to participate in CCTs via the 
use of an online survey. They found that distrust increased unwillingness to enroll 
participate in CCTs in both Whites (p < .01) and Blacks (p < .05).  Moreover, willingness 
to participate in CCTs was significantly influenced by Blacks seeking CCT information 
from hospitals (p < .05) and by religious belief (p < .05).  Via the use of focus groups, 
Linden et al. (2007) explored the willingness or unwillingness of 58 African American 
women (ages 30 to 65) to participate in a hypothetical randomized clinical trial for breast 
cancer.  None of the participants had ever been diagnosed with breast cancer.  In all the 
focus groups, there emerged a general distrust of the healthcare system, with frequent 
reference made to the Tuskegee Study.  However, the focus groups felt that this distrust 
could be ameliorated by culturally sensitive recruitment to CCTs.  Interestingly, four 
other common themes emerged from the focus groups that reflected a willingness to 
participate in a CCT:  (1) if participation was personally meaningful to the individual or 
to the community, (2) the necessity of being able to make an informed choice, (3) a 
preference among some members of the focus groups for spiritual or alternative/natural 
treatments, rather than medical care, and (4) use of a cost-benefit analysis, whereby the 
subjects weighed the benefits and costs of participation in a research clinical trial versus 
the costs and benefits of travel, medication and medical care, and time expended.    
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  Recent research indicates that Blacks have moved beyond the specter of Tuskegee 
as a deterrent to medical research participation.   In fact, as found by Linden et al. (2007) 
and Meng et al. (2016), Black cancer patients were willing to participate in CCTs as 
much as White cancer patients (Byrne et al. 2014; Ford et al., 2013).  However, other 
factors such as concerns about insurance, lower socioeconomic status, and ineffective 
physician-patient communication have emerged in the literature as barriers to CCT 
participation (Brown et al., 2013; Byrne et al., 2014; Ford et al., 2013; Du et al., 2005; 
Lara et al., 2005).  Ford et al. (2013) conducted six racial and ethnically homogeneous 
focus groups of Latinos and Blacks from the general population of six counties in South 
Carolina.  They sought recommendations for removing barriers to clinical trials from 
members of the two groups who are under-represented in clinical trials.  Both groups 
identified barriers and offered solutions for their amelioration   Using content analysis, 
the researchers formulated themes common to Blacks and Latinos, exclusive to the Black 
participants, and exclusive to the Latino participants.  The Black participants stated 
willingness to participate in clinical trials (1) in health systems that performed patient 
satisfaction surveys and admitted and formally apologized for mistakes, (2) if clinicians 
were trained in improved patient communication, and (3) with more racially diverse 
clinical trial teams.  Themes common to both groups included (1) lessening costs 
associated to clinical trials, (2) moving recruitment to the community (especially to 
churches), (3) the necessity for clinicians to use ample time to discuss clinical trial 
associated risks, learn communication skills targeted to diverse groups, and permitted the 
24 
 
participants’ physicians to remain involved in their treatment, and (4) physicians 
accepting more responsibility for the adverse effects of clinical trials.         
 In their survey of 1100 Black, Hispanic, and White patients from a Florida cancer 
registry with lung, breast, colorectal, and prostate cancer, Byrne et al. (2014) did not find 
a difference in willingness to participate among the three groups.  Only eight percent of 
the sample reported having participated in a CCT.  The top five reasons the sample cited 
for CCT enrollment were (1) the desire to improve cancer treatment, (2) the oncologist 
advised undertaking enrolment in a CCT, (3) the CCT offered optimum treatment for 
their cancer, (4) the CCT offered more information, and (5) the CCT was the sole 
treatment option (Byrne et al., 2014).  The most cited barrier by over 90% of the sample 
was concern whether insurance would cover the costs of CCT enrollment.  Other top 
barriers reported included (1) fear of side effects from CCT medications, (2) the belief 
that their physician did not want the individuals to participate, (3) the cancer patient did 
not want to transfer his care from his present physician, and (4) the cancer patient not 
wanting to be a “guinea pig” (Byrne et al., 2014).          
 Du et al. (2005) conducted a retrospective chart review of 427 lung cancer 
patients eligible to participate in CCTs for the years 1994 through 1998 at a 
comprehensive cancer center in Detroit, Michigan, to determine predictors of CCT 
enrollment. Only 91 of the 427 cancer patients participated in a CCT.  Using univariate 
and multivariate analyses to compare CCT enrollees and non-enrollees, as well as non-
Black and Black cancer patients, the researchers determined that Blacks were more likely 
to live in low rank census tracts (83% vs. 23%, p < .001), less likely to have an Eastern 
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Cooperative Group (ECOG) performance status equivalent to zero (27% vs. 35%, p = 
.054,
2
 and less likely to have commercial insurance (27%-49%, p <. 001) (Du et al., 
2005).  Conversely, non-enrollees were more likely to be Black (45% vs. 25%, p = .001), 
to live in a low rank census tract (52% vs. 37%, p =. 028), and less likely to have 
commercial insurance (37% vs. 55%, p = .002) (Du et al., 2005).  Black cancer patients 
significantly were less likely to have commercial insurance (conventional, HMO, and 
private party provider) and significantly more likely to live in lower socioeconomic areas. 
   Disparate communication patterns between Black cancer patients and their 
oncologists have been cited as contributing to less information-sharing regarding cancer 
care and CCT information.  Studies have shown that oncology physicians engage in more 
relationship building language, have longer appointments, have more utterances at 
appointments, and have higher frequencies of information-sharing statements (Eggly et 
al., 2015; Gordon et al., 2006; Siminoff et al., 2006).  Also, when CCTs were discussed, 
the discussion involved less statements containing information concerning 
diagnoses/prognoses, explanations, risk/benefit, and treatment options (Eggly et al., 2015; 
Gordon et al., 2006; Siminoff et al., 2006).  In Eggly, Barton, Winckles, Penner, and 
Albrecht (2015), the researchers analyzed the word count and word content of 
conversations that occurred in videotaped clinic interactions between Black cancer 
patients and their oncologists.  Eggly et al. (2015) determined that appointments with 
                                                          
2
 The ECOG performance status is a measure of a patient’s functional status, i.e., a measure of a patient’s 
ability to carry on his activities of daily living, self-care activities (dressing, feeding oneself, etc.), and 
strenuous physical activity (Oken et al., 1982).  It is meant to be an objective measure of a patient’s 
functional status prior to clinical trial participation, as well as a means of evaluating a patient’s changes in 
functional status during the course of a clinical trial.  It is a six-point scale which ranges from zero to five, 
with zero representing optimum functional status and five signifying death.       
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Black cancer patients were shorter in length than White cancer patients and had fewer 
discussions of CCTs.  Mean word counts of oncologists’ visits with Black cancer patients 
were shorter, than for visits with White cancer patients (4877.73 vs. 7247.18).  The topic 
of CCTs was raised less frequently during visits with Blacks, than with Whites.  Even in 
discussions involving offers of CCTs, oncology physicians were found to have 
discussions with Black cancer patients that had lower mean word count (1089.64 vs. 
1867.09) and contained fewer elements of informed consent, than the same discussions 
with White cancer patients (Eggly et al., 2015).   
 Researchers have surmised a probable reason for this disparate information-
sharing by oncology physicians is the ineffective communication styles of Black cancer 
patients, which have been criticized as being passive and less interactive (Eggley et al., 
2013; Gordon et al., 2006a; Gordon Street, Sharf, & Souchek, 2006b).  In their review of 
video-recorded clinic interactions between 109 Black and White cancer patients (30 of 
the cancer patients were Black) and their White oncologists, Eggly et al. (2011) 
determined that there was a significant difference (p = .008) between the mean total 
number of questions asked by Black cancer patients (7.83 questions, SD=7.81) and the 
mean total number of questions asked by White cancer patients (11.56, SD=9.23).  The 
researchers concluded that the difference amounted to less information being sought by 
Black cancer patients and less information being shared with them by their White 
oncologists.    
 However, as noted by the focus groups conducted in Williams et al. (2008), Black 
cancer patients and their families have their own communication expectations 
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surrounding quality of life.  The members of the six focus groups identified two domains 
of communication the participants felt were essential:  effective communication and 
decision-making.  The themes of personhood and tailoring communication were 
embedded within the domain of effective communication.  Inherent in personhood was 
the admonition that, as a prerequisite to effective communication, physicians must 
establish a relationship with a patient in order acquire knowledge about the patient and 
her family (Williams et al. 2008).  The patients and family caregivers expected the 
physicians to initiate, maintain, and monitor the effectiveness of communication existent 
in the relationship.  In terms of tailoring communication, the focus group members 
expected oncology physician to use language appropriate to their education and literacy 
levels and to control the amount and timing of information based upon the needs of the 
patient, the complexities of the patient’s care, and where the patient was in terms of 
accepting or denying her disease state (Williams et al. 2008).     
A few studies have considered the issue of CCT participation from the 
perspectives of Black cancer patients.   Brown et al. (2013) and Wenzel et al. (2014) 
focused on Black cancer patients who had accepted, or declined, CCT enrollment.  
Wenzel et al. (2014) considered the processes and reasons influencing 32 Black cancer 
patients to accept, or to decline, CCT participation.  Seven focus groups comprised of 
Black cancer patients who had been offered CCT participation were conducted.  The 
focus group participants who refused CCT enrollment stated that their decisions were 
influenced by such factors as distrust of physicians, lack of awareness of CCTs, cost, 
transportation, discouragement by family and friends, and negative experiences with 
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healthcare providers.  Some of the focus members expressed regret that they had allowed 
family and friends to persuade them to decline CCT enrollment.  The focus group 
members who accepted CCT enrollment reported that participation was influenced by 
family and friend support and spiritual motivations.    
The investigators in Brown et al, (2013) interviewed 22 Black cancer patients 
who refused participation in Phase 1-Phase 3 CCTs, the researchers found that 
participants cited more than one factor underlying their decision to decline CCT 
participation.  The top four factors were (1) increase in burden related to CCT treatment 
(12, or 55%), (2) possibility of increase in symptom side effects (11, or 50%), (3) concern 
surrounding the process of randomization (8, 36%), and (4) family members 
recommending non-participation (8 participants, 36) (Brown et al., 2013).  Of the 22, 
only one participant declined due to mistrust of clinical researchers, and one participant 
declined secondary to concern of not receiving optimum care (Brown et al., 2013).  In 
terms of prior knowledge or opinions of CCTs, only nine (41%) of the participants lacked 
prior knowledge or opinions of CCTs. Significantly, the researchers observed that the 
participants and their family members (accompanying participants) did not understand 
crucial CCT information during the CCT consultation.  For this reason, Brown et al. 
(2013) suggested that CCT participation could be improved if interventions were 
developed which targeted the CCT information and decision-making needs of Black 
cancer patients and their families (Brown et al., 2013).   
 A more recent qualitative study by Robinson et al. (2016) investigated the 
perspectives and opinions regarding CCTs from eight focus groups comprised 
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exclusively of Black cancer patients, patient family members and caregivers, religious 
leaders in the relevant Black community, and healthcare providers.  The Black cancer 
patients were undergoing chemotherapeutic treatment.  The researchers did not indicate 
whether any of them were participating in CCTs.   The Black cancer patients felt it was 
important for Blacks to be involved in CCTs, since Blacks were disproportionately 
affected by disease, and it was very important to include all racial, socio-economic, age, 
and gender groups in research. In discussing ways to encourage to CCT participation 
among Blacks, they suggested the CCT participants should talk about their experiences in 
CCTs, physicians should educate their patients about CCTs as a way of encouraging 
participation, and information should be disseminated in the Black community in 
churches, social workers’ offices, elevators, and hospitals.  In order for them to enroll or 
to encourage other Black cancer patients to participate in CCTs, the Black cancer patients 
stated that they needed to trust the physician and to understand all of the CCT 
information, the side effects of the CCT intervention, and the effects of the CCT 
intervention on their existing comorbid conditions. 
Family Member Factors 
 Family members have been mentioned tangentially as “companions” being 
present during physician-patient CCT discussions and/or interactions in the outpatient 
setting, with no mention of their roles in the lives of Black cancer patients external to the 
clinical setting (Albrecht et al., 2008; Albrecht et al., 2009; Eggly et al., 2006; Eggly et 
al., 2011; Penner et al., 2012).  Several studies have begun to acknowledge the vital roles 
of Black family members (spouses, partners, children, etc.) in CCT discussions.  Eggly et 
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al. (2011) found that White cancer patients were more likely to have a companion present 
at their appointments than Black cancer patients (p < .000).  There was a significant 
difference (p < .000) between the number of questions asked at clinical interactions by 
patients and their companions (22.50 questions per interaction with a SD=14.65) versus 
questions asked by patients who came alone (9.50 questions per interaction with a 
SD=9.23).       
 Studies have noted that Black cancer patients expect oncology healthcare 
providers to exhibit respect for their family members, as well as to tailor cancer 
information to the health literacy and education needs of family members (Song, 
Hamilton, & Moore, 2012; Williams et al., 2008). Clearly, the Black cancer patients’ 
expectation of familial inclusion espouses participation of their family members in the 
CCT process, despite such familial inclusion being absent from the research literature.  
Family members are more than just individuals in the periphery of CCT decision-making.  
 Wenzel et al. (2014) confirmed the valued status of family members and friends 
in CCT decision-making.  The researchers reported that Black cancer patients who had 
accepted, or declined, CCT participation relied on family and friends as sources of CCT 
information and as participants in shared CCT decision-making.  Brown et al, (2013) 
noted the strong influence of family members of Black cancer patients on CCT decision-
making. In this study, 14 of the 22 participants reported discussing CCT information with 
family members during and after the initial CCT consultation—eight participants’ family 
members advised declining CCT participation. Clearly, researchers have found that the 
presence of “companions” (most of whom were identified as spouses, partners, or 
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children) increased the information received by Black cancer patients during their clinical 
interactions with oncologists.  This finding has bearing on the relevant impact of their 
presence during CCT discussions.    
Physician Factors 
 Attitudes of oncologists towards CCTs significantly affect accrual of cancer 
patients to CCTs.  Somkin et al. (2013) surveyed 77 oncologists and followed their 
accrual patterns over a two-year period.  Oncologists who had high CCT accrual saw 
perceived value in CCTs (p = .023) and indicated awareness of open CCTs and specific 
eligible patients with whom they initiated CCT discussions (p < .0001).  Indicators of 
oncologists with low accrual patterns included appreciation that patients initiated CCT 
discussions (p = .04), did not offer CCTs to patients who they feel are likely to do well on 
standard treatment (p = .0092), and perceived CCTs to be an inappropriate use of 
resources (p = .023).  
 Oncologists’ attitudes and perceptions of Black cancer patients figure prominently 
in whether they are deemed eligible for CCTs.  Oncology physicians have denied Black 
cancer patients CCT participation because of anticipated non-compliance, perceived 
mental status or cognitive impairment, and the presence of comorbidities (Penberthy et 
al., 2012; Simon et al., 2004).  In Penberthy et al. (2012), the researchers reported that 
Blacks were more likely than Whites to be deemed ineligible for CCTs by oncologists 
(47.8% vs. 40.8%, p < 0.004) because of expected non-compliance and perceived 
inappropriate mental status. Prospective enrollees were deemed non-compliant by 
oncologists due to (1) consistent failure to attend appointments, (2) active substance 
32 
 
abuse, and (3) perceived instability. Inappropriate mental instability signified the 
perceived inability of Black cancer patients to understand and provide informed consent 
(Penberthy et al., 2012).  In fact, oncology physicians have also declined to offer CCT 
participation to Black cancer patients based on physician preference for standard care 
versus CCT care, concern for patient inability to tolerate CCT treatment secondary to 
comorbidities, and likelihood of being ineligible (Langford et al., 2014; Simon et al., 
2004; Somkin et al., 2013).  
 Simon et al. (2004) surveyed oncologists at an urban, NCI comprehensive cancer 
center to determine practice patterns for referral and enrollment of Black women to breast 
cancer CCTs.  The sample included 319 self-identified Black, White, or other (Asian 
Pacific, Arab/Chaldean, and Hispanic) women who had new patient visits with 
oncologists.  At the time of the survey, ten breast cancer trials were available.  Using 
univariate analysis, the researchers determined that oncologists enrolled approximately 
33% of the sample who were offered enrollment in a CCT—with White women being 
more likely to be offered CCTs than Black women (42% vs. 21%).  Moreover, Black 
women were more likely found to be ineligible in comparison to White and other race 
patients (61% to 53%), and Blacks were more likely to be considered ineligible because 
of poor performance status and unsatisfactory organ function.         
 Kehl et al. (2014) surveyed a large cohort of lung and colorectal patients (or their 
surrogates, if the patient had died or were too ill to respond to the survey) three to six 
months after their cancer diagnosis to investigate their discussions pertaining to CCTs.  
Of the 7887 respondents surveyed, 1114 (14%) reported having discussions about CCTs 
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as a treatment option.  The researchers ascertained that specific factors were significantly 
associated with occurrence of CCT discussions: (1) increasing educational level (p =.01), 
higher income (p <.001), possessing no self-reported comorbidities (p <.001), and being 
White (p = .01).  Moreover, respondents who had these CCT discussions were less likely 
to enroll in CCTs, if CCT decision-making were physician-controlled (13.4% enrolled), 
as compared to shared CCT decision-making (35% enrolled) or patient-controlled CCT 
decision-making (29.2 enrolled, (p < .001).      
 Finally, as discussed previously, research indicates significant differences in 
cancer information communication between oncology physicians (predominantly White 
in the reported studies) and Black and White cancer patients (Gordon et al., 2006; Eggly 
et al., 2013; Siminoff et al., 2006; Song et al., 2014).  In support of these findings and as 
discussed previously, oncologists have been shown to have shorter appointments with 
Black cancer patients and discuss CCTs with Black cancer patients less often than with 
White cancer patients (Eggly et al., 2011; Eggly, et al., 2013).  Instead of solely laying 
the burden on the interactive style of Black cancer patients, Eggly et al. (2013) suggested 
that the problem may lie with physicians.  They posit that the differences in cancer 
communication may reflect oncologists’ concerns about Black cancer patient distrust, or 
the oncologists’ racial attitudes and beliefs which make the discussions less patient-
centered (Eggly et al., 2013). 
Protocol Factors 
 Inherent in all CCTs are eligibility criteria which define the targeted patient 
sample, as well as safeguard subject safety and make CCT results precise and meaningful 
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(NCI, 2014).  Establishment of eligibility criteria challenges investigators to define 
accurately sample qualifications without excluding potential subjects who may contribute 
significantly to the generalizability of CCT outcomes.  Studies have reported statistically 
significant exclusion of Black cancer patients from to CCTs due to the presence of 
comorbidities, multiple primary cancers, poor performance status, prior chemotherapy, 
and poor compliance (Penberthy et al., 2012; Simon et al., 2004; Adams-Campbell et al., 
2004).  Adams-Campbell et al. (2004) examined 13 CCTs to understand the influence of 
study design on recruitment and accrual of African Americans in these trials. The study 
found that exclusions included presence of co-morbidities, multiple primary cancers, high 
serum testosterone levels for participation in prostate cancer clinical trials, poor 
performance status, prior chemotherapy, and poor compliance.    
 By contrast, CCT protocols are more likely to recruit Black cancer patients, if the 
protocols seek subjects with advanced stage (or regional spread of) cancer, are 
therapeutic in nature, and/or possesses accrual targets (Diehl et al., 2011).  These findings 
are consistent with existent literature indicating that Black cancer patients tend to 
experience more cancer treatment delays than White cancer patients and present for 
initial cancer treatment with later stage disease (Hines & Markossian, 2012; Nurgalieva 
et al., 2013). 
 Costs of clinical trials and cancer care. 
 Looking beyond the physiological characteristics and the disease profile of the 
Black cancer patients, there are other protocol factors that adversely affect CCT 
enrollment. CCTs do not necessarily include all costs related to medical treatment and 
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diagnostic tests secondary to CCT participation.  The presence of routine medical costs 
incident to CCT participation poses a financial dilemma to potential and existing Black 
cancer, especially where state policy mandates do not exist to require insurance coverage 
(Chun & Park, 2012; Klamerus et al., 2010).  Chun and Park (2012) compared the 
presence of CCTs (2001 to 2007) in predominantly Black areas in the United States after 
implementation of state law mandating insurance coverage for routine costs associated 
with CCTs.  They were interested in determining whether adoption of the insurance law 
mandates resulted in CCT sponsors locating more CCTs in low income and 
predominantly Black areas, thereby increasing access to these populations.  Interestingly, 
they reported no difference in the availability of CCTs in low income areas. However, the 
researchers cited a 36% increase (p = .05) in the location of Phase 2 CCT
3
s in 
predominantly Black areas, after the insurance mandate.      
 Klamerus et al. (2010) explored the association between CCT denial and 
insurance coverage for cancer patients denied and accepted for CCTs at Johns Hopkins 
Medical Center.  There were no statistically significant relationships between CCT denial 
and sex, race, cancer stage, or prospective subject comorbidities.  However, CCTs were 
denied to prospective subjects who were younger (mean age= 54.9; p = .0001) and lived 
in Pennsylvania (p = .0009).  The mean age of subjects accepted for CCTs was 59.2 and 
reflects the proportionately larger number of CCT participants in this group who had 
Medicare, which authorizes payment of routine CCT related costs.  John Hopkins 
                                                          
3
 Phase one clinical trials are the first use of a drug in a small sample humans; as result, the goal is to 
determine safety, a safe dose range, and side effects resulting from use the drug.  By contrast, Phase two 
clinical trials evaluate the effectiveness and safety of a drug in a larger number of humans, with the already 
established dosage range.       
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recruited most of its CCT subjects (81.3%) from Pennsylvania, Maryland, and Virginia.  
The latter two states had state law mandates that require insurance organizations to cover 
medical costs associated with CCTs.  Pennsylvania did not have such an insurance law 
mandate at the time of the study.     
 Prior to passage of the Patient Protection and Affordable Care Act (PPACA) of 
2010, approximately 29 states had policy mandates to require payment of routine costs 
associated with CCTs (Klamerus et al, 2010).  The absence of these insurance mandates 
have a chilling effect on access to CCTs, since prospective subjects living in states 
lacking the CCT insurance mandate are denied insurance coverage for CCT participation 
at disproportionate rates (Klamerus et al., 2010).  The PPACA with its minimum 
requirement of insurance coverage for therapeutic clinical trials has offered a glimmer of 
hope for improving access to CCTs (Kircher, Benson, Farber & Nimeiri, 2012; Martin et 
al., 2014). Unfortunately, room still exists to address the financial burden associated with 
CCTs and associated cancer care.   
 Zafar et al. (2013) indicated that despite the presence of insured cancer patients, 
they nevertheless experienced high financial burden.  The data was collected from 254 
participants in a state with mandated insurance coverage for routine cancer costs, 
following enactment of the PPACA.  The median monthly out-of-pocket expenses for 
cancer care-related expenses for the samples were $456 (interquartile range was $213-
$827).  The majority of the sample (N = 190) was recruited from a non-profit 
organization providing financial assistance for payment of cancer care-related costs; the 
remaining participants were recruited from an academic cancer center.   Seventy-five 
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percent of the sample received financial assistance for costs associated with their cancer 
care, including payment for prescription copays, insurance premiums, and coinsurance.  
They were more likely to employ a host of cost-saving strategies to ease the financial 
burden accompanying payment of their prescription medication and cancer treatment,
4
 
than the other 25% of the sample who did not apply for financial assistance.  The use of 
at least one of these cost-saving strategies was correlated positively with high subjective 
financial burden (p < .01).  Although, not correlated significantly with race, high 
financial burden was correlated significantly with younger age (p < .001), large 
household size (p = .008), communications with physicians regarding costs (p = .020), 
and applying for financial assistance (p = .007).   
 The financial toxicity, or financial distress resulting from cancer treatment, 
extends to CCT decision-making (Nipp et al. 2016; Wong et al., 2016; Zafar et al., 2013).  
Although the sample in Wong et al. (2016) was broadly defined as “White” and “Non-
white,” the financial concerns expressed by the 1,211 participants were glaring and 
indicated distress and decisional conflict in CCT decision-making.  Prospective subjects 
who expressed financial concerns had lower self-efficacy (p =.004) and were less 
prepared ( p < .001) for CCT decision-making, as well as had greater distress ( p < .001) 
and decisional conflict ( p < .001) pertaining to CCT decision-making (Wong et al., 
                                                          
4
 The cost-saving strategies used by the participants to offset prescription medication, who also received 
financial assistance included: (1) receiving medication samples from oncologists (used by 63%, p < .001), 
(2) reduced spending on food and clothing (used by 53%, p < .001), (3) used credit or borrowed funds to 
pay for medication (used by 49%, p < .001), and (4) filled only a portion of the medication prescription 
(used by 24%, p = .029).  The cost-saving strategies used by participants to offset cancer care costs, who 
also received financial assistance included: (1) reduced spending on leisure activities (used by 73%, p = 
.005), (2) reduced spending on food and clothing (used by 51%, p = .021), and (3) used credit or borrowed 
funds to pay for medication (used by 42%, p = .001).   
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2016).  Clearly, barring changes to all CCT protocols affording coverage of all costs, the 
PPACA and the state laws mandating insurance coverage for CCT costs have not shown 
consistent association with access to CCTs.  Ambiguities exist in financial coverage for 
cancer care that permit insurers to deny coverage to CCTs offered by providers outside of 
a patient’s insurance network, to deny applicability of CCT insurance mandates to 
patients who are members of self-insured insurance groups, and permit insurers to 
determine what they consider standard, routine, and/or customary CCT care and costs 
(Martin et al., 2014).  Where the CCT insurance coverage mandates are lacking or 
inconsistently applied and when CCT protocols fail to cover all costs associated with 
participation,   prospective CCT participants may be incapable of shouldering the CCT 
out-of-pocket costs (Chun & Park, 2012).  
Review of Research on Real-time Data Capture 
Real-time Data Capture  
 The last section of this literature review will focus on a discussion of Real-time 
Data Capture (RTDC) as a methodological strategy to improve our understanding of the 
experiences of Blacks as they consider enrollment and participation in CCTs.  RTDC is 
the acquisition of self-reported health information “in real time in the real world” (Stone 
et al., 2007).  It is a data collection methodology which seeks to collect participants’ 
experiences as they unfold—thereby minimizing the occurrence of recall bias (Stone et 
al., 2007). RTDC is facilitated by the use of several participant data collection methods, 
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such as experience sampling or ecological momentary assessment (EMA).
5
  Typically, 
EMA is characterized by frequent and intensive acquisition of self-reported information 
and experiences as they occur within the individual’s own environment (Stone et al., 
2007). RTDC via EMA has been used by a multitude of research disciplines to study 
pain, depression, drug use, cancer-related pain and fatigue, smoking cessation, and sexual 
risk behavior as well as incident sexually transmitted infections (Hachizuka et al., 2010; 
Hacker & Ferrans, 2007; Hensel, Fortenberry, Harzelak & Craig, 2012; O’Connell et al. 
1998; Palmier-Claus et al., 2010; Shiffman et al., 2008).  It comprises a constellation of 
research methods and methodologies united by the following characteristics (1) 
recordation of participant behaviors and experiences as they occur in the natural 
environment, (2) assessment of a participant’s current, or most recent, behavioral or 
experiential state, (3) collection of data at strategic points in time, either random or 
centered on particular features or events of interest, and (4) use of multiple assessments 
to capture varied participant behavior and experiences over time or within situational 
contexts (Shiffman et al., 2008).  
Considerations Regarding the Use of Elements of EMA  
 EMA facilitates recording of the dynamic interaction of a participant with his 
environment, as well as how individual experiences and behaviors vary per 
environmental influences, contextual associations, or the concurrent interaction of 
phenomena (Shiffman et al., 2008; Stone et al., 2007). Recording a participant’s 
immediate experiences in the context of their environment produces ecologically valid 
                                                          
5
 Experience sampling requires participants to stop at specified times during the day and describe or record 
their experiences and behaviors (Stone et ao., 2007).    
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data potentially generalizable to the participant’s daily life and, possibly, to the real-
world experiences of similarly-situated individuals (Shiffman et al., 2008). EMA’s 
strength is its ability to reduce recall bias, or systematic errors in retrospective data self-
report, by focusing on a participant’s current emotional, mood, physiological, symptom, 
or psychological state (Shiffman et al., 2008; Stone et al., 2007).  
 Researchers utilize EMA in order to avoid the biased, imperfect memory 
constructed by individuals who typically summarize and aggregate their experiences, 
rather than recollect their experiences as discrete moments (Palmier-Claus et al., 2010; 
Shiffman et al., 2008; Stone et al., 2007). Memory retrieval is influenced unconsciously 
and involuntarily by momentary moods, emotional states, and physical symptoms 
(Shiffman et al., 2008). For example, researchers have found that individuals (1) in a 
negative mood are more likely to recall negative experiences, (2) experiencing pain have 
more difficulty remembering pain-free moments, or (3) are more likely to recollect events 
or experiences that occur more frequently and, therefore, are more readily available for 
self-report (Hacker & Ferrans, 2007; Shiffman et al., 2008; Stone et al., 2007). As a 
result, questionnaire and interview methods which seek retrospective attitudinal and 
detailed self-report information are subject to recall bias.   
 There are three types of data sampling with EMA:  time-based, random, and 
event-based.  Time-based sampling seeks to capture phenomena which may vary, occur 
continuously, or occur at fixed time intervals (Shiffman et al., 2008; Stone et al., 2007). 
Data collection may occur at fixed intervals, in order to acquire a summary of a 
participant’s experiences during the course of a day, while avoiding interruption of 
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desirable events such as meals (Hacker & Ferrans, 2007).  Researchers may choose 
random, or variable, intervals in order to obtain representative examples of participant 
behaviors, experiences, and psychological or mood states (Badr, Basen-Engquist, Taylor, 
& De Moor 2006).  Event-based sampling centers data collection on the occurrence of a 
specific event, behavior, or phenomenon, such as the urge to smoke, the intensity of pain 
during and after self-administration of pain medication, or the occurrence of risky 
behavior (Hachizuka et al., 2010; O’Connell et al., 1998).   In addition, researchers have 
combined both methods of data collection in order to capture not only the occurrence of 
specific phenomena, mood states, behaviors, or experiences, but also to document the 
environmental milieu and antecedent events surrounding their occurrence (Hachizuka et 
al., 2010).  
 Use of EMA in Cancer Research 
 EMA has been used in studies involving cancer patients to assess pain and mood 
states, measure fatigue preceding and following intensive chemotherapy, and evaluate 
sleep, mood, and physical symptoms in the period surrounding a chemotherapy cycle for 
breast cancer (Hachizuka et al. 2010; Hacker & Ferrans, 2007).  In Hachizuka et al. 
(2010), the investigators’ tested the use of a personal data assistant (PDA) (a small, hand-
held device utilized for computational and information storage/retrieval purposes) to 
collect real-time information on pain and associated symptoms (i.e., anxiety, nausea, 
depression, drowsiness, and fatigue) from 15 terminally-ill cancer patients, who were 
receiving home hospice care.  Their purpose was to devise a means of effectively 
assessing pain, and its associated symptoms, in order to improve the quality of life of 
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terminally-ill cancer patients. The investigators used this method to avoid patient use of 
retrospective recall to assess pain, since they felt retrospective recall produced biased 
data.  Moreover, there was concern that physicians’ personal assessments, and patients’ 
self-reports, of the pain experience were equally unreliable (Hachizuka et al. 2010).  As a 
result, the terminally-ill cancer patients used the PDA to record pain and associated 
symptoms several times a day over a one-week period at three distinct times: (1) at two 
random times during the day, (2) two to three times proximal to regularly scheduled pain 
medication administration, and (3) whenever the patients required additional pain 
medication for breakthrough pain.  The response rates for the random and regularly 
scheduled assessments were 90.3%; the response rates for the acute pain exacerbations 
were 80.2%. The researchers acknowledged that limitations included small sample size, 
unclear true compliance rates since the pain medication system was run voluntarily by the 
study participants, and only pain intensity was measured.  
 Hacker and Ferrans (2007) described their use of EMA as a data collection 
methodology to evaluate fatigue among cancer patients prior to, and subsequent to, a 
hematopoietic stem cell transplant (HSCT)
6
.  The researchers sought to determine the 
intensity, incidence, and timing of cancer, or cancer treatment-related, fatigue, in order to 
assist in its management and/or to enable the development of interventions to ameliorate 
its effects. They acknowledged the biasing effects of such factors as other intense 
symptom experiences and negative mood on accurate retrospective recall of fatigue 
                                                          
6
 Patients who receive a HSCT receive high-dose chemotherapy prior to instillation of the stem cells, either 
furnished by the patient or by another individual, in order to eradicate their immune system.  The stem cells 
function to replace the patients’ immune system with a new immune system free of cancer.   
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(Hacker & Ferrans, 2007).   The cancer patients used an Actiwatch three days before and 
three days after a HSCT, in order to measure their fatigue at baseline and when they were 
likely to experience the most severe effects of cancer treatment-related fatigue (Hacker & 
Ferrans, 2007).  The Actiwatch prompted the cancer patients to enter self-report fatigue 
data three times a day (at 10:00 a.m., 2:00 p.m., and 6 p.m.), as well as stored their self-
report data.  Using a repeated measures design, the researchers assessed that the patients 
were willing and able to provide real-time fatigue data.  For the first three days, the 
response rates were 90%, 83%, and 92%.  During this period, the patients experienced 
mild fatigue.  The patients had response rates of 82%, 94%, and 82% for the last three 
days, and reported moderate to severe fatigue.  Limitations included small sample size (N 
= 20 before HSCT, and N = 17 after HSCT) and measurement of fatigue at three set times 
during the day—other episodes of fatigue may have been missed,    
Summary and Gaps in the Literature 
 The purposes of this study were to identify and to describe the patient, family 
member, physician, and protocol factors Black cancer patients consider in CCT 
participation, as well as to understand their daily experiences as they navigate the CCT 
process.  There is no existing research explicating the daily experiences of Black cancer 
patients in CCTs.  Further, there is neither a theoretical framework, nor a study or group 
of studies, which definitively provides guidance for identifying and describing the 
complex level of factors that assist Black cancer patients in their research participation 
decisions.  Albrecht’s Model lists a select number of factors as influential in CCT 
enrollment, but does not define the nature or the specific attributes of these factors.  In 
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addition, there are a few qualitative research studies involving Black cancer survivors and 
their families and Black cancer patients who refused CCT participation, however, none of 
these studies include actively enrolled Black CCT patient-participants in their samples 
(Brown et al., 2013; Kehl et al., 2014; Owens et al. 2013; Somayaji & Gates, 2015).    
 Although trust and distrust is discussed extensively in the research literature as a 
barrier to CCT participation, it does not state to what extent CCT-enrolled Black cancer 
patients trust or distrust their oncology physicians, healthcare providers, and/or CCT 
teams, or how trust is engendered, just that distrust exists.  It is also not known whether 
CCT-enrolled Black cancer patients continue to exhibit cancer information-seeking 
behaviors prior to, during, or after CCT participation.  The impact of insurance, financial 
and economic pressures, and educational knowledge on potential out of pocket costs 
associated with CCT research participation needs more study, particularly with Black 
cancer patients, to better understand their needs in such trials.  Family member issues also 
remain an important component of CCTs.  For example, the reviewed studies did not 
address how CCT-enrolled Black cancer patients feel their family members support them 
at their initial CCT consultation, advocate for them during the CCT process, and enable 
them to cope with the daily emotional, physical, symptom, and financial pressures of 
living with cancer while participating in a CCT.  Neither did the reviewed studies for this 
dissertation address the challenge that Black cancer patients might feel by disclosing a 
cancer diagnosis along with ensuing CCT participation to spouses, companions, children, 
and employers.  Some literature discusses transportation issues and other logistical 
burdens as well as fear of physical burdens of research participation (Ulrich, et al, 2016) 
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such as side effects.  But, a gap still exists in understanding Black CCT cancer patients’, 
balancing of symptom burden, CCT treatment appointments, and on-going employment 
with caregiving responsibilities for children and parents.       
 Interventions responding to these questions would do much to close the gap 
between Black cancer patient mortality and CCT participation.  Arguably, until these and 
many other questions are answered, how can researchers hope to understand why Black 
cancer patients enroll in CCTs in numbers inconsistent with the cancer burden they bear? 
Rather than relying on surveys with predetermined answers, the qualitative descriptive 
design of this dissertation study along with some elements of RTDC will help give voice 
to CCT-enrolled Black cancer patients.  This will afford Black CCT participants an 
opportunity to share their experiences in their own words and to answer the many un-
asked questions regarding the influence of patient, family member, physician, and 
protocol factors on their CCT research participation activities.  Qualitative description 
plumbs the perceptions and sensitivities of a target population (here, Black cancer 
patients), absent transformative interpretation by the researcher—since its purpose is to 
describe an event or phenomenon (Sandelowski, 2000; and Sullivan-Bolyai, Bova, & 
Harper, 2005).   Finally, this dissertation study has begun to fill slowly the cavernous 
gaps in nursing research concerning how the daily experiences of Black cancer patients 
impact their continued CCT participation and how these experiences can be used to 
develop patient-, family- and community-based resources for future Black cancer patients 
seeking to navigate the CCT process.    
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CHAPTER III:  METHODLOGY 
Introduction 
The primary purposes of this dissertation study were to identify and describe the 
patient, family member, physician, and protocol factors that Black cancer patients 
consider important when participating and remaining in CCTs and to record in real-time 
their everyday experiences as Black cancer patients navigate the CCT process.  This 
chapter will present the research design, sample and setting, sampling procedures, data 
collection procedures, data analysis, and human subject protections.   
Research Design 
 
 This study used a multimethod approach and primarily focused on a qualitative 
descriptive design with semi-structured face-to-face interviews
7 
and cell phone interviews 
with Black cancer patients involved in CCTs, and secondarily, descriptive quantitative 
items of the sample’s sociodemographics and a measure of symptom burden (the 
Memorial Symptom Assessment Scale-Short Form).  Elements of real-time data capture 
were also used to understand patient-participants’ everyday qualitative experiences in 
CCTs.  A multimethod approach is appropriate when the researcher uses two types of 
data collection methods to understand the research problem; and, the data are not usually 
combined (Tashakkori & Teddlie, 2003).  As stated, the qualitative descriptive design 
                                                          
7
 The “face-to-face” interview was defined, and intended, to be the initial interview conducted and 
immediately proximal to completion of the Informed Consent form, the HIPAA Authorization, the 
Sociodemographic form, and the Memorial Symptom Assessment Scale-Short Form.  For this reason, it 
was considered the face-to-face interview.  It was conducted in the patient-participants’ private infusion 
room or in a private room in the Radiation Oncology department.  Three patient-participants requested the 
initial interview to occur at a later time in their homes.  Since the patient-participants routinely used cell 
phones, the initial interviews were conducted via cell phones.  These three initial. “face-to-face” interviews 
were included only in the Specific Aim One data. 
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was primary in this study and is appropriate when one wants to describe the perceptions 
and experiences of the target population, as well as an accurate accounting of the 
phenomena and events surrounding occurrence of the phenomena (Sandelowski, 2000; 
Sullivan-Bolyai et al., 2005).  Qualitative description enables a “straight descriptive 
summary of the informational contents of data organized in a way that best fits the data 
(Sandelowski, p. 338-339, 2000).”  A broad range of data may be used to describe the 
phenomenon, or event, under study.  However, the descriptions must depict accurately 
the event in the proper sequence and have descriptive validity, or present an event in a 
manner that individuals observing the event would state is truthful (Sandelowski, 2000).   
Qualitative description is the preferred method for this dissertation study for 
several reasons. First, it provides a rich description of the experiences of Black cancer 
patients during the CCT process; second, it identifies and explains the nuances of external 
and internal influences on treatment decision-making; third, it grounds the patient-
participant’s experiences and perceptions within the context of a specified event—CCT 
participation, and; fourth, it ascertains the elements of a patient-participant’s intra- and 
inter-personal experience which cannot be quantified by a questionnaire (Hsieh & 
Shannon, 2005; Kearney, 2001; Sofaer, 1999).  Use of qualitative description permits 
chronicling of CCT experiences in the everyday language of the patient-participants, 
while shedding light on what was happening outside of the clinical setting as the patient-
participants navigated through the clinical trial process and the daily events of their lives.  
Qualitative content analysis, the preferred method of analysis for qualitative description, 
is used to analyze the semi-structured face-to-face interviews and the semi-structured cell 
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phone interviews with both a deductive and inductive lens (Sandelowski, 2000).  This is 
described later in the chapter. 
Setting and Sample 
  A large northeastern Cancer Center, a National Cancer Institute-designated (NCI-
designated) comprehensive cancer center, was the setting for this dissertation study. In 
2010, this Cancer Center enrolled 1,322 individuals in therapeutic cancer clinical trials.  
Of this number, 242 individuals who self-identified as Black or African American were 
enrolled in these specific types of cancer clinical trials.  For the purpose of this 
dissertation study and as defined by the Cancer Center, a therapeutic cancer clinical trial 
was defined as a cancer clinical trial with curative intent that uses ”drugs, radiation, 
surgery, other biological agents, or behavioral or other interventions” (Vicki Sallee, 
personal communication, July 8, 2011).  
  The sample for this study was drawn from a purposive sample of Black cancer 
patients enrolled in CCTs at the Cancer Center’s outpatient oncology departments.  The 
outpatient setting was chosen to minimize the likelihood of severe symptom burden.  
Patient-participants who were 18 years of age or older were drawn from the following 
types of CCT:  breast, colorectal, lung, prostate, multiple myeloma, leukemia, cervical, 
pancreatic, head and neck (oral cavity, pharynx, and esophagus), gastric, liver, and 
uterine.  Of these cancers, breast, prostate, lung, and colorectal cancer are the four 
leading causes of cancer death among Black cancer patients and have the highest 
incidence among Black adults with cancer (National Cancer Institute, 2012).  In the 
remaining cancer types, Black men and women had higher incidence rates than White 
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men and women (DeSantis et al., 2016).  Both men and women were eligible to 
participate in the dissertation study.  Transgender individuals were not excluded from the 
study.  Children were not included in this study, because the study was focused on adults 
with cancer.   
Sample Size 
 The projected sample size for this study was 30 patient-participants who self-
identified as Black.  This original sample size was estimated to be 30 for two reasons: 
first to gather data qualitatively from a heterogeneous sample of cancer patient-
participants, and second, to quantitatively compare symptom burden at two different time 
points (see below for discussion of this approach).  First, qualitative researchers have 
agreed that there is no principal rule for absolutely determining the appropriate sample 
size for a qualitative study (Patton, 2002; Sandelowski, 2000; Waltz, Strickland & Lenz, 
2010).  However, the sample size chosen must provide the relevant information to answer 
the research questions being posed and provide information-rich qualitative data to 
describe the phenomenon being studied (Malterud, 2001: Sandelowski, 2000; Patton, 
2002, Waltz et al., 2010).  Based on leading qualitative methodologists, 20-30 patient-
participants usually are adequate to reach saturation, or when no new themes or patterns 
emerge from the data (Granehiem & Lundman, 2004; Hsieh & Shannon, 2005; Im & 
Chee, 2006; Sandelowski, 1995).  Second, to quantitatively compare participants’ 
symptom burden at two different time points, a sample of 30 achieved 80% power to 
detect a mean of paired differences equal to 0.4 with an estimated standard deviation 
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equal to 0.7 and with a significance level (alpha) of 0.05 using a two-sided paired t-test 
(Hofso et al., 2012)  
 Inclusion criteria for the study included cancer patients who were male, female, or 
transgender and who self-identified as Black and were 18 years of age or older;  had a 
diagnosis of any of the following cancers:  breast, gynecologic (uterine, cervical), 
gastrointestinal (colorectal, gastric, liver, pancreatic), lung, genitourinary (prostate), 
hematological (multiple myeloma, leukemia), and head and neck (oral cavity, pharynx, 
and esophagus); subjects actively participating in a CCT occurring in the outpatient 
setting for a minimum of one month; able to speak, read, write, and understand American 
English; and able to provide informed consent. Exclusion criteria included participation 
in a CCT as a palliative measure, enrollment in hospice or palliative care, inability to 
speak, read, write, or understand American English because of a physical, cognitive, or 
anatomic impairment, and inability to provide written consent.   
 A total of 21 patient-patient-participants successfully were recruited.  The 21 
patient-participants provided a total of 21 semi-structured face-to-face interviews and 45 
semi-structured cell phone interviews.  The face-to-face interviews range in length from 
30 minutes to 120 minutes, while the cell phone interviews range in length from 15 
minutes to 60 minutes.  Nine patient-participants answered the items on the symptom 
burden (MSAS-SF) scale at baseline and again at the completion of all four time points 
for the cell phone interviews.  Data saturation was reached for the qualitative portion of 
this study with 21 participants, when no new information emerged from the qualitative 
data (Guest, Bunce, & Johnson, 2006).   
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Data Collection Procedures 
   Once approval was acquired from the IRB, the Clinical Trials Scientific Review 
and Monitoring Committee (CTSRMC), and the oncology attending physicians, eligible 
prospective patient-participants were contacted in person in order to acquire their assent 
to discuss this study. If assent was given, the doctoral candidate described this study to 
the prospective patient-participant, who was given the Informed Consent and HIPAA 
Forms to take home to review at their leisure with their families.  A minimum of two 
attempts were made to re-connect with prospective patient-participants to discuss the 
Informed Consent and HIPAA Forms in person on the day of an outpatient appointment 
at the Cancer Center.  If these attempts were unsuccessful, she attempted to contact them 
by cell phone or by their home telephone, where applicable. As stated, five prospective 
patient participants could not be contacted. 
 For those who chose to participate, the prospective patient-participants were met 
at their next appointment at the Cancer Center to discuss further the study and to obtain 
formal, written informed consent and HIPAA approval.  Also, during this meeting and 
after acquisition of Informed Consent and HIPAA, a semi-structured face-to-face 
interview was performed and socio-demographic and symptom burden data were 
collected, when possible.  Occasionally, due to the patient-participants’ schedules, 
personal preference, or symptom burden, the semi-structured face-to-face interview, 
socio-demographic data, and/or symptom burden data were collected at another meeting 
or by cell phone.  Twenty of the twenty-one patient-participants completed the face-to-
face semi-structured interview, socio-demographic form, and the MSAS-SF.  As stated, a 
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modification was sought and received to retain only the face-to-face interview of one 
patient-participant.  This participant did not complete the socio-demographic form and 
MSAS-SF.  Cellphones were also used in this study as a means to speak with participants 
about their everyday experiences related to cancer clinical trials over time and within 
their situational contexts (this is discussed under Elements of RTDC) (See Figure 3-2 in 
Section Discussing Real Time Data Collection). 
8
 
Semi-structured Interview, Demographics, and Assessment of Symptom Burden 
  A socio-demographic form and symptom burden measure, the Memorial 
Symptom Assessment Scale, Short Form (MSAS-SF), were administered to each patient-
participant following acquisition of informed consent and HIPAA approval.  The MSAS-
SF measure provided information about physical and psychological symptom burden 
(e.g., fatigue, loss of appetite, irritability, feeling sad).   The MSAS-SF was given a 
second time to patient-participants who completed all four cell phone interviews.  The 
intended purpose was to perform an assessment of symptom burden at baseline and then 
following completion of the four cell phone interviews for all enrolled patient-
participants.  Twenty of the twenty-one patient-participants completed the MSAS-SF at 
baseline.  Only nine patient-participants completed the MSAS-SF at both time points (see 
Chapter 4 for baseline descriptive data).   
 The face-to-face interview was expected to last approximately 45-60 minutes.  It 
was comprised of several open-ended questions, approved by the IRB, and adapted from 
                                                          
8
 At the time the doctoral candidate applied successfully for F31 funding (1F31NR013847-01A1) from the 
dissertation study from the National Institutes of Health in 2012, the use of cell phones to collect qualitative  
data was considered novel. 
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Figure 3-1:  Brief Telephone Interview 
Questions for Real-Time Data Capture 
1. How are you today?  Can you briefly 
describe how you are feeling today?  How 
long have you been in the trial at this point? 
 
2.  Would you briefly describe (in your own 
words) ONE EVENT today that stands out in 
your mind related to your participation in the 
CCT.  The event you describe can be positive, 
negative, or neutral. 
 
3.  In your own words, briefly describe your 
experience with the clinical research team.  
What has been helpful or not so helpful in 
your care and treatment? 
 
4.  Can you share and describe any symptoms 
that you have been experiencing and how you 
are managing them. This can be of any type 
that is important to you.   
 
5. What are the challenges that you have been 
facing as you continue to participate in the 
cancer clinical trial? Can you share a few of 
these that are most important to you?   
 
 
Ulrich et al. (2012) (e.g., “I would like to start by having you tell me in your own words 
what made you decide to enroll in a CCT”) accompanied by spontaneous and planned 
probes to clarify patient-participants’ thoughts on the relevant aspects of CCT 
participation (See Appendix A).  The semi-
structured face-to-face and cell phone 
interviews were conducted by the doctoral 
candidate. 
Adapted Use of Element of Real-Time Data 
Capture (RTDC) and Procedures for Cell 
Phone Interviews  
 Adapting elements of RTDC via EMA 
enabled patient-participants to self-report their 
present, or most recent, (1) thoughts and 
experiences about participation in clinical trials 
in their own words, (2) advantageous and 
disadvantageous factors influencing their continued participation in their specific clinical 
trial, and (3) experiences navigating the clinical trial process.  By using elements of 
RTDC, recall bias was reduced by focusing on patient-participants’ immediate, or most 
recent, experiences as they occurred within the context of their environment.  During the 
course of their CCT enrollments, patient-participants self-reported symptom distress, 
such as fatigue and pain—all of which may have influenced their self-report.  RTDC 
afforded the ability to gather self-report data in each patient-participant’s environment 
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and to identify contextual associations, or the concurrent interaction of phenomena such 
as events or experiences, which may have impacted decisions to participate or remain in 
CCTs.  This was done through the use of cell phone interviews with a combination of 
random and event-based data collection methods. Event-based sampling involves data 
collection concentrated around a specific occurrence or experience; in this dissertation 
study, it was centered on patient-participants’ scheduled CCT outpatient appointments 
(Stone et al., 2007).    The four cell phone interviews were also conducted randomly, (i.e., 
at variable intervals in order to collect representative examples of experiences), during a 
patient-participant’s waking hours and ideally within 24-48 hours of a patient-
participant’s outpatient appointment with a member of the CCT team (i.e., oncologist, 
nurse practitioner, or clinical trial research nurse) (Badr, Basen-Engquist, Taylor, & De 
Moor, 2006).  Patient-participants were instructed to self-report information, impressions, 
and/or experiences as of that moment, rather than provide a summary of this information.  
By using cell phones to collect qualitative experiential data in real-time, instances of 
recall bias may have been avoided.    
 The five basic questions in Figure 3-1 were used initially during the first real-time 
telephone interview to gather the patient-participants’ real-time life issues associated with 
their participation in their respective trial.  These questions were sufficiently general to 
elicit a broad range of responses, which could be narrowed or clarified through the use of 
spontaneous and planned probes.  For example, the questions ascertained how the patient-
participants’ were feeling and their general thoughts on their participation in the trial.  In 
addition, the patient-participants were asked questions about symptoms that might impact 
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their thoughts on continued participation and also any challenges they were currently 
facing.  Each subsequent real-time interview was uniquely representative of the patient-
participant’s experiences and perceptions of CCT decision-making factors for that day.  
As is standard in qualitative methodology, the cell phone interview questions changed 
slightly each time a patient-participant was called to reflect the effect of on-going data 
analysis and the acquisition of new information regarding patient-participants’ 
experiences.     
 Each patient-participant was called four times over a two-month period (i.e., six 
to eight weeks).  If the patient-participant was non-responsive when called, the doctoral 
candidate attempted three more times at five minute intervals to contact the patient-
participant.  If the patient-participant remained non-responsive, she attempted to contact 
the patient-participant again 24 hours later—using the same procedure.  If the patient-
participant continued to remain non-responsive, the doctoral candidate attempted to 
contact the patient-participant 24-48 hours proximate to when their next outpatient 
appointment was performed.  At the end of the two-month study period, each patient-
participant was given an opportunity to ask any final questions, and to review several 
portions of their interviews to confirm they were accurate representations of their 
responses. Patient-participants who were unable to complete all four cell phone 
interviews (and who were not lost to follow-up) also were given an opportunity to ask 
any final questions.    
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Figure 3-2: Data Collection Procedure 
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Privacy During Data Collection  
 Initial semi-structured interviews were administered in private rooms where 
patient-participants received their CCT treatment, or in a private room in the radiation 
oncology department provided by the Director of Clinical Research (for the patient- 
participants receiving radiation therapy). Three patient-participants’ requested that their 
initial interview be conducted via cell-phone while they were in their homes.  For all 
interviews, privacy procedures were maintained.  
 For any cell phone interview (initial, if requested, and for those that took place as 
part of the second aim),the doctoral candidate ascertained (according to the subject’s 
willingness to provide this information) (1) where the patient-participant was located and 
whether a secondary telephone number at the location was available, (2) who was present 
in close proximity and their contact information, (3) whether the patient-participant felt 
safe and secure where they were located, (4) whether the patient-participant felt 
comfortable sharing private information and/or information related to their cancer clinical 
trial over the phone, (5) whether the patient-participant had any resources in close 
proximity or readily available in case of severe symptoms (e.g., oxygen or 
bronchodilators for breathlessness or shortness of breath, or the telephone number of their 
physician or a caregiver who can be contacted immediately), and (6) in case of a medical 
emergency, whereby the patient-participant was unable to respond to first responders on 
the scene and provide medical information, the doctoral candidate had permission to 
provide the patient-participant’s private medical information. 
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  To address privacy
9
 concerns, the doctoral candidate also developed a formal, 
verbal script to be used during the course of cell phone interviews that included the 
following sample queries prior to the initiation of the interview as required by the IRB: 
• “Are you comfortable talking to me at this point? Are you by yourself or are there 
other individuals present? Is this okay with you? Would you like me to call you back at 
another time to protect your privacy?”  
• “At this moment where are you located?  Is someone close enough to you to hear 
your conversation with me?  If someone is close enough to hear our conversation, are you 
comfortable with that person listening to our conversation?”   
“If yes, do you want me to start our conversation about your experiences in your 
cancer clinical trial?” “If no, would you like me to call back at another time?  Would you 
like to move to a place where you can answer my questions without anyone listening 
nearby?” 
 To further ensure the privacy of the patient-participants, the doctoral candidate 
included the formal, verbal script in the IRB application and collected all information in 
the aggregate so that personal information was not identifiable. In addition, prior to 
initiating the cellphone interviews, each patient-participant was told that the cellphone 
conversation was being audio-recorded and asked their permission to audio-record the 
conversation.  Finally, HIPAA requirements were followed for the collection of private 
information during the course of the cellphone interview 
                                                          
9
 Privacy is the right of an individual to control access to their personal, or private, information. Private 
information is inclusive of information occurring in the context that the individual would not expect 
recording or observation to occur, is provided for a specific purpose, and is provided with the expectation 
that the information will not be made public.   
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Human Subjects Protection 
 This study involved data collection from individuals actively involved in a 
therapeutic CCT.  Approval from the IRB and the CTSRMC were obtained on August 13, 
2013, and June 27, 2013, respectively, before the proposed study was initiated.  Upon 
agreeing to participate and completing the Informed Consent and HIPAA documents, 
each patient-participant was assigned a patient-participant number for confidentiality 
purposes.  Further, each patient-participant received a pseudonym to be used throughout 
the entire study as part of all qualitative interviews.  Patient-participants were permitted 
the opportunity to choose their pseudonym.  Two patient-participants refused 
pseudonyms; they were assigned a pseudonym.  The patient-participant number and 
pseudonym were matched and recorded on a document.  This document and all data (hard 
copies of written documents, including field notes, transcripts, and audio-recordings) in 
the proposed study, were stored at the University of Pennsylvania School of Nursing in a 
locked drawer in a locked office specifically dedicated for research files.  Only the 
doctoral candidate and members of the Dissertation Committee (Study Personnel) had 
access to the data. 
 A telephone located in a locked, secured office at the University of Pennsylvania 
School of Nursing was used to call the patient-participants for this study. The interviews 
(face-to-face and cell phone) were audio-recorded using a password-protected digital 
audio-recorder.  A research database was created and stored on a password protected 
secured drive at the University of Pennsylvania School of Nursing.  Access to the 
database was available only to Study Personnel.  All interviews were transcribed by a 
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professional transcription service.  The transcribed interviews were scanned into a 
dedicated, password-protected, research computer drive for review by the doctoral 
candidate and her sponsors.  All research drives are backed up daily by OTIS.  The data 
on the research drive will be housed for five years and then destroyed.  Finally, 
anticipation of the possibility of severe symptoms occurring during the cell phone 
interviews was addressed by developing an Emergency Action Plan to deal with any 
situation in which a patient-participant experienced severe symptoms during the cell 
phone interview.  The Emergency Action Plan was not implemented during the course of 
the study.   
Compensation 
 Patient-participants were compensated the equivalent of a $5.00 gift card for the 
initial face-to face interview, the initial MSAS-SF assessment, each successfully obtained 
cell phone interview, and the final MSAS-SF assessment.   Use of personal time and the 
risk of temporary fatigue were the most reasonably foreseeable burdens of this research 
study.  For the entire study period, a patient-participant had the opportunity to receive 
$35 for their involvement.  This mode of payment was consistent with the wage-payment 
model which is based on the premise that research patient-participants should be paid on 
a payment scale commensurate with unskilled labor, provided that the payment is 
augmented for uncomfortable or burdensome procedures (Dickert & Grady, 1999).   
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Instrumentation 
Demographic and Clinical Characteristics 
 A socio-demographic form collected demographic information from the patient-
participants, such as age, gender, educational level, insurance status, and marital status. 
(See Appendix D).  Clinical factors gathered included items such as medical history, 
cancer diagnosis, stage of cancer, healthcare coverage and benefits, caregiver and social 
supports, and communication with healthcare providers.  Data from the socio-
demographic form were supplemented by data from the patient-participants’ electronic 
medical record. 
Memorial Symptom Assessment Scale-Short Form (MSAS-SF) 
 The MSAS-SF is a shortened form of the Memorial Symptom Assessment Scale 
(MSAS) (See Appendix E).  The MSAS-SF is a 32-item, patient-rated instrument that 
measures the most common physical and psychological symptoms experienced by cancer 
patients during cancer treatment; it also includes a global distress scale (Chang et al., 
2000; Portnoy et al., 1994; Trammer et al., 2003; Kirkova et al. 2006). The benefits of 
using the MSAS-SF were three-fold: (1) it contained one-third the number of items of the 
original measure; (2) it took approximately five minutes to complete; and, (3) it captured 
the important components of physical and psychological burden (Chang et al., 2000).  
The MSAS-SF had subscales measuring physical symptom distress (PHYS), psychologic 
symptom distress (PSYCH), and a 10-item global distress index (GDI). Also, a total score 
was calculated and represented an average of the symptom scores (TMSAS).  Items in the 
MSAS-SF were measured on a Likert scale from 0 (no symptoms) to 4 (symptom present 
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and causes very much distress) for the PHYS symptoms and from 0 (symptom is absent) 
to 4 (symptom is present and occurs constantly) for PSYCH symptoms (see Appendix). 
For the PHYS and PSYCH scales, a higher number indicates greater symptom distress 
and increased presence of physical and psychological symptoms, respectively. 
Psychometric Properties of the MSAS-SF 
 The psychometric properties of the MSAS-SF include both reliability and validity 
testing. Internal consistency Cronbach alpha coefficients for the MSAS-SF subscales 
were:  0.80 for the GDI; 0.82 for the PHYS; 0.76 for the PSYCH; and 0.87 for the 
TMSAS (Chang et al., 2000).  It also had been shown to exhibit convergent validity with 
extent of disease, performance status, and inpatient status (Chang et al., 2000).  The GDI 
has an internal consistency reliability of 0.87.   
 The MSAS-SF also has demonstrated convergent validity with the Functional 
Assessment Cancer Therapy General (FACT-G), a general, validated 28-item measure of 
quality of life for all cancer types (Chang et al., 2000).  It has been used among patient-
participants in cancer clinical trials and has demonstrated sensitivity for determining 
performance status and extent of disease (Chang et al., 2000). For criterion validity, 
assessment of the MSAS-SF subscales with the FACT-G subscales showed the following 
correlation coefficients:   -0.74 (P < 0.001) for the MSAS-SF physical symptom 
subscales and the FACT-G physical well-being subscales, -0.68 (P < 0.001) for the 
MSAS-SF psychological subscales and FACT-G emotional well-being subscales, and -
0.70 (P < 0.001) for the MSAS-SF global distress scale and the FACT-G summary of 
quality-of-life subscales (Chang et al., 2000).   
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Qualitative Data Analysis 
 Qualitative data for this study were analyzed using qualitative content analysis 
(Graneheim & Lundman, 2004; Hsieh & Shannon, 2005).  Qualitative content analysis is 
a qualitative research method that is used for the “subjective interpretation of the content 
of text data through the systematic classification process of coding and identifying 
themes or patterns (Hsieh & Shannon, p. 1278, 2005).”  It can be employed to validate an 
existing conceptual or theoretical framework (directed content analysis) or to elucidate 
phenomena for which a paucity of research exists (inductive content analysis) (Hsieh & 
Shannon, 2005). Content analysis of the text-based information from the audio-taped 
interviews was instrumental in identifying and describing the decisional factors that 
influenced the patient-participants research decisions (deductive approach), as well as 
their everyday experiences in CCTs (inductive approach).  The face-to-face interviews 
and cell phone interviews were audiotaped, transcribed verbatim by a professional 
transcription service, and loaded onto a computer for analysis using ATLAS software.  
Field notes were entered in ATLAS software and analyzed, as well.  Confidentiality of 
the data was maintained at all times consistent with IRB guidelines and HIPAA 
requirements (see Human Subjects).  Content analysis began with reading the text data in 
their entirety repeatedly, in order to get a sense of the data.  From this point, the analytic 
path diverged, depending upon whether directed content analysis, or inductive content 
analysis, was employed (See Figure 3-3).     
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 Directed content analysis was used for analysis of data for the first specific aim.  
Characterized by a more structured process based upon existing theory or theoretical 
framework, Coding was begun by using the four factors of the Albrecht Model (patient, 
family member, physician, and protocol) as initial coding themes (Hsieh & Shannon, 
2005). Coding of the initial semi-structured interviews continued based upon the four 
themes and moved on to the two categories for this aim:  CCT participation and CCT 
retention (Elo & Kyngas, 2008).  From there, analysis progressed to sub-categories where 
the depth and breadth of the data permitted—then, the data was coded (first level codes 
were collapsed into second level codes) according to the categories and sub-categories 
(Elo & Kyngas, 2008; Hsieh & Shannon, 2005).   
 Inductive content analysis was used for Specific Aim Two.  Text was extracted 
from the four cell phone interviews that took place after the initial interview at baseline 
and was divided into content areas, characterized by common patterns, phrases, and 
important features.  The language was categorized into groups with similar meanings and 
themes emerging from the categories were identified (Graneheim & Lundman, 2004; 
Hsieh & Shannon, 2005). Last, commonalities and differences between the data were 
identified and extracted for further analysis, formalization of themes from the data were 
drawn, and the themes were analyzed and compared.  The following also were 
formulated from the data: (a) meaning units, (b) condensed meaning units, (c) codes (first 
level codes were collapsed into second level codes), (d) a list of codes, (e) codes with 
quotes or exemplars, (f) a frequency table for the occurrence of codes, (g) sub-categories 
(where applicable) and categories, (h) themes, and (i) matrices displaying the themes, 
66 
 
categories, sub-categories (where applicable), and codes (Curry, Nembhard, & Bradley, 
2009; Elo & Kyngas, 2008; Graneheim & Lundman, 2004). Codes were in vivo for both 
directed and inductive content analyses.  Data were reviewed by the Dissertation Chair, 
the Qualitative Methods Consultant,  by senior members of the Advanced Qualitative 
Collective (Sarah Abboud, PhD, RN; Elizabeth Froh, PhD, RN; and Kim Mooney-Doyle, 
PhD, RN), and the  Advanced Qualitative Collective, a group of doctoral and post-
doctoral students from the University of Pennsylvania School of Nursing and other 
academic departments of the University of Pennsylvania who, facilitated by a faculty 
member of the University of Pennsylvania expert in qualitative research, met on a regular 
basis to provide support and study of qualitative inquiry.  
Scientific Adequacy and Rigor 
 Scientific adequacy and rigor in qualitative studies required adherence to well-
established practices that ensured trustworthiness.  Trustworthiness, or what is considered 
the reliability and validity of qualitative research, was measured by credibility, 
dependability, and transferability (Curry, Nembhard & Bradley, 2009; Graneheim & 
Lundman 2004).  Credibility was the certainty that the data and analytical processes 
address the phenomenon being studied and in this case reflects patient-participants’ 
experiences in CCTs (Graneheim & Lundman, 2004; Sandelowski, 1986).  Member 
checks were an acceptable means of ensuring credibility by confirming that the 
respondents’ accounts were accurate representations of their experiences (Curry, 
Nembhard & Bradley, 2009).   At their final meetings, the nine patient-participants who 
completed all four cell phone interviews reviewed portions of their qualitative data for 
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accuracy.  At the completion of data collection and following completion of the data 
matrices, member checks were conducted with three patient-participants to determine 
whether the data accurately represented their experiences and the factors that influenced 
their decisions to participate and to remain in their CCT.  Credibility also was maintained 
because the individuals comprising the sample were heterogeneous
10
 and provided a 
variety of thoughts on the issue under study (Graneheim & Lundman, 2004).  
Confirmability was achieved by leaving a clear decision trail during the research process 
for others to review.  An audit trail was maintained by providing clear descriptions of the 
doctoral candidate’s progression throughout the research process (from IRB application 
through data analysis).  This includes the data collection process and outcomes, decisions 
and judgments in data analysis (formulation of meaning units, codes, categories, etc.), 
and scheduled meetings with the Dissertation Chair and the senior members of the 
Advanced Qualitative Methods.  An additional independent coder was not used as part of 
this dissertation study.  
The use of independent coders to verify qualitative analysis was not strictly 
required. As noted by Wu, Thompson, Aroian, McQuaid, and Deatrick (2016), the goal 
of qualitative analysis is the training of qualitative researchers to be rigorous in data 
gathering, as well as using systematic procedures to document decision-making.  
Moreover, rather than  “evaluating if two independent raters came to the same numeric 
rating, reviewers of qualitative manuscripts should judge to what extent the overall 
process of coding, data management, and data interpretation were systematic and 
                                                          
10
 Although all patient-participants self-identified as Black, they were heterogeneous in areas such as 
cancer type, cancer stage, age, education level, and place of residence.     
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rigorous” (Wu et al., p. 500, 2016).  To this end, the formulation of codes, sub-categories 
(where applicable), categories, themes, and data matrices were reviewed and refined at 
various points during analysis of the data with the Dissertation Chair, the Qualitative 
Consultant, the senior members of the Advanced Qualitative Collective, and the other 
members of the Advanced Qualitative Collective.  Memoranda of the meetings with all 
relevant parties also were kept to ensure auditability or replication of the same study 
results by another researcher (Graneheim & Lundman, 2004; Sandelowski, 1986).   
 To ensure dependability of the research, there was consistency in the data 
collection methods and, again, scheduled meetings with the Dissertation Chair to assess 
consistency, similarities, and differences in the data (Graneheim & Lundman, 2004).  
Finally, to ensure transferability, the doctoral candidate provided clear descriptions of the 
sample characteristics, sample selection methods, and data procurement methods and 
analyses (Graneheim & Lundman, 2004).     
Data Management and Quality Control 
 To maintain data quality and control, there were scheduled meetings with the 
Dissertation Chair to address any issues that might arise in the course of the study. Here, 
issues surrounding the consistency of the face-to-face and cell phone interviews, data 
saturation, development of key themes and patterns related to the data, and data 
classification, summarization, categorization, and coding were discussed.  In addition, 
any ethical considerations (such as informed consent or respondent burden) that arose 
were discussed and addressed (See Human Subjects section).    
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Quantitative Data Analysis 
 Descriptive statistical analysis is used to summarize the information from the 
socio-demographic form and the MSAS-SF.  Representative statistics include measures 
of central tendency, including means, variances, standard deviations, and frequencies.  A 
descriptive analysis of the MSAS-SF data is presented in Chapter 4 and provides 
important information for future research and hypothesis generating questions. SPSS was 
used to store quantitative data reported in the aggregate.  Data was housed on a research 
database created and stored on a password protected secured drive at the University of 
Pennsylvania School of Nursing. Data were entered twice in SPSS and checked for 
accuracy and completeness.  Furthermore, data were reviewed with a statistician at the 
School of Nursing (Dr. Alexandra Hanlon) for completeness, processing, and 
interpretation.  There were no missing data for the MSAS-SF and the socio-demographic 
form. 
Summary 
 In summary, this chapter presents the research design, methodology, data 
collection procedures, data analysis, and human subjects protections used to address the 
purpose of the dissertation research.  Qualitative description methodology captures the 
rich experiences of Black cancer patients actively enrolled in therapeutic CCTs.   
Analysis of data collected from semi-structured face-to-face interviews and semi-
structured cell phone interviews via RTDC presents a rich, descriptive accounting of the 
patient-participants’ CCT and every day cancer experiences, as well as a more complete 
representation of the Black cancer patients’ symptom experience.   
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CHAPTER IV:  FINDINGS 
 This chapter describes the findings of the research.  It begins with an overview of 
the sample, wherein demographic information and descriptions of the members of the 
sample are provided. There will also be a presentation of the data results of the MSAS-
SF.  Next, an overview of the qualitative findings will be presented.  Last, the two 
specific aims are addressed individually through explanation of the themes, categories, 
and sub-categories that emerged from the data. Supporting evidence from interviews is 
included.  Themes are in bold font and underlined, categories are in bold font, sub-
categories are italicized and underlined, and components (codes) are italicized. 
Recruitment of Sample 
 Following receipt of approval from the Institutional Review Board at the 
University of Pennsylvania and the CTSRMC, the doctoral candidate sought and received 
email approval from oncology attending physicians to access and to recruit their patients 
enrolled in outpatient therapeutic CCTs.  A meeting was held with the Cancer Center’s 
clinical trial coordinators and clinical trial research nurses to discuss the purpose of the 
dissertation study.  At this meeting and in the emails sent to the oncology attending 
physicians, written IRB and CTSRMC approval and appropriate supporting documents 
describing the dissertation study were provided.  The Cancer Center’s Regulatory Affairs 
Program Manager and the Director for Clinical Research for Radiation Oncology assisted 
the doctoral candidate in identifying the Black cancer patients who were enrolled in, or 
would be accruing to, eligible CCTs.   
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 Both administrators provided lists of prospective patient-participants from 
October 2013 to November 2014, who were enrolled in CCTs in the cancers and cancer 
types eligible for recruitment for the dissertation study. The 48 prospective patient-
participants identified by the two administrators were reduced to 46, following removal 
of duplicate records.  The doctoral candidate reviewed the records of the 46 prospective 
patient-participants, individually as the lists were received, to determine eligibility for the 
dissertation study.  Nineteen patient-participants were deemed ineligible on the following 
bases:  (1) physically unable to participate secondary to laryngectomy (n = 1); (2) 
withdrawn from CCT before recruitment made by doctoral candidate (n = 3); (3) 
administrator listed prospective patient-participant enrolled in non-therapeutic CCT(n = 
8); (4) self-identified as White (n = 2); (5) not enrolled in CCT (n = 1); (6) less than two 
appointments per month per CCT protocol (n = 2); and (7) died before recruitment 
attempt by doctoral candidate (n =1).   
 The doctoral candidate submitted successfully a modification to the dissertation 
study to include the face-to-face interview of one prospective patient-participant enrolled 
in a Phase 0, non-therapeutic CCT.  This patient-participant only provided a face-to-face 
patient interview.  Because she was a clinical trial coordinator at another nationally-
ranked, Philadelphia healthcare/research institution, her participant perspective was 
singularly unique, as was her interview.  Further, her understanding of the factors 
influencing clinical trial accrual and retention was unparalleled and her comments were 
candid and very insightful.  With the addition of this face-to-face interview, there were 28 
patient-participants eligible for recruitment.  Of this number, two-patient participants 
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refused participation and the doctoral candidate was unsuccessful in her attempts to 
contact five patient-participants (See Figure 4-1).  
 
 Figure 4-1:  Recruitment Flowchart 
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Overview of the Sample 
Demographic Information 
  A total of 66 interviews were completed with 21 patient-participants who met the 
inclusion criteria. Of the 66 interviews, 21 were face-to-face interviews and 45 were cell 
phone interviews.  As discussed in Chapter 3, the first cell phone interview for each 
patient-participant began with the same five general questions.  Each subsequent cell 
phone interview was uniquely representative of the patient-participant’s experiences and 
perceptions of CCT decision-making factors for that day.  Nine patient-participants 
(43%) completed the proposed dissertation study interview total:  one face-to-face 
interview and four cell phone interviews.  The remaining 12 patient-participants (57%) 
completed one face-to-face interview and zero to three cell phone interviews.       
 Patient-participants were drawn from a purposive sample of Black cancer patients 
enrolled in therapeutic CCTs at The Cancer Center.  Of the 23 Black cancer patients 
approached, twenty-one agreed to participate and signed the requisite Informed Consent 
and HIPAA documentation.   Consistent with the inclusion criteria, all of the patient-
participants self-identified as Black.  However, the 20 individuals whose demographic 
data were collected more specifically self-identified in the following manner:  one 
Black/Other (5%), three Black/African (15%), and 16 Black/African American (80%).  
One patient-participant self-identified as Hispanic or Latino. The Black cancer patients 
comprising the sample were a demographically diverse group.  They ranged in age from 
42 years to 74 years (SD = + 9.19), had educational attainment from grade school to post-
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graduate school, and had been receiving cancer treatment for less than one year to over 
ten years.    
 To acquire the richest data and to increase study accrual, patient-participants were 
drawn from the following cancer types:  breast, colorectal, lung, prostate, multiple 
myeloma, leukemia, cervical, pancreatic, head and neck (oral cavity, pharynx, and 
esophagus), gastric, liver, and uterine.  The 21 patient-participants were diagnosed with 
the following cancers types:  breast (25%), prostate (25%), lung (15%), colorectal (15%), 
pancreatic (10%), and multiple myeloma (10%).  Forty percent of patient-participants 
reported a stage four cancer status.  All patient-participants had insurance coverage and 
reported spiritual or religious beliefs.  Seventy percent of the sample had comorbid 
conditions.  The sample was either equally, or nearly equally equivalent (55%-45%) on 
employment status and place of residence (suburban versus urban). Seventy-five percent 
of the Black cancer patient-participants reported having a caregiver, or caregivers, who 
supported them during their CCT participation—this percentage increased to nearly 
100% when the data of the cell phone interviews were analyzed.  Caregivers took various 
forms; they were spouses, children (below and above 18 years of age), close friends, 
cousins, and daughters-in-law.   
 The patient-participants comprising the sample valued information regarding their 
cancer diagnosis and CCT treatment.  Eighty-five percent felt that it was extremely 
important to receive information about their cancer diagnosis and treatment.  Sixty-five 
percent felt it was extremely important to receive information regarding their CCT 
treatment.  Forty percent reported they had excellent communication with their oncologist 
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and rated their ability to get information from their oncologist about their cancer 
treatment and cancer diagnosis as excellent.  Conversely, 45% of the patient-participants 
reported their ability to receive information regarding their cancer diagnosis and 
treatment from their nurse practitioner as excellent. For more detailed information 
regarding the sample’s demographic characteristics, see Table 4-1 below:   
Table-4-1:  Demographic Characteristics of Patient-participants 
Characteristic       Patient-participants (N=20)
a
 
 
Age (Years)       56.70 (SD: +/- 9.19) 
        (range: 42-74) 
 
Gender (% male)      30% (n = 6) 
 
Racial Background 
 Black/African      15% (n = 3) 
 Black/African American    80% (n = 16) 
 Black/Other        5% (n = 1) 
 
Ethnic Background 
 Hispanic or Latino       5% (n = 1)  
 
Education (Highest Achieved) 
 8
th
 Grade or Less       5% (n = 1) 
 Some High School       5% (n = 1) 
 High School Graduate               15% (n = 3)    
 Some College      40% (n = 8)  
 College Graduate     15% (n = 3) 
 Graduate/Post-Graduate    20% (n = 4)   
  
Marital Status 
 Never Married      35% (n = 7) 
 Married      35% (n = 7) 
 Divorced      25% (n = 5) 
 Separated        5% (n = 1)  
 
Cancer Type 
 Breast       25% (n = 5)  
 Lung       15% (n = 3) 
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 Colo-rectal      20% (n = 4)    
 Prostate      20% (n = 4) 
 Multiple Myeloma     10% (n = 2) 
 Pancreatic      10% (n = 2) 
 
Years Living With Cancer 
 0 to 1 Years      55% (n = 11) 
 2 to 5 Years      35% (n = 7) 
 6 to 10 years      10% (n = 2) 
 
Cancer Treatment 
 Chemotherapy                 70% (n = 14) 
 Radiation      25% (n = 5) 
 Chemotherapy and Radiation      5% (n = 1) 
 
Cancer Stage 
 Don’t Know      25% (n = 5)      
 Stage 1                   5% (n = 1) 
 Stage 2                 15% (n = 3) 
 Stage 3                 10% (n = 2) 
 Stage 4                 40% (n = 8) 
 No Stage        5% (n = 1)  
 
Comorbid Condition* 
 Yes       70% (n = 14) 
 No       30% (n = 6) 
 
 High Blood Pressure      35% (n = 7) 
 Blood Clots       15% (n = 3) 
 High Cholesterol      25% (n = 5) 
 Diabetes       20% (n = 4) 
 Migraine Headaches        5% (n = 1) 
 Diverticulosis         5% (n = 1) 
 GERD          5% (n = 1) 
 
Living Area (Place of Residence) 
 Urban        55% (n = 11) 
 Suburban       45% (n = 9) 
 
Insurance* 
 Yes       100% (n = 20) 
  
 Private Insurance       65% (n = 13) 
 Out of Pocket/Self Pay        5% (n = 1) 
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 Medicare        40% (n = 8) 
 Medicaid        10% (n = 2) 
 VA           0% (n = 0) 
 Other         15% (n = 3) 
 
Spiritual or Religious Beliefs 
 Somewhat Important       5% (n=1) 
 Important      15% (n=3) 
 Very Important     35% (n=7)  
 Extremely Important     35% (n=9) 
 
Employment 
 Yes       50% (n=10) 
 No       50% (n=10) 
 
Caregiver 
           Yes       75% (n=15) 
 No       25% (n=5) 
 
Importance of Caregiver 
 A Little Important     10% (n=2)  
 Somewhat Important       5% (n=1) 
 Important        5% (n=1)  
 Very Important     25% (n=5)  
 Extremely Important     30% (n=6) 
 Not Applicable     25% (n=5) 
 
Caregiver Type* 
 Spouse                  30% (n=6) 
 Sibling       20% (n=4) 
 Parent       10% (n=2) 
 Child       35% (n=7) 
 Friend       10% (n=2) 
 Daughter-in-law       5% (n=1) 
 Cousin         5% (n=1) 
 
Importance of Receiving Information 
 
About Cancer Diagnosis and Treatment 
 Important        5% (n=1) 
 Very Important     10% (n-2) 
 Extremely Important     85% (n=17) 
 
Importance of Getting Information About 
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   CCT Treatment 
 Very Important     35% (n=7)  
 Extremely Important     65% (n=13) 
 
 Rate Communication with Oncologist 
 Fair       10% (n=2) 
 Good       15% (n=3)  
 Very Good      40% (n=8)  
 Excellent      35% (n=7) 
 
Rate Communication with Nurse Practitioner 
 Fair       15% (n=3)  
 Good       10% (n=2) 
 Very Good      35% (n=7) 
 Excellent      40% (n=8) 
 _______________________________________________________________________            
Note.  
a
 One of the patient-participants was involved in a non-therapeutic Phase 0 CCT (a 
CCT non-curative in nature whose purpose is to determine the pharmacodynamics and 
pharmacotherapeutics of Bortezomib). Her demographic information does not appear in 
Table 4-1.  *More than one choice was available; resulting percentage may not equal 
100%. 
Symptom Distress and Symptom Frequency (The MSAS-SF) 
 The MSAS-SF measured the symptom distress and frequency of symptoms 
experienced by the patient-participants.  The MSAS-SF data were collected at baseline 
(following receipt of Informed Consent and always prior to the face-to-face interview) for 
each patient-participant.  As stated in Chapter Three, there were three symptom distress 
subscales which encompassed measurement of physical distress (PHYS), psychological 
distress (PSYCH), and global distress (GDI).  The PHYS distress scale measured 
physical symptom burden and was calculated by the average of 12 symptoms (i.e., lack of 
appetite, lack of energy, pain, feeling drowsy, constipation, dry mouth, nausea, vomiting, 
changes in taste, weight loss, feeling bloated, and dizziness).  These and the remaining 
physical symptoms were scored in increments of 0.8 (indicated that a symptom was 
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present and caused no distress) up to 4.0 (indicated a symptom was present and resulted 
in very much distress).  Zero was assigned when a patient-participant did not experience 
a symptom.  The PSYCH scale assessed the distress corresponding to the following six 
psychological symptoms:  worrying, feeling sad, feeling nervous, difficulty sleeping, 
feeling irritable, and difficulty concentrating.  The PSYCH scale is scaled in increments 
of one up to four, with one indicating the patient-participant experienced a symptom 
“rarely” and 4 indicating a symptom was experienced for “almost constantly.”  Zero 
represents that the patient-participant did not experience a symptom.  The GDI was 
calculated by averaging the frequency of four prevalent psychological symptoms (i.e., 
feeling sad, worrying, feeling irritable, and feeling nervous) and six prevalent physical 
symptoms (i.e., lack of appetite, lack of energy, pain, feeling drowsy, constipation, and 
dry mouth).    
 The PHYS distress scale values for patient-participants ranged from 0 to 2.93.  
The mean PHYS distress scale value was 1.09—zero signified that patient-participants 
did not experience any overall symptom distress, while 2.93 represented a moderate level 
of symptom distress.  The PSYCH distress values ranged from 0 to 2.43.   The mean 
PSYCH value was 0.77.  For the patient-participants, the GDI ranged from 0 to 2.90.  
The mean GDI for the sample was 1.09.  Overall, patient-participants were mildly to 
moderately distressed with their physical symptoms and minimally distressed with 
psychological symptoms. Patient-participants experienced the following symptoms the 
most frequently: “Lack of Energy,” “Pain,” and “Change in Taste.”  The following 
symptoms were tied for the fourth most frequently experienced symptom: “Changes in 
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Skin,” “Numbness and Tingling,” “Lack of Appetite,” and “Feeling Irritable.”   “Hair 
Loss” and “Changes in Skin” were the most distressing symptoms for the study sample.  
“Difficulty Swallowing” was the least distressing symptom. The only symptom not 
experienced by at least one member of the sample was “Mouth Sores.”   Patient-
participants’ symptom experience will be discussed in more detail when reporting their 
real-time experiences.  For more detailed information regarding the sample’s symptom 
distress and symptom frequency, see Table 4-2 and Table 4-3 below:      
Table-4-2:  Physical Symptom Frequency (MSAS-SF) (n=20)
a
 
Symptom Did not 
Experience 
Symptom 
N (%)
b
 
No 
Distress 
 
N (%) 
Little 
Bit 
Distress 
N (%) 
Somewhat 
Distress 
 
N (%) 
Quite a 
Bit 
Distress 
N (%) 
Very 
Much 
Distress 
N (%) 
Difficulty 
Concentrating 
16 (80) 1 (5) 1 (5) 2 (10) -- -- 
Pain 7 (35) 1 (5) 2 (10)  5 (25) 3 (15) 2 (10) 
Lack of Energy 4 (20) -- 3 (15) 7 (35) 4 (20) 2 (10) 
Cough 14 (70) -- 2 (10) 1 (5) 2 (10) 1 (5) 
Changes in Skin 10 (50) 1 (5) 2 (10) 3 (15) -- 5 (20) 
Dry Mouth 12 (60) -- 5 (20) 1 (5) 2 (10) -- 
Nausea 12 (60) -- 5 (20) 1 (5) 1 (5) 1 (5) 
Feeling Drowsy 10 (50) 1 (5) 3 (15) 3 (15)  3 (15)  -- 
Numbness/Tingling 
(Hands/Feet) 
9 (45) -- 2 (10) 3 (15) 3 (15)  3 (15) 
Difficulty Sleeping 11 (55) -- 2 (10) 3 (15) 2(10)  2 (10)  
Feeling Bloated 13 (65) -- 4 (20) 1 (5) 2 (10) -- 
Problems with 
Urination 
15 (75) -- -- 3 (15) 1 (5) 1 (5)  
Vomiting 17 (85)  -- -- 1 (5) -- 2 (10) 
Shortness of Breath 12 (60) -- 5 (25) -- 3 (15) 0 
Diarrhea 11 (55) 1 (5) 2 (10)  2 (10) 2 (10) 2 (10) 
Sweats 10 (50) 1 (5) 5 (20) 2 (10) 1 (5) 1 (5) 
Mouth Sores 20 (100) -- -- -- -- -- 
Prob. Sexual 
Interest/Activity 
14 (70) -- 2 (10)   2 (10)  1 (5)   1 (5) 
Itching 13 (65) -- 3 (15) 1 (5) 2 (10) 1 (5) 
Lack of Appetite 9 (45) 1(5)  4 (20) 3 (15) 2 (10) 1(5)  
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Dizziness 16 (80) -- 3 (15) -- 
 
-- 1 (5) 
Difficulty 
Swallowing 
17 (85) 1(5) -- -- 2 (10) -- 
Changes Food 
Taste 
8 (40)  1 (5) 2 (10) 3 (15) 3 (15) 3 (15) 
Weight Loss 13 (65) -- 2 (10) 3 (15) 1 (5) 1(5)  
Hair Loss 14 (70) -- -- 2 (10) 2 (10) 2 (10) 
Constipation 12 (60) -- 2 (10) 1 (5) 1 (5) 4 (20) 
Swelling Arms or 
Legs 
16 (80) 1 (5) -- -- 1 (5) 2 (10) 
Don’t Look Like 
Self 
15 (75) -- -- 2 (10) 3 (15) -- 
 
 
Table 4-3:  Psychological Symptom Frequency (MSAS-SF) (n=20)
a
 
Symptom Did Not 
Experience  
Symptom 
N (%) 
Rarely  
 
 
N (%) 
Occasionally 
 
 
N (%) 
Frequently 
 
 
N (%) 
Almost 
Constantly 
 
N (%) 
Feeling Sad 
 
11 (55) 5 (25) 3 (15) 1 (5)  -- 
Worrying 
 
12 (60) 4 (20) 3 (15) -- 1 (5) 
Feeling 
Irritable 
10 (50) 6 (30) 3 (15) -- 1 (5) 
Feeling 
Nervous 
11 (55) 5 (25) 2 (20) 1 (5) 1 (5) 
Note:  Table 4-2 and Table 4-3 are derived from the MSAS-SF, Portenoy, R. K., Thaler, 
H. T, Kornblith, A. B., Lepore, J. M., J. M., Friedlander-Klar, H., Kiyasu, E., Sobel, K., 
Coyle, N., Kemeny, N., Norton, L., & Scher, H. (1994). The memorial symptom 
assessment scale: An instrument for the evaluation of symptom prevalence, 
characteristics, and distress. European Journal of Cancer, 30A(9), 1326-1336.  
a
 One of the patient-participants was involved in a non-therapeutic Phase 0 CCT (a CCT 
non-curative in nature whose purpose is to determine the pharmacodynamics and 
pharmacotherapeutics of Bortezomib).  Due to her uniqueness as a study patient-
participant (she was a clinical trial coordinator at another institution), only her face-to-
face interview data and cancer diagnosis were included in the dissertation study.  Her 
demographic information does not appear in Table 4-2 and Table 4-3.  
b
In Table 4-2 and 
Table 4-3, the “N” value signifies the number of patient-participants who experienced a 
distress level for a particular symptom.  The percentage sign (%) represents the 
associated percentage of patient-participants who experienced a distress level for a 
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particular symptom.  The dashes represent the absence of distress for a particular 
symptom in the sample of patient-participants 
 
Description of the Patient-Participants 
 As stated, the sample participants were twenty-one Black cancer patients spread 
over six cancer types: breast, prostate, lung, colo-rectal, pancreas, and multiple myeloma.  
The members of the sample are described here, in order to facilitate ease of identification 
during the presentation of the dissertation findings later in this chapter.  They will be 
presented according to cancer type, although there was no commonality of experience 
based upon cancer type.  The following descriptions are meant to provide a cursory 
introduction to each participant; additional details will be provided during the 
presentation of the data.   
 Breast cancer. 
 The patent-participants who participated in breast CCTs were among the youngest 
in the study sample.  They had a mean age of 48.8 years and ranged in age from 44 years 
to 58 years.  Three of them were participants in the I-SPY II CCT, a multi-arm adaptive 
CCT that utilizes biomarkers to guide determination of trial eligibility, screen the use of 
novel therapies, and determine treatment therapy effectiveness based upon tumor 
subtypes. Mrs. Washington was a newlywed with two adult children.  She postponed her 
honeymoon in lieu of beginning initial treatment of her breast cancer via CCT 
participation. Her husband provided her immeasurable support. In turn, Mrs. Washington 
became a valuable source of support for other women diagnosed with cancer, who turned 
to her for information and support.  Kit was a mother of three teenagers, and an education 
administrator trying to juggle home, work, and her pursuit of a doctoral degree. Katie, a 
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divorced mother of two teenagers, had just fully recovered from a motor vehicle accident, 
when she received her cancer diagnosis.  She reacted with shock and dismay, when she 
learned that that her older female relatives shared an extensive (but hidden) history of 
breast cancer.   
 The remaining two women with a breast cancer history were participants in a 
randomized yoga/radiation therapy CCT, where the participants were randomized to yoga 
or supportive care for symptom management.  Both women shared strong family support, 
but differed in support from their employers.  Lee, a nurse, had an extensive support 
system among her family and friends.  Her employer supported her during her cancer 
treatment.  She received treatment during her work hours.  Reecy was supported 
predominantly by her teenage sons.  Her employer was unsupportive and terminated her 
from her position, secondary to work days missed for cancer and CCT treatment. As a 
result, she lost her home and sought living arrangements with supportive relatives.   
 Prostate cancer. 
 Four patient-participants were diagnosed with prostate cancer and had a mean age 
of 59.5 years.  Three of them participated in a yoga/radiation CCT, where yoga was 
taught to assist the men in managing symptoms associated with radiation therapy:  Steed, 
Ro, and RR.  Two of the men, Steed and Ro, received proton therapy as part of the CCT.  
RR and the remaining prostate cancer participate, Eric, both received standard external 
beam radiation.  Steed was the only participant in the sample who articulated initial 
distrust for research.  His distrust was overcome by having a racially concordant 
oncologist and CCT research coordinator (his oncologist CCT research coordinator were 
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both Black) and by the open communication he shared with his oncologist. Ro came to 
the Cancer Center for a second opinion, because he was dissatisfied with his first 
oncologist.  He was very pleased with his experience and with his oncologist and at the 
Cancer Center.    
 RR came to the Cancer Center for treatment five years after a cancer diagnosis, 
when he finally had qualified for Medicare coverage.   He stated that he could not afford 
the co-payments required to receive proton therapy.  RR frequently discussed his 
symptoms and symptom management and declined to discuss his CCT participation with 
certain members of his nuclear family and his church family.  Eric did not participate in 
the yoga/radiation CCT.  He was receiving external beam radiation therapy along with a 
phase 1 medication, following a prostatectomy.  Per his words, Eric freely questioned the 
care he was receiving and “pushed the issue” on symptoms he was experiencing that he 
felt were not being addressed (Eric, Face-to-Face Interview). 
 Lung cancer. 
 The patient-participants with lung cancer had a mean age of 60.7 years.  Niecy 
had participated in more than one CCT.  She had a deep and abiding faith in her spiritual 
beliefs and in her family and fully expected her family to support her during her CCT 
participation.  She had a close and trusting relationship with her oncologist.  Due to 
disease progression, Jill was removed from her CCT soon after completion of her initial 
face-to-face interview, which occurred during a hospitalization.  Soon after her interview, 
she was placed on home hospice.  She repeatedly voiced indications that she was 
overwhelmed by the financial burden of fees related to medication costs and “usual and 
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customary care” fees related to her CCT participation.  Diane had been a participant in 
several CCTs for lung cancer.  She felt that she received support from her children and 
husband, as well as her church cancer support group.       
 Colo-rectal cancer. 
  The four participants with colo-rectal cancer ranged in age from 48 years to 74 
years and had a mean age of 63.3 years. Mrs. L was enrolled in a CCT contemporaneous 
with being informed of her cancer diagnosis.  As a result of CCT medication, she 
experienced debilitating pain and peripheral neuropathy.  Mrs. L was the primary 
caregiver for her adult daughter who suffered from a chronic illness, while receiving 
scant support for herself.  Jay was concerned with living as normal a life as possible, as 
well as with how he was perceived by others. For this reason, he preferred the CCT oral 
chemotherapeutic agent over the standard treatment intravenous agents administered 
continuously through a portable infusion pump, which he had previously received.    
  Willie was diagnosed with stage four colo-rectal cancer six months short of her 
next screening colonoscopy.  She came to the Cancer Center for a second opinion.   Her 
daughters were very supportive and did research for her, regarding treatment of her colo-
rectal cancer; she was recently separated from her husband.  Ellie had an extremely 
supportive family, comprised of her husband and children.  Her youngest adult daughter 
and husband were committed advocates for her and routinely were present at all of Ellie’s 
oncologist appointments and CCT treatments.        
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 Pancreatic cancer. 
 Bob and Mrs. S were diagnosed with pancreatic cancer.  Their mean age was 61 
years.  Mrs. S was the wife of a minister, who also was being treated at the Cancer Center 
for multiple myeloma. Her children and their spouses supported her participation in the 
CCT and formed a vigilant support network that ensured that she was never alone and 
had everything she needed.  Bob actively sought randomization prior to CCT accrual.  He 
viewed CCT participation as an opportunity to receive optimal care for a life-limiting 
cancer.  Bob acknowledged that he felt that he “was pretty much the aggressor,” when it 
came to inquiring about CCTs at the Cancer Center (Bob, Face-to-Face Interview).  
Moreover, his husband constantly was seeking promising pancreatic CCTs for him, as 
well as bringing them to the attention of Bob’s oncologist.       
 Multiple myeloma. 
 Finally, three patient-participants were diagnosed with multiple myeloma and had 
a mean age of 52.7 years.  Each had lived with multiple myeloma for at least four years. 
Previous to CCT participation, Tammy had received only standard treatment.  She relied 
primarily on her father for tangible and emotional support and described him as her 
“number one” (Tammy, Face-to-Face Interview).  Tammy reported having good support 
from her family.  Although, she admitted that only her parents, an aunt, and her children 
were aware of her CCT participation, because she felt that other members of her family 
would not understand.  Gina had enrolled in several CCTs in order to forestall 
progression of her multiple myeloma. Gina was very well-informed of the multiple 
myeloma disease process and treatment options, pursuant to self-study, attendance at 
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multiple myeloma conferences and participation in support groups wherein multiple 
myeloma patients shared information.  During her CCT accrual, she continued to work 
full-time while she received her lengthy CCT treatment (four to five hours once a day 
during the week), and was the sole caregiver for her elderly mother who suffered with 
moderate to advanced dementia.   Nellie worked full-time during her CCT participation; 
she scheduled early CCT visit appointments in order not to disrupt her work schedule.  
She was enrolled in a non-therapeutic CCT.  Nellie was supported by her friends during 
her previous standard and CCT treatment.  She was very knowledgeable of CCTs and 
chose CCT participation to help other Black cancer patients.   
Findings 
Specific Aim One:  Identify and Describe the Patient, Family Member, Physician, and 
Protocol Factors that Black Cancer Patients Consider Important in Their Decision to 
Participate and to Remain in CCTs 
 Consistent with Albrecht’s Model, the four themes for Specific Aim One are: 
Patient Factors, Family Member Factors, Physician Factors, and Protocol Factors.  
Patient Factors concerns the patient-participant decisions, preferences, and expectations 
that influenced their enrollment (Why I Came Here) and retention (My Treatment) in 
CCTs at the Cancer Center.    Why I Came Here has three sub-categories that more fully 
describe the patient-participants’ reasons for arriving at the Cancer Center and choosing 
CCT participation:  Get a Second Opinion, To Help Myself, and To Help Others.  My 
Treatment describes the treatment expectations of patient-participants who remained in 
CCTs and has two sub-categories:  How I Want to Be Treated and Managing My 
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Treatment.  Family Member Factors explicates the influence of family members on 
CCT participation and retention.  It has two categories:  They Helped Me Decide 
(Participating) and Family and Friends Support Me (Remaining).  The latter category 
treats the various ways in which family members and friends assisted CCT retention.  
Physician Factors describes the manner in which oncologists influenced patient-
participants to enroll and to remain in CCTs at the Cancer Center.  Why I Participated 
explains the oncologist characteristics that prompted patient-participants to choose their 
respective oncologist (Doctor I’m Dealing With (Choosing My Doctor) and the role of 
oncologists in CCT enrollment (He Asked Me and Told Me (Enrolling in the Cancer 
Clinical Trial)).  Why I Remain conveys the continued influence of oncologists on CCT 
retention from the perspectives of the patient-participants. (See the matrices below for 
Patient Factors, Family Member Factors, Physician Factors, and Protocol Factors; 
all matrices serve as a guides for the discussion of each theme.)     
Table 4-4:  Patient Factors 
Theme Patient Factors 
Category Why I Came Here (Participation) 
 
My Treatment 
(Remaining)     
Sub-category Get a 
Second 
Opinion 
 
 To Help 
Others  
 
To Help 
Myself  
How I Want 
to be 
Treated 
Managing 
my 
Treatment   
Code “unhappy 
where I 
was” 
“go 
somewhere 
else”  
 
 
 “I’m a 
pioneer or a 
trailblazer”   
“help 
somebody 
else”   
“our 
ethnicity”   
“go to the 
study for 
you”  
“help me”  
“give 
myself the 
best 
possible 
“like a 
person”   
“have some 
kind of 
compassion”   
“push the 
issue”    
 
“they have 
to get 
answers for 
you”   
“weighing 
the options”    
“I tell 
everything”   
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 chance” 
“learn more 
about my 
condition” 
“if one trial 
doesn’t 
work”  
 
“tap into 
the 
resources”   
 
 
 Patient factors.  The Black cancer patients enrolled in this dissertation sample 
were demographically diverse in several aspects (e.g., age, education, marital status, and 
cancer status, yet shared many commonalities of experience).  The majority of patient-
participants were forthright in their choice of seeking cancer treatment at the Cancer 
Center.  Many of study participants came to the Cancer Center for a second opinion, 
before enrolling in a CCT.  Once enrolled, they regarded CCT participation as a means of 
helping themselves and others.  Moreover, during their continued enrollment in their 
CCT, they had expectations of how they wanted to be treated and how they wanted to 
share management of their CCT treatment.  
   Why I came here.  Why I came here represents patient-participants’ personal 
reasons for coming to the Cancer Center.  This category depicts the conditions under 
which some patient-participants came to the Cancer Center seeking second opinions for 
treatment of their cancer, as well as the altruistic and self-interested reasons they gave for 
their CCT enrollment.   
 Get a second opinion.  Some patient-participants experienced discontent or 
displeasure with an oncologist physician prior to going to their present oncologist 
physician for a second opinion (unhappy where I was).  This discontent motivated them 
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to seek cancer treatment elsewhere for cancer treatment at another medical facility or 
with another oncologist (going somewhere else).  In so doing, the patient-participants 
found their present physician and enrolled on the present CCT.   For the patient-
participants in the dissertation study sample, a diagnosis of cancer was a necessary 
precursor to their experiences in clinical research at the Cancer Center.  However, some 
of the patient-participants sought out a second opinion at the Cancer Center after being 
diagnosed with cancer at another healthcare institution (go somewhere else) 
 That’s, you know, I had some, uh, bleeding one morning from the rectum.  It was 
 pretty bad, so my husband rushed me to the hospital, which was ________ here in 
 T_________.  Um, so.  And, um, that’s where they detected it there.  They kept 
 me in the hospital for a week.  All kind of test they ran.  So, um, they found it. 
 They were gonna give me chemo there, but I wasn’t really happy with what they 
 wanted to do, so I wanted to get a second opinion.  And that’s why I went to 
 [the Cancer Center].  And I’m, and I’ve been with [the Cancer Center] since. 
 (Willie, Face-to-Face Interview). 
Diane did the same: 
 No, I was at _________when they diagnosed it, and I just felt like I needed to 
 go somewhere else more knowledgeable.   So that’s why I came to the [Cancer] 
 Center.  They worked on that and everything was good for about a year and a half.  
 I was on maintenance [chemotherapy] and everything.  (Diane, Face-to-Face 
 Interview). 
After leaving other oncologists and other cancer centers, patient-participants purposively 
sought consultations with oncologists at the Cancer Center.  At these consultations, 
standard treatment options (the customary treatment for a cancer type) and cancer clinical 
trial participation (voluntary involvement in a medical research study to test new methods 
of treating their cancer type) were discussed.  In general, the patient-participants were 
discerning in their decisions to undergo treatment with an oncologist following a second 
opinion and consultation.   
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 Ellie arrived at the Cancer Center after visiting three other cancer centers for 
initial treatment recommendations and decided to stay, because she was impressed by the 
time spent by the oncologist to perform a thorough evaluation of her cancer (Ellie, Face-
to-Face Interview).  By contrast, Bob chose the Cancer Center because his oncologist, 
ironically the same oncologist treating Ellie, expediently began treatment. Gina came to 
the Cancer Center for a second opinion after her initial oncologist had suggested a cancer 
regimen for her progressive multiple myeloma: 
 And, uh, so now I’ve been going for a series of thing.  I was going—I actually 
 participated in a study before the study I’m now on.  Dr. _____suggested it.  I 
 came to him for a second opinion because they wanted me to take like a, a cyto—
 Cytoxan with decadron and something else.  I’m like, ‘Look, before I do this,’ 
 ‘cause I said, ‘Okay, I know the devil that I’m dealing with as far as drugs are 
 concerned.’  I said, ‘So I still got to work every day.’  I said, ‘That might throw 
 me into something else.”  I said, “Let me get a second opinion,” so I actually 
 came here and talked to Dr. _______ to get a second opinion.   (Gina, Face-to-
 Face Interview). 
 Ro expressed intense displeasure (unhappy where I was) with the oncologist who 
initially diagnosed him with prostate cancer, because of prior experience with another 
physician.  He related sitting in the first physician’s office and hearing him say, “If you 
came in here with a PSA 20, or something I would tell you I can’t do nothing for you 
(Ro, Face-to-Face Interview).” So, after he was told ten months later by another 
physician that his PSA was 20, he went to the Cancer Center for a second opinion 
following a referral from a friend who had been treated there for prostate cancer.  His 
comments are below:  
 I was recommended by a friend of mine who had prostate cancer. And he was 
 working with Doctor ____.  And um you know he told me to come down  you 
 know, cuz I was very unhappy where I was at before so. Uh I didn’t like the 
 way my um doctor handled the situation, and I didn’t like—like the way the 
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 oncologist at Einstein handled the situation. So I came down here and I—I met 
 Doctor ____. And uh then Doctor ____ put me in touch with Doctor ____.  (Ro, 
 Face-to-Face Interview).   
  RR’s dissatisfaction stemmed from an oncologist’s rush to perform robotic 
prostatectomy surgery for his prostate cancer, without discussing other treatment options 
(RR, Face-to-Face Interview).  He felt that the oncologist was rushing him to treatment, 
rather than considering his quality of life following the surgery: 
 No, I didn’t do it.  I—the reasons were the doctor was too much in a rush.  He 
 didn’t give me both sides of things.  He was, you know, just, “Oh, yeah, you want 
 to save your life?”  [Chuckles] It—he didn’t - he didn’t seem to have any concern 
 with quality of life.  He was just tryin’ to sell me on getting the thing.  At least, 
 that’s my perception.   (RR, Face-to-Face Interview).  
Ellie shared the same experience of being unhappy with her previous oncologist, because 
she felt that she was rushed to treatment: 
 like the oncologist at _______ it seemed like he was in a hurry to get me in the 
 operating room or...whatever he was gonna do.  Excuse me.  But Dr. ______‘s 
 people, they were careful.  They-they wanted more information that I already 
 had.  Cuz I had all my information from ________sent to ______.  And they-they 
 were...very, very good at-at making sure that they were on the right track.   (Ellie, 
 Face-to-Face Interview). 
By contrast, Bob felt an urgency to receive cancer treatment.   Initially diagnosed with 
stage four pancreatic cancer at another comprehensive cancer center in the area, Bob’s 
displeasure with his prior oncologist stemmed from her slowness in beginning treatment.  
He was impatient with the sheer number of diagnostic tests he had to undergo, before he 
could be treated (Bob, Face-to-Face Interview).      
  To help others.  The sub-category, To Help Others, reflects the shared, personal 
altruistic reasons the patient-participants provided for enrolling in CCTs, once they came 
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to the Cancer Center.  Gina viewed herself as a trailblazer (I’m a pioneer or a trailblazer) 
assisting in the development of science intended for the benefit of future cancer patients:     
 I told my friends, I’m not a guinea pig.  Um, I’m a pioneer or a trailblazer.  
 Somebody...went through something before I even got here—to take us to this  
 point.  So now I wanna be able to not only help myself, but help other people in 
 the process, because it might be somebody that’s going through the exact same 
 thing that I’m going through.  (Gina, Face-to-Face Interview).   
CCT participation was viewed as a means to help somebody else: 
 So I don’t look at it on the lines of ‘No, I’m not gonna do dis,’ cuz there’s 
 something out of all this that you’re doin’ that you’re gonna get, it may help 
 somebody else somewhere down the line. But if we say no to everything like this 
 how do you get the information to help the next person.  (Reecy, Face-to-Face 
 Interview). 
Implicit in the patient-participants’ altruism was the recognition that they may not benefit 
from their respective CCTs.  Helping others by participating in CCTs was viewed as a 
refusal to be selfish, an appreciation for the importance of research, as well as a duty 
owed to document cancer information for all individuals with cancer.  Lee shared a 
widely expressed need to do more for others: 
 I mean, I’m a nurse as well. I do research. I think it’s important. I think research is 
 important. I think that’s how we get our information that can help the person,  
 benefit the person, or it helps other people for the future. I think that’s the main 
 reason. I think that if I can help someone else, even if it doesn’t personally benefit 
 me, then it’s okay.  (Lee, Face-to-Face Interview). 
However, as a patient-participant in a CCT and a member of a CCT team in a different 
medical discipline, Lee had a unique perspective: 
 I’m a patient.  I know from my experience when we gather information from  
 patients that are in clinical trials, it gives us feedback and information that can 
 help us with future things.  I just wanna be able to see a positive, a plus.  (Lee, 
 Face-to-Face Interview).  
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 Recognizing the symptom burden they experienced, the patient-participants hoped 
that enrollment in CCTs could lessen symptoms such as fatigue, aches and pains, and hair 
loss for future cancer patients.  For this reason, Katie felt that enrollment in a CCT was 
perceived as an opportunity to spare others from the symptom burden she was 
experiencing:   
 That, you know, even though I'm always thinkin' about the next person but that 
 would be satisfying to me knowing that—that they can get something out of it,  
 That this won't be so harsh, as far as all this other stuff that you have to go 
 through.  You know, every time you get the infusion, of the fatigue, of the aches, 
 the pains, the hair loss, all that stuff—Interviewer:  Mm-hmm.  Interviewee:  
 – will be alleviated a little for the next person.  (Katie, Face-to-Face Interview).    
 Steed and Katie viewed CCT participation as a chance to help our ethnicity, or 
other Black cancer patients:      
  We need to have a-we need to have a-a collection of information—and data that 
 our ethnicity has on record.  So that the medical profession will know how to 
 treat, um, diseases.  The-the things that we are afflicted with.  And, not only that, 
 just our concerns.  (Steed, Face-to-Face Interview).  
 
Hence, Steed viewed his CCT participation as an opportunity for researchers to collect 
information on a Black individual, in order to assist the medical profession in treating 
other Blacks with cancer.  Katie viewed CCT participation as a way to help another Black 
patient-participant like herself: 
 That whatever they find out, whatever the results are, whatever they're looking for 
 to find out, you know, in a person, maybe a African—maybe based on just me, 
 African-American female, 45 years old, that may be similar to me or, you know, 
 may be at the same stage or presented at the same, you know, during the same 
 time, that it would benefit them.  (Katie, Face-to-Face Interview). 
 To help myself.  Although the patient-participants shared altruism as a motivation 
for CCT enrollment, the desire to help themselves was expressed by all patient-
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participants as a motivating factor for CCT enrollment. Ro voiced the necessity to go to 
the study for you, or for Black cancer patients to make a personal decision to participate 
in CCTs  
 But if somebody come tell you, ‘Yeah man, you know it’s really good and 
 everything.’ Yeah, listen to them, but go to the study for you. Because if you go 
 to the study saying, ‘Cuz somebody said this and that and everything,’ then 
 you’re not goin’ for yourself. And you’re not gonna pay attention the way you 
 should.  (Ro, Face-to-Face Interview). 
This sentiment was shared by Lee: 
 It’s your personal decision.  Something that the person has to feel comfortable 
 with.  I don’t think there’s anything wrong with participating in a clinical trial.  
 That’s my opinion, but it is still that person’s personal decision.  I’ll tell them it’s  
 how comfortable you feel about it.  If you don’t feel comfortable then you don’t 
 do it.  (Lee, Face-to-Face Interview). 
 In making the decision to participate in a CCT, the patient-participants were 
motivated by the desire to help themselves (help me): 
 Interviewer:  Why - why did you decide to participate in the research that you're 
 participating in?  Interviewee:  Because I - I - I feel as though, uh, that it can help 
 me more than it could hurt me, I think.  I asked the question, would it hurt me?  
 Would it hurt me?  And the doctor said, no, it wouldn't.  So the only thing it could 
 be is a plus.  (Eric, Face-to-Face Interview). 
 For the patient-participants, helping themselves through CCT participation was an 
attempt to save their lives and to prolong their lives as long as they could.  Jill viewed her 
decision to enroll in a CCT as taking a chance to help herself: 
  I said let me take a chance because maybe it will help.  Maybe they'll find 
 somethin'.  It—it'll help or maybe it won't help.  But if it helps that’s—I'm two 
 points ahead in the game.  (Jill, Face-to-Face Interview).  
Participation in a CCT was more than a taking a chance for some patient-participants to 
help themselves.  Wanting the best care was the reason given by the vast majority of 
participants for CCT enrollment. They ascertained that CCTs provided better treatment 
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for their cancer.  Mrs. S stated very frankly, “Plus I would like to get the best of care and 
best of what I could get, out of what I could get, as long as I could get” (Mrs. S, Face-to-
Face Interview).  Hence, from the perspective of the individual patient-participant, it was 
a desire to give myself the best possible chance to treat my cancer.  Gina wanted a CCT 
targeted medication which specifically attacked her cancer cells and which did not have 
secondary cancers as a side effect, as did many medications for multiple myeloma.  As 
conveyed by Gina:  
 Right, because it’s targeted therapy.  So that interested me, because with all the  
 other stuff, and especially with Revlimid...you can develop a cancer in another 
 part of your body.  That’s the chance that you kinda, sorta,  have to take, you  
 know, when you’re on these drugs...So I realized that [pause]—I still needed 
 to give myself the best possible chance.  (Gina, Face-to-Face Interview). 
 Several participants reported that CCTs afforded the opportunity to learn more 
about my condition.  Participation in the I-SPY II CCT with its additional diagnostic tests 
and genetic testing appealed to Mrs. Washington’s willingness and need to learn more 
about her cancer, “I want to learn more about my condition, what's goin' on and 
everything, which I probably could get from my Doctor ____ “(Mrs. Washington, Face-
to-Face Interview).  Diane was a veteran of other lung CCTs, before enrolling in her 
present CCT.  Enrollment in subsequent studies permitted her to acquire additional 
diagnostic information and become knowledgeable about her cancer status and treatment, 
as well as motivating her to seek enrollment in other available CCTs whenever her cancer 
progressed: 
 They had some other—maybe three more things they could try.  But they weren’t 
 working, and two clinical trials that I was under they didn’t work, either.  It 
 seemed like it grew.  And I actually told them you can stop this one because it’s—
 whatever these pills are they’re not working with me.  So then, um, each—
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 between each one you still have to wait, like, six weeks or whatever before they’ll 
 start so it can get out of your system.  So this came along, and she offered it to 
 me, and, um, so far it—it hasn’t been growing so it’s already big enough, so it 
 hasn’t grown.  And as long as we can keep my fluid retention under control—I 
 will—I should be okay.  (Diane, Face-to-Face Interview). 
 Finally, a few participants with late stage cancer were frank in their use of CCTs 
as a means of prolonging their lives and, who hoped, if one trial doesn’t work, there 
could be another CCT which could work.  Reecy, who had newly diagnosed stage four 
breast cancer with multiple metastases, saw her CCT as the first of many CCTs in which 
she would be enrolled for the remainder of her life, because of her tumor burden: 
 ...and it was like too much cancer areas throughout my stomach and, and back, 
 so they really, they didn’t wanna operate....so they thought the best thing for me 
 to do is just to live with it, and, um, and take the, the chemo treatments.  And like 
 I did have radiation for, I guess it was about six or eight weeks.  So they’re not  
 gonna give me any more of that.  So now they told me I would be on chemo 
 for the rest of my life...And, and when, if one trial doesn’t work, you know, 
 they’ll  just keep putting me on different ones until it works.  (Reecy, Face-to-
 Face Interview).  
For several years, Gina had monitored the progression of her multiple myeloma by 
following the levels of certain laboratory levels of her blood (her “numbers”) (Gina, 
Face-to-Face Interview).  She had been enrolled in at least two prior CCTs, until her 
numbers indicated that her cancer was no longer responding to the medication.  She had 
hoped the oncologist: 
 could make a cocktail and it might do something for a while, but I felt as though I 
 had a good shot of getting my numbers down far enough or just to eradicate the 
 disease. You now, itself. So that’s why I agreed.  (Gina, Face-to-Face 
 Interview).    
The CCT in which Diane was participating had halted the growth of the large tumor in 
her abdomen, although she still experienced side effects such as acute shortness of breath 
from the ascites (extra fluid accumulating in her abdominal cavity as a result of the 
98 
 
metastases).  She knew the CCT in which she participated was her last chance to manage 
her cancer: 
 they were saying that they don’t have anything else as far as treatment that they 
 can give me. Because they’ve tried everything.  So they wanted to, you know, try  
 this one in particular... it’s not really a cure, but if—in the meantime, if they can 
 stop the growth of it, who knows down the line?  They might find something else 
 that can get rid of it.  (Diane, Face-to-Face Interview).  
 My treatment.  Except for the few patient-participants who had participated in 
other CCTs as a means of prolonging their life, the patient-participants perceived the 
CCTs as, and the CCTs were, the first medical intervention for their cancer:       
 Oh, um, I initially found out from the radiologist and then, um, she was telling me 
 about the clinical trial.  And then when I got diagnosed and met with the 
 oncologist, they, um, the oncol – oncologist talked to me about it again.  And, um, 
 then I met the researcher and it went from there.  (Kit, Face-to-Face Interview).   
The patient-participants had expectations of how they wanted to be treated and how they 
wanted to manage their cancer treatment. Fulfillment of these expectations kept them in 
their CCTs. 
 How I want to be treated.  The participants had an expectation of how, and in 
what manner, they expected to be treated while they were enrolled in the CCT.  Kit 
voiced the shared expectation of many of the participants of being treated with respect, or 
treated with positive regard for them as individuals (like a person):     
   like a person with cancer who needs help, but also like a person.  And a person 
 who needs information and who needs to be, uh, treated like, what’s the word—I  
 need the people who take care of me to be knowledgeable.  I need them to be 
 intelligent.  I need them to know me.  If I don’t get that, it’s not happening.  
 (Katie, Face-to-Face Interview).     
Kit was treated like a person: 
 Interviewer: Okay?  Um, one question.  Um, tell me about your experience?  
 So, I mean over the last two months.  Interviewee: Um.  It’s been fine.  Um, 
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 they’ve been very thorough with everything.  Um.  The team, like I said, 
 continued the same, with the same consistency they were always at every 
 appointment.  (Kit, Cell Phone Interview #4). 
Patient-participants wanted their decisions to be accepted and respected, especially as it 
pertained to additional CCT participation—as explained by Lee: 
 I work in this and this is what I often have to say sometimes to people in my 
 department.  They’ll say, ‘I don’t know why this person is—‘  They’ll identify a 
 patient.  Of course, we need patients to participate on the trials because that’s 
 how we’re grant funded.  We need people to participate in order to, so to speak, 
 in reality keep our jobs.  You still have to respect the person.  If the person says, 
 ‘No.  I don’t wanna do it.’  Just let her go.  (Lee, Face-to-Face Interview). 
 At the most basic level, Niecy expressed the desire that her healthcare providers have 
some kind of compassion when they communicated with her:   
    I mean you have to—you can’t be so cocky that you know you just come off to 
 people like—‘This is what you need to do.’  Interviewer: Right.  Interviewee:
 You know you may get better, you may not get better, and I mean fighting this 
 disease, I mean—  Interviewer:  Mm-hmm.  Interviewee: - you’ve gotta have 
 some kind of compassion, some kind of—some kind of, “If it was me,” or, “If it 
 was my daughter, if it was my aunt.  If it was my mother, how would I want them 
 to talk to her?  (Niecy, Face-to-Face Interview) 
Niecy found this compassion in her oncologist, as she describes a discussion she had with 
him, “I says, ‘The feeling I get, the feeling in my stomach, I can’t shake it.  I don’t want 
to mess with you.’  I just found a good oncologist.  Wherever we go from here, you know 
I’m okay” (Niecy, Face-to-Face Interview). 
  There were times when a patient-participant, or family member, wanted to have s 
an important health problem or issue addressed (push the issue).  Eric was concerned 
about his persistent rib pain: 
 I told him last week that, uh—that my ribs were swollen, and I'm gonna tell him 
 again this week.  And I'm gonna not demand, but I'm gonna push the issue on, 
 okay, it still hurts. It's still hurting.  It's still hurting. Let's do something about it. I 
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 mean, like, this week or whatever or next week, check me out for something to 
 see what's going on here because it's been swollen for two weeks.  (Eric, Face-to-
 Face Interview). 
Eric addressed his pain with his oncologist and was given medication. Bob’s husband 
was a stalwart advocate for him.  When he noticed that Bob had begun losing weight on 
the CCT, Bob husband began asking the nurse practitioner questions at an appointment:  
 Um, I can’t say that she mentioned it like it was—she just said—because I mean - 
 I think because Tom was so focused on—he was asking questions, so she 
 mentioned that there was an eight-pound weight loss difference between the last 
 month... And she’s, like - she’s, like, ‘You’re not really like in a danger zone, but 
 you don’t wanna continually, you know, keep losing weight, you know, each 
 month.’  (Bob, Cell Phone Interview #4).    
As a result of Bob’s husband directing his concerns to the nurse practitioner, Bob began 
to understand the importance of maintaining his weight: 
 Which kind of surprised me because I was, like, ‘What?  I mean I am eating.’   
 Interviewer: Mm-hmm.  Interviewee:  But, um, you know, I guess I just have 
 to, you know, keep it up.  Tom wants me to, you know, talk to a nutritionist so—I 
 guess it wouldn’t hurt... (Bob, Cell Phone Interview #4). 
 Managing my care.  Patient-participants had a clear idea about how they wanted 
their care to progress and assertively advocated for themselves, or had family members 
who advocated for them (Managing My Care).  They have to get answers for you meant 
seeking information about the CCT in which an individual was enrolled: 
 But uh, you know, just-just put them in a position where they have to get answers 
 for you. Because what happens is, I think, is they get answers for themselves, as 
 well.  Interviewer:  Yeah, that’s true.  Interviewee: They do.  I really do believe 
 they-they get answers for themselves, because people ask questions that they  
 don’t have answers to.  And they—and they know they wanna keep their-their 
 patient, they’re gonna have to come up with—they’re gonna have to get some 
 reliable answers to your questions.  (Ellie, Face-to-Face Interview). 
It enabled participants to ask relevant and meaningful questions during the CCT.  Katie 
began while she was deciding on CCT participation:   
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 And I asked questions about, you know, ‘How many people are participating?  
 Is—is it just done here at Penn?  Where else is it done?  Like, is it done at the 
 other local Philadelphia hospitals?’  Um, um, ‘Are there mostly just people my 
 age?  Um, are there other ages that participate?  Um, is it ethnic-based [inaudible 
 07:19]?’  Uh, we had a lot of dialogue.... (Katie, Face-to-Face Interview). 
Her questions continued throughout the CCT: 
 Um, I just know that I just have like some questions I am gonna ask about like, 
 you know, far as reconstruction is, like, surgery, reconstructive surgery and um, 
 therapy and all that stuff.  Not, not just—I didn’t even like really know about the 
 therapy until I went to therapy for my ankle and found that it, that there’s a 
 therapy, therapist there that works with people after they have um, like 
 mastectomies.  (Katie, Cell Phone Interview #4). 
Ellie’s continued participation depended upon whether the CCT treatment was reducing 
the size of her tumor (Ellie, Face-to-Face Interview).  By staying informed about the 
status of her cancer and asking questions about her progress during the CCT, she 
remained in the CCT: 
 Interviewer: I remember—actually, I remember you had said that you and your 
 husband had talked about not continuing on if there wasn’t a change, you know, 
 in—Interviewee:  Mm-hmm.  Interviewer:  Are you still having that discussion?   
 Interviewee: No because we have seen a change for the better.  And, uh, uh, 
 because when we took the other CAT scan, where there was this mass in my 
 belly had already shrunk by 40 percent.  (Ellie, Cell Phone Interview #3). 
  Participants were always weighing the options of continued CCT enrollment, i.e., 
considering the advantages and disadvantages of cancer clinical trial treatment and/or 
cancer treatment.  Niecy had been with her oncologist through more than one CCT and 
had followed him to the Cancer Center from another comprehensive cancer center.  Her 
decision to not remain in her CCT was based upon her consideration of the advantages of 
the treatment versus the symptom burden that she was experiencing.  She explained very 
simply, “He’s gonna listen to my point, and I’m a listen to his point, and I’m gonna weigh 
the options” (Niecy, Face-to-Face Interview).  Ultimately, when Niecy felt that the 
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“medication wasn’t workin,” (Niecy, Face-to-Face Interview) Niecy weighed the options, 
communicated her decision to her oncologist, and withdrew from the CCT after only two 
CCT cycles.   
 Patient-participants wanted to be informed of their progress in the CCT—and, in 
furtherance of that goal, communicated everything that they experienced to the CCT team 
(I tell everything), as exemplified by Kit: 
 Interviewee: I tell everything.  Interviewer:  Okay.  Interviewee:
 [Inaudible] blurry vision.  Interviewer:  Okay.  Interviewee: Everybody  knows 
 everything.  Numb – tingling fingers.  (Kit, Face-to-Face Interview).   
The information shared between the patient-participants and the Cancer Clinical Trial 
Team (CCT Team) varied.  Participants, such as Niecy, notified the oncologist or the 
nurse practitioner when the CCT medication was not resolving the symptom burden 
associated with their cancer (Niecy, Face-to-Face Interview).  Lee informed the CCT 
Team of her wound care needs and received non-adherent dressing for her breast wound 
(Lee, Face-to-Face Interview).  Gina and Ellie were concerned about possible reactions to 
their treatment.  Gina was experiencing “hot flashes” again, after having experienced a 
natural menopause ten years earlier: 
 ...I’ve gone through all of that before, so I, I don’t know what this is, but I have to 
 make sure that I tell, um, the, uh, the clinical nurse what’s going on because, 
 because this is such a, you know, a new drug, they need to know peoples’ 
 reactions to things.  (Gina, Cell Phone Interview #1). 
Ellie was experiencing severe peripheral neuropathy in both of her hands, which 
prevented her from touching anything for several days (Ellie, Face-to-Face Interview).    
After notifying the clinical trial research nurse, one of the CCT chemotherapeutic agents 
was eliminated.   
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 Last, patient-participants were referred to internal resources (offered by the 
Cancer Center) and sought external resources (tap into the resources) in order to ensure 
their continued participation throughout the CCT.  Seeking and using these resources to 
support them during CCT participation was an integral part of the patient-participants’ 
managing their CCT treatment.  Patient-participants were referred to resources for 
transportation, counselling, nutrition, and stress management.  Gina required more than 
one type of resource.  She balanced a full-time job, visits to the Cancer Center twice a 
week, and was the sole caregiver for her mother who had dementia.  For stress 
management and counselling services, she received external support from her employer.  
She received the services of Carebridge, an employee assistance program provided by her 
employer, which provided five free counselling and stress management sessions (Gina, 
Face-to-Face Interview).  Later, she was referred by the Cancer Center to the Breathing 
Room Foundation, a local non-profit organization which provides care and support to 
individuals and families affected by cancer.  Gina received $200 which enabled her to 
offset transportation costs and pay for respite services for her mother’s care: 
 And there’s—the Breathing Room Foundation gives you a one-time stipend of 
 $200.00—Interviewer:  Okay.  Interviewee: - to, you know, to help you out with 
 whatever.  So I faxed her—I talked to her today, and um, they’re willing to pay 
 this lady for the time that she’s gonna stay with my mom, which is good, ‘cause I 
 don’t have to do out of pocket.  And they’ll just, you know, cut the lady a check.  
 But I’m trying to find out as many organizations as I can to assist, and there’s so 
 many out here as far as cancer patients are concerned—Interviewer:  Right.   
 Interviewee: - that people are not aware of that will help you.  So just trying to 
 tap into the resources that are available.  (Gina, Face-to-Face Interview).     
Transportation resources were needed by Reecy and Mrs. L, both of whom had limited 
financial means.  Absent these resources, neither one of them would have been able to 
104 
 
continue to come to the Cancer Center.  Initially relying unsuccessfully on social work at 
Cancer Center, Reecy arranged her own transportation through Medicaid: 
 I got a—they gave me a monthly TransPass.  The social workers here didn’t fix 
 that for me.  I fixed it for myself.  Interviewer:  You t—how’d you do that?   
 Interviewee: I went to Welfare and I got my Welfare situated.  I caught the  
 transportation people.  I fixed that myself.  Interviewer:  Okay.  Interviewee:
 Waiting for the social workers, nothing was getting done— .  (Reecy, Face-to-
 Face Interview). 
The Cancer Center referred Mrs. L to a taxi service funded by a non-profit cancer 
organization, to transport her and her disabled daughter to the Cancer Center for her CCT 
appointments (Mrs. L, Cell Phone Interview #1).  Despite feeling that the taxicab service 
was burdensome, she continued to use it during her CCT enrollment.   
Table 4-5:  Family Member Factors 
Theme Family Member Factors 
Category They Helped Me Decide 
(Participating)   
Family and Friends Support Me 
(Remaining)   
Sub-category  
 
“my children heard”    
“he talked to all my children”    
 
My Family My Friends 
Code “my family is 
close” 
“we support 
each other”   
“my rock”   
“they’re in my 
world”   
 
 
“friends that 
support me”   
“we’re like 
sisters”   
 
 
 Family member factors.  Family members were integral elements in the lives of 
the patient-participants.  They accompanied them to initial oncology appointments, sat 
with them through innumerable hours at the Cancer Center, offered heart-felt 
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encouragement to carry them through the CCT process, and provided needed home care 
for them.  However, very few of the patient-participants discussed the influence of family 
members in their CCT enrollment decisions (They Helped Me Decide (Participating)).  
Most of their discussions centered on the tangible and intangible ways that family 
members sustained them during their CCT participation (Family and Friends Support 
Me (Remaining).    
 They helped me decide.  Only two patient-participants mentioned their family 
members’ involvement in CCT enrollment decision-making.  Mrs. L had little 
recollection of her initial discussion with the oncologist regarding her CCT; she relied on 
her children to listen for her (my children heard).  When asked how she decided to 
participate in her CCT, she stated, “I don’t know that I did.  [Laughter].  They just 
automatically, like I said, handed me the papers, told me what was what and, of course, 
like I do, I’m being the airhead so my children heard” (Mrs. L, Face-to-Face Interview).  
Niecy’s oncologist actively involved her and her children in CCT decision-making (he 
talked to all my children):  
 From Dr.____’s standpoint, this is uh, the best thing that he has—I guess, far as 
 trial medicine, for me with the lung cancer—so he wanted to try it, and I mean 
 he—he just didn’t talk to me.  He talked to all my children, and— Interviewer:
 Oh good, so he talked to all—everybody?  Interviewee:  Right.  Interviewer:
 Okay.  Interviewee: Right, it’s—and when—there’s somethin’ and— ‘bout 
 changin’, and what’s goin’ on with me—he tells me that you know, ‘I need all 
 your kids to come in, and we can talk about this.’  (Niecy, Face-to-Face 
 Interview).  
 Family and friends support me.   
 
 My family.  The influence of family members on the participants’ CCT 
participation emerged early in the face-to-face and cell-phone interviews. As described, 
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“family member” was broadly defined to include members of participants’ nuclear 
family, friends, significant others, spouses, and ex-spouses. Gina discussed the constant 
presence of her friends, since she was estranged from her siblings (Gina, Cell Phone 
Interview #2).  For Ro, a family member included not only individuals who shared 
consanguineous ties, but also his ex-spouse (Ro, Cell Phone Interview #3; Ro, Face-to-
Face Interview).  Many patient-participants described the “closeness” with their family 
members and, how they gathered around them following their cancer diagnosis and 
during their CCT participation (we’re very close).  Lee shared how her family had rallied 
around her and offered emotional support: 
 We’re very close.  I guess we don’t mind talking and sharing because that’s how 
 we help to educate each other.... We just—I mean my family, when they learned 
 that I had this everybody was calling.  Everybody was calling, everybody was 
 coming.  That’s just how we are.  Even my Auntie who’s 93 years old.  I was just 
 talking to her yesterday.  She calls me every week.  My cousin who lives down 
 south called to check on me.  The one’s that’s in New York. They call to check on 
 me, make sure I’m okay.  My cousin Earl reminds—my Aunt Cleo, she didn’t 
 have daughters.  She had two sons.  My cousin Earl.  He’s 60—I’m 56, he’s at 
 least 10 years older than me.  When he got the news he called me.  He was like, 
 ‘Cousin I heard.’  He says, ‘Don’t worry about it.  You know Mama had it and 
 she lived all those years cancer-free after that.’  He told me, reminded me.  He 
 just went on, ‘You’re gonna be alright.  You’re gonna be alright.  Just like mom.’   
 (Lee, Face-to-Face Interview). 
This closeness was indicative of the strong family relationships existing within the 
patient-participants’ families.  Reecy expressed the sentiment shared by many of the 
sample of an expectation of family closeness as she discussed her sons, “I think this is 
what we supposed to do.  I think we’re supposed to stick together.  I think we’re 
supposed to help each other, you know” (Reecy, Face-to-Face Interview).   
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 At the most basic level, being present was the first line of support and was valued 
greatly by the participants (we support each other).  Ro expressed the importance of his 
family members during his CCT participation: 
 So I mean my family, my family has had illnesses, but we have always said you 
 know you gotta fight.  And we, and we support each other.  That supportin', that's 
 a lot—comin' down here every day and you see the ones who have support with 
 'em, the people who have support with 'em.  You know, it's just incredible when 
 you have somebody sittin' beside you, your brother, your sister, your mother, your 
 father, your aunt and uncle, somebody down there with you.  (Ro, Cell Phone 
 Interview #3). 
 Ro and many of the participants were not alone, as they waited for their oncologist 
appointments, radiation treatments, or CCT medication infusion visits.  Being present for 
the participants extended into the oncologist and nurse practitioner appointments, where 
the participants’ family members asked questions the participants may have forgotten and 
made requests for consults, such as Bob’s husband who requested a nutrition consult 
following concern surrounding Bob’s eight-pound weight loss.  Ellie felt that the 
presence of her family members positively impacted her CCT treatment: 
 I really am very satisfied with uh, the way—the kind of treatment I’m getting.  
 But you let—I’ll just say this on the side.  I think, if I were just me coming in 
 there all the time—Interviewer:  Right.  Interviewee:  I don't know how good it 
 would be.  Interviewer:  Okay.  Interviewee:  But because it’s my daughter and 
 my husband, and he never, ever lets me come alone—Interviewer: Right. 
 Interviewee: - um, because they’re there asking the questions that I don't think 
 of to answer—to ask—Interviewer: Mm-hmm.  Interviewee:  I think—I think it 
 encourages a little more attention than I would get otherwise.  (Ellie, Face-to-Face 
 Interview). 
When family members were not able to be physically present, the participants could 
expect a call or text to remind them of family members’ support (Mrs. Washington, Cell 
Phone Interview #2).  As shared by Mrs. Washington, support could come in a call: 
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 What do my sons do for me? They'll call me up...and ask me, ‘Do you need  
 me to come and stay with you? Or, do you need me to, um, go to the store?  
 Do you need anything to eat?’  (Mrs. Washington, Face-to-Face Interview). 
Diane affirmed the power of a call.  Her sisters called her “all day and night” inquiring 
about her needs and offering her rides from the Cancer Center to home, as did her sons 
(Diane, Face-to-Face Interview).    
 Participants noted that family members would do whatever they could to support 
them through the CCT.  Bob explained that his husband acted as a “buffer” between him 
and the prying questions of other members of his family, regarding his CCT and his 
health status (Bob, Cell Phone Interview #3).  Katie’s sister helped her by assuring that 
her two sons’ clothes were ironed for the week (Katie, Cell Phone Interview #3).  During 
the summer of 2014, Katie had been spending at least one day a week receiving 
chemotherapy and/or diagnostic testing at the Cancer Center, secondary to her CCT 
participation (Katie, Cell Phone Interview #2).  This made it difficult for her to plan a 
summer getaway with her two sons. In addition, her sons had been choosing to spend 
more time with their father (Katie is divorced) that summer. Katie acquiesced, since she 
felt that they were trying to adjust to her cancer diagnosis.  Katie received much-needed 
assistance from a paternal aunt, who gave her a summer timeshare at the New Jersey 
shore (Katie, Cell Phone Interview #2).  In this way, Katie was able to spend time with 
her sons before the school year began. 
    Some family members were actively involved in many aspects of the patient-
participants’ lives during their CCT participation (they’re in my world) as exemplified by 
Steed’s comments regarding his family, “And they are in my world all the time.  You 
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know, cross-examining me, asking me—everything.  There’s nothing off limits to my 
family, because they’re-they’re in there.  They’re in my world” (Steed, Face-to-Face 
Interview).  Diane’s husband had supported her through several CCTs.  Diane recalled 
during one CCT that he had questioned whether it was helping her and whether she 
should consider withdrawing from it: 
 when I was doing the one before this my husband actually did say to 
 me—but I was already thinking anyway. He knew it. He said, ‘It’s just not 
 working.  It’s not working for you. It’s not working for you, baby.’ And I said, 
 ‘Yeah, I understand and I am going to say something,’ and I did. I stopped it, 
 stopped it altogether.  (Diane, Face-to-Face Interview). 
Ellie’s daughter and husband were constant fixtures at her CCT appointments.  They 
accompanied her to every appointment, asked the clinical trial research nurse, nurse 
practitioner, and oncologist questions regarding her progress in the CCT, and made 
recommendations to Ellie about her treatment and assessing her involvement in the CCT 
(Ellie, Cell Phone Interview #3).  Like Diane, Ellie’s family members talked with her 
about her CCT participation and gave her “feedback from their point of view” which she 
valued (Ellie, Cell Phone Interview, #2).   
 Receiving CCT treatment at home was common among the participants and 
offered another opportunity for family members to be involved in the patient-
participants’ lives during their CCT participation.  In order to deliver at-home 
chemotherapy and anti-nausea medications associated with her CCT, Ellie’s husband and 
daughter were trained how to use a mini-infusion pump (Ellie Cell Phone Interview #1).  
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As stated previously, Bob’s pleural effusions11 required insertion of a pleur-x-catheter12 
to drain his lungs.  After insertion, a home nurse made a few visits to continue to drain 
pleural fluid and to instruct Bob’s husband on the pleural effusion draining procedure. 
Bob’s husband took over care and draining of the pleur-x-catheter indefinitely (Bob, Cell 
Phone Interview #3).     
 The Black cancer patients invariably described one person they called my rock, or 
that individual who provided unwavering support, or more than one type of support, 
during their cancer and CCT experiences. Diane’s rock was her older son: 
 ... he’s my rock, but I do have other people that are there for me.  In fact, during 
 most of the time when I first started coming and—and getting chemo and stuff 
 like that, my older son was the one would be here all the time.  (Diane, Face-to-
 Face Interview). 
Ellie’s twin rocks were her daughter and husband who never wavered in their support—at 
least one of them was constantly present at Perelman, in the home to assist and care for 
her in any manner necessary, and emotional support (Ellie, Cell Phone Interview #1; 
Ellie, Cell Phone Interview #2; Ellie, Cell Phone Interview #4).  Kit’s rock was her 
boyfriend who was with her at every chemotherapy appointment, as well as everywhere 
she needed to go (Kit, Cell Phone Interview #1). Diane described how her husband had 
adjusted to being a caregiver and now did everything for her when she returned home 
exhausted from work—a role reversal which redefined their thirty-year marital 
                                                          
11
 A pleural effusion is the presence of excess fluid in the fluid-filled lining surrounding 
each lung.  The excess fluid prevents the lung from expanding, thereby resulting in 
shortness of breath and impaired oxygenation. 
 
12
 A pleur-x-catheter is a flexible plastic tube inserted through the chest into the pleural 
space.  It remains in place until no longer needed and permits drainage of pleural 
effusions in a patient’s home.      
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relationship (Diane, Face-to-Face Interview; Diane, Cell Phone Interview #2).  He 
cooked for her, cleaned the house, and assisted her in making decisions about her CCT 
treatment (Diane, Cell Phone Interview #2; Diane, Cell Phone Interview #4).  Tammy’s 
father was her “number one” who drove her to every appointment and cared for her 
grandchildren when she could not care for them (Tee, Face-to-Face Interview).  Reecy 
depended on her oldest son who stayed overnight with her during hospitalizations and 
came with her to every appointment (Reecy, Cell Phone Interview).  Finally, Ro turned to 
his ex-wife, a breast cancer survivor, who understood his cancer experience more than 
anyone: 
 She knows how I am. We laughed. We joked. We talked. Cuz she had cancer. 
 She beat breast cancer, my ex-wife. I was with her then when she was fighting 
 that. And uh so she knows. So she sat down here with me.  (Ro, Face-to-Face 
 Interview). 
 My friends.  When a patient-participant explained he had friends that support me, 
they were describing the ways in which their friends assisted them during their CCT 
participation. Friends did not differ from family members in their support of members of 
the sample.  They accompanied the participants to their appointments, sent them cards 
and flowers, called them every “damn” day, and laughed, cried, and prayed with them 
(Gina, Cell Phone Interview #3; Katie, Cell Phone Interview #2; Mrs. L, Face-to-Face 
Interview; Mrs. S, Face-to-Face Interview).  Gina’s friends were essential for her, 
because of her estrangement from her family.  They offered the support she would have 
received from family members: 
 Yeah, I do have friends that support me.  They, you know, call me on a daily 
 basis.  How are you doing?  How are you feeling—are you feeling medically?   
 You know, how are you feeling emotionally?  You know, what is it, you know, 
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 that, you know, um, while this is going on, why don’t we go out and do this or, 
 you know, how about this or what’s happening in the house?  That kinda thing.  
 So, I mean, I’m-I’m-I’m fine as far as that’s concerned, you know.  (Gina, Cell 
 Phone Interview #2).  
Ro described a moment early in his CCT treatment, when he was despondent.  A friend 
who lived across the street, who was a prostate cancer survivor, spoke to him and 
provided the support he needed:    
   And he told me, ‘First of all, Ro, take a deep breath and settle down.’  He said, 
 ‘You don’t know how bad it is...God is usin’ you to-to put this out there.’  He 
 said, ‘Look at it that way.’  He said, ‘Don’t-don’t be with that grueling look on 
 your face and everything.’  And I thought about it, and I said, ‘You know what?  
 You’re absolutely right.’  And I still to this day talk to everybody the way I do is 
 because he-he told me that.  He told me that when I was feelin’ like really down.  
 Like he just told me that, you know, you got prostate.  Your PSA is high.  I was 
 feelin’ really bad.  And I felt bad for ten minutes, and then as I talked to him, I 
 said, ‘You know what?  He’s absolutely right.’  (Ro, Cell Phone Interview #3). 
Ro’s interaction with his friend gave him hope and cemented Ro’s resolve to share his 
experience with the men of his social circle—as his neighbor had done for him (Ro, Cell 
Phone Interview #3).    
 Friends helped them to understand and to endure the silence of family members 
and their unspoken questions about their cancer.  Katie’s best friend was her “rock” and 
more like a sister (we’re like sisters): 
 And then, my best friend, we've been friends since high school, M____.  She's  
 excellent—excellent support.  You know, we—we're like sisters.  We're like 
 sisters.  We talk a lot, share a lot.  We cry.  We laugh.  We—we do everything.  
 She's—she's um, she's always there.  She's always there.  (Katie, Face-to-Face 
 Interview).   
Since many of her family members were unprepared to discuss her cancer and CCT 
experiences, her best friend filled the void by talking and praying with her as often as 
Katie needed (Katie, Cell Phone Interview #1; Katie, Cell Phone Interview #3).  Katie 
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related her discussions with another friend who had sisters who were breast cancer 
survivors.  Her friend shared a personal experience and asked a pointed question: 
 ... some of her siblings, she had to ask them about another sister, like, do  
 you think that she’s gonna die? Do you think that she’s not gonna survive this? 
 And she said, ‘Maybe that’s what they feel like.’  Maybe...she said, ‘Maybe 
 that’s what they’re feeling.’  (Katie, Cell Phone Interview).  
With her friends’ assistance, Katie began to learn to cope with her family’s reticence to 
share their opinions and feelings about her cancer and CCT participation.  She began to 
talk about her cancer and CCT experiences with her family, whether or not they asked, in 
response to their discomfiture 
Table 4-6:  Physician Factors 
Theme 
 
 
Physician Factors 
Category 
 
 
Why I Participated   Why I Remain  
Subcategory 
 
 
 Doctor I’m Dealing 
With (Choosing My 
Doctor)   
He Asked Me and Told 
Me (Enrolling in the 
Cancer Clinical Trial)   
“Trust”  
“He’s in the ethnic 
group”  
 “They have people 
that address things”    
 
Code 
 
 
“Doctor was very 
careful”  
 “He took time out to 
explain”  
 “Seemed to have 
more going on”  
  
  
  
“She mentioned the 
trial”  
“Offered me other 
treatments”  
“Handed a paper to 
sign”  
“He thought it was a 
good idea”  
 
 Physician factors.  Patient-participants shared how their positive perceptions of 
their oncologists influenced their decisions to enroll and to remain.in CCTs.   They 
discussed trust in their oncologist, the ethnicity of the oncologist, the attentiveness of the 
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oncologist, and timely referral to other healthcare providers.  Oncologists had active roles 
in motivating CCT enrollment and retention, whether by personally recruiting patient-
participants or referring them to other oncologists managing CCTs.    
 Why I participated.  The patient-participants in this study discussed their 
oncologists’ diagnostic prudence, openness and candor, and willingness to evaluate 
thoroughly their disease process and available treatment and CCT options.  These 
qualities attracted participants to their respective oncologist, encouraged them to choose 
treatment at the Cancer Center, and, ultimately, to enroll in a CCT.   Participation in 
CCTs was effectuated principally by oncologists who recruited a large number of the 
participants, by either asking them to participate or by referring them to oncologists who 
were seeking participants for CCTs. 
 Doctor who I’m dealing with (choosing my doctor).   Patient-participants cited the 
seriousness of purpose and thoroughness in their CCT treatment.  Bob described it as 
having a type of tunnel vision where the oncologist appeared to be entirely focused on his 
treatment (Bob, Face-to-Face Interview).  Also, Bob based his choice of oncologist on his 
perception that funding was readily available at the Cancer Center for cancer research: 
 There’s more money being funneled in here.  It seemed to have more going on 
 with pancreatic cancer than __________.  Even though _________’s an excellent 
 hospital, it just seemed the [Cancer Center] had a little bit more going on with 
 pancreatic cancer.  (Bob, Face-to-Face Interview). 
For Ellie, it was characterized by thoroughness in the initial evaluation of her disease and 
subsequent recommendations for treatment tailored specifically to the genetic structure of 
her cancer (doctor was very careful):  
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 And I felt really—Dr. ____ was very careful.  He wasn’t in a rush to get me 
 going.  He told me, he-he said, ‘I—what I wanna do is to do a gene—a genealogy 
 [genetics] test.’  You test your genes or something.... They went back and looked 
 at all the pictures, everything.  And that—only after that did he design a 
 chemotherapy for me.  And then that’s when the chemo—then it was another 
 month before I really got started with it.  Interviewer:  Okay, so—  
 Interviewee:  But he—I-I-I-I like the idea that he wasn’t in a hurry, like the 
 oncologist at J_______ it seemed like he was in a hurry to get me in the operating 
 room or whatever.  (Ellie, Face-to-Face Interview). 
Another important physician factor was the oncologists’ ability to explain in an 
understandable manner the cancer diagnosis, cancer treatment, and/or cancer treatment 
options (he took time out to explain).  Ro chose the Cancer Center, because the first 
oncologist he had consulted failed to offer him treatment options:     
 And we got to talking and you know he explained it.  I think that the best part 
 about it is that he took time out to explain it in laymen terms about everything that 
 was going down as far as the regular radiation, the radiation, and chemo or 
 protons... And then they explained to me that you know they found that uh 
 women with breast cancer and some other types of cancer when they do yoga it 
 seem to help them with them—with their symptoms.  And uh you know gettin’  
 past, or gettin’ through some of the symptoms.  And it’s illness, and illness too.  
 So I said, ‘Okay, I’ll give it a try.’   (Ro, Face-to-Face Interview). 
This sentiment was shared by Eric and Katie (Eric, Face-to-Face Interview; Katie, Face-
to-Face Interview). 
 He asked me and told me (enrolling in the cancer clinical trial).  Only one of the 
patient-participants related enrolling in a CCT based largely upon an oncologist’s 
recommendations (he thought it was a good idea): 
 Interviewer: Um.  I guess the first thing I’m gonna ask you about is what were 
 some of your personal reasons for deciding to participate in a cancer clinical trial? 
 Interviewee: Because the doctor told me he thought it was a good idea and 
 anything that will help.  You know, help the cancer, to help shrink it and 
 whatever.  Interviewer:   Okay.  Interviewee:  And I was a good, uh, client for it. 
 Interviewer:  Uh.  Okay.  Um.  Were there any other considerations besides what 
 the doctor said?  Interviewee:  No.  (Mrs. S, Face-to-Face Interview). 
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Many of the patient-participants related that their oncologist described the study 
objectives of the CCT and the risks and benefits associated with CCT participation.  In 
nearly all instances, the patient-participants’ oncologists were the principal investigators 
for the CCT.  Katie, Kit, and Mrs. Washington were the only patient participants who 
were referred to the physician, who became their oncologist and administered the CCT.  
She was referred by the surgical oncologist who performed her breast biopsy (she 
mentioned the trial).  Once referred, the oncologist and other members of the CCT team 
provided Katie with written information, discussed the details of the CCT, and answered 
her questions (Katie, Face-to-Face Interview): 
 after having the biopsy and then meeting with Dr. ___, she went over, like, she 
 mentioned the trial also.  And then she talked that—she said that she thought I 
 would be—I may be a good candidate for the trial, but there was more 
 information to come... But I remember just—I was—I was given the information.  
 I know Dr. ____ talked to me about it, and I know the research team, um—at the 
 time it was like L____ and the other girl, L____.  (Katie, Face-to-Face 
 Interview).   
Kit related how she enrolled in her CCT.  She was referred by her radiologist to her 
present oncologist, who, in turn, enrolled her in the breast CCT which has been her initial 
treatment (Kit, Face-to-Face Interview).  Much like Katie, Kit’s oncologist explained the 
details of the CCT, provided her with detailed written information, and answered Kit’s 
questions:  
 I initially found out from the radiologist and then, um, she was telling me about 
 the clinical trial.  And then when I got diagnosed and met with the oncologist, 
 they, um, the oncol – oncologist talked to me about it again.  And, um, then I met 
 the researcher and it went from there.  (Kit, Sami-structured Interview).   
 As stated, participants’ perceived CCT participation as a means of being given 
options for cancer treatment, rather than as opportunities to advance medical research 
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(offered me other treatments).  For example, Steed related how his oncologist discussed 
proton radiation therapy, which was part of his CCT for his prostate cancer: “[t]hey 
offered me other treatments, and, um, I-I just said no.  I said no to those other treatments.  
When protons was explained to me, and how effective the percentage, I said, I’m going 
with this” (Steed, Face-to-Face Interview).    
 Only one patient-participant reported not being asked to participate in a CCT.  As 
stated previously, Mrs. L stated she was told that she was in a CCT, until she decided that 
she no longer wanted to participate.  When asked why she decided to enroll in a colo-
rectal CCT, Mrs. L explained that she was just handed a paper to sign, “And, um, next 
thing I was handed a paper to sign and was told that if I changed my mind about going 
through the trial, then they would destroy the paperwork” (Mrs. L., Face-to-Face 
Interview).  Although, she admitted that the oncologist most likely did explain the details 
of the CCT (Mrs. L, Face-to-Face Interview).  Following her cursory enrollment to her 
CCT, Mrs. L conceded that she did not know what to expect and characterized her 
participation as “...something like the lamb being led to slaughter cause you sure didn't 
open your mouth.  You just went along with things.  That’s how I felt.  Uh, I guess that’s 
how I still feel and, you know” (Mrs. L, Face-to-Face Interview). 
 Why I remain.  None of the patient-participants readily fit the stereotype of the 
uninformed, distrustful Black cancer patient afraid to participate in cancer clinical 
research.  The lack of trust that drove several of the participants to the Cancer Center to 
seek a second opinion was not typified by a general distrust of clinical research.  It was 
epitomized by feelings derived from personal interactions with oncologists, such as 
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experienced by RR who felt pressured by an oncologist to undergo an unwanted surgery 
(RR, Cell Phone Interview #1) and by Niecy who encountered a flippant oncologist who 
was displeased by a refused surgical recommendation and told her regardless of her 
decision he was “gonna get paid either way” (Niecy, Face-to-Face Interview).  In the 
same manner, trust in their oncologist kept the participants at the Cancer Center actively 
enrolled in a CCT.   
  In defining trust, the Black cancer patients offered various meanings. Ro 
described it as “strong faith in the doctors that you workin’ with....” (Ro, Cell Phone 
Interview #2).  At its most elemental level, Bob described it as a “vibe” he felt when he 
met his oncologist for the first time, or a way of knowing experienced during that first 
handshake and first eye contact (Bob, Face-to-Face Interview. For Steed, it was 
something much more concrete—his oncologist was in the ethnic group: 
 He is-he is in the ethnic group.  He’s in the ethnic group [laughter]...it’s a 
 blessing.  It is so wholesome to see this, you know, because, um, it really does 
 something for the ethnicity.  And, uh, we have to have beacons.  We have to have 
 beacons of hope.  Educational beacons of hope.  We have to have that.  (Steed, 
 Face-to-Face Interview).   
He trusted his oncologist, because he was Black.    
 Also, there was a commonality of honesty and frankness noted by the patient-
participants about their oncologists.  In describing the reason she trusted her oncologist, 
Niecy shared that “he keeps it real (Niecy, Face-to-Face Interview).”  Her trust in him 
prompted her to follow him to the Cancer Center, when he left another comprehensive 
cancer center.  She went further to say that “he had talked me into things that I knew 
would have been “No” with any other doctor (Niecy, Face-to-Face Interview).”  After 
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disclosing his decision to stop radiation treatment and rely on prayer to cure his prostate 
cancer, RR was silenced by the frankness of his oncologist’s answer: 
 He says, ‘Well, how would you know if God’s healed you? I mean, we can’t do 
 another biopsy in at least—for a period.’ But not within the period that we were 
 talkin’ about...So, he talked me out of that. He said—well, one, he said, this is a- 
 a very, um, pressurized business.  They’re workin’ with people to try to save 
 them. And that he likes to feel that well, if the Lord’s healin’ them, then he may 
 be one of the Lord’s instruments.   (RR, Face-to-Face Interview). 
  
Despite his candor, RR opined later, “I think he’s a trustworthy guy.  He tries to give it 
the way it is” (RR, Cell Phone Interview #1). 
  In furtherance of their scrupulous treatment in the CCT, participants observed that 
their oncologists often referred them to other medical or rehabilitative services or 
healthcare providers secondary to continued CCT participation (they have people that 
address things).  RR’s oncologist had referred him to other healthcare providers 
secondary to his CCT; he accepted the referral as a corollary to CCT participation as 
issues arose, “So, but I mean, and anything you bring up they - they have people that 
address things” (RR, Cell Phone Interview #3).  He was referred to a dietician for chronic 
constipation, which may have impacted his radiation: 
 Well, they just talked about the need to have regular bowel movements, and, um, 
 yeah.  They - they didn’t really recommend that people use a lot of laxatives or 
 artificial stuff.  They try to use more natural stuff like yogurt (RR, Cell Phone 
 Interview #3).   
 Other patient-participants were referred to otolaryngologists (physicians who specialize 
in evaluation and treatment of the ear, nose, and throat) for hearing loss, physical 
therapists to improve their functional status, and surgeons for placement of pleur-x-
catheters to drain accumulating fluid in their lungs (pleural effusions).     
120 
 
Table 4-7:  Protocol Factors 
 
Theme 
 
 
Protocol Factors 
 
Category 
 
 
Participation    
 
Code 
 
 
“it’s more targeted”   
“help myself if I was randomized (randomization)”    
“extra treatment I’m Getting (additional surveillance)”   
 
 
 Protocol factors.  The data from the face-to-face and cell phone interviews 
indicated that protocol factors only had bearing on the patient-participants’ enrollment in 
CCTs.  As reported previously by Gina, targeted therapy was a CCT feature that appealed 
to her, because it directly affected cancer cells instead of all of the cells in her body 
(Gina, Face-to-Face Interview).  However, the patient-participants with prostate cancer 
also preferred the choice of more targeted radiation therapy (it’s more targeted): 
 It’s more targeted.  Interviewer:  Right.  Interviewee:  It is more targeted, and, 
 um, I don’t need that-that other stuff, where it just goes everywhere.  
 Interviewer: Exactly.  Exactly.  Interviewee:  And-and affects other organs. 
 (Steed, Face-to-Face Interview). 
Ro was determined to receive proton therapy, even though he knew that health insurance 
companies often withheld coverage: 
 Because I know that I went through a lot fillin' in that I wanted the proton.  You 
 know they just sayin', ‘Well, the insurance probably don't like to pay for it for 
 everybody,’ and, you know, I thought, I thought that was crazy because here I 
 had—I have never, ever used my medical insurance for anything, and now that I 
 need it, you don't want me to get the best treatment possible for me.  (Ro, Face-to-
 Face Interview). 
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  Bob chose to participate in his CCT, because he wanted the opportunity to be 
randomized to an experimental treatment, hydrochloroquine.   Diagnosed with life-
limiting stage four pancreatic cancer, Bob articulated: “I thought maybe it would help, 
um, help myself if I was randomized to get the hydrochloroquine (Bob, Face-to-Face 
Interview).”  He rationalized that randomization to experimental treatment would offer a 
better benefit than the standard treatment: 
 ... just thinking that...if I had been randomized that it could possibility, um, 
 have a positive outcome as opposed to just the regular standard, um.I don’t know 
 why I thought that but I did because it—they certainly never said that it was 
 necessarily better, but I just assumed that anybody that’s doing a—a study of 
 something, they’re leaning towards thinking or hoping that it would do some good 
 or it’s—it’s better than the alternative.  (Bob, Face-to-Face Interview).  
 The I-SPY II CCT interested Kit, because she wanted additional diagnostic 
surveillance.  She viewed CCT participation as a vehicle to receive extra treatment that 
she otherwise might not receive.  As participants in the I-SPY2 CCT, she, Mrs. 
Washington, and Katie would receive additional diagnostic surveillance beyond the 
standard of care for breast cancer treatment—at no cost to them: 
 So, the standard – the standard treatment would be two MRIs.  Under the study, I 
 get four MRIs.  Um, standard, I think, for biopsy is one.  With this, I get three.  
 Uh, then, um, MRI, biopsy, um, I think that’s it.  Um, and then with all of my 
 appointments, the – the researcher is there—making sure that things are going 
 well.  Um, just documenting and asking questions.  Seeing how she can help and, 
 um, so it’s been a great experience for me.  (Kit, Face-to-Face Interview). 
Specific Aim Two: Describe the Everyday Experiences of Black Patient-Participants 
Living with Cancer as They Navigate the CCT Process.    
 Three themes address Specific Aim Two and embody the experiences of the 
Black cancer patients as they progressed through, withdrew, and/or were withdrawn from 
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their CCT.  Data was gathered in real-time by cell phone interviews.   Patient-participants 
provided vivid and poignant descriptions of their CCT treatment, expectations and events 
surrounding CCT participation, their symptom experience, personal thoughts and feelings 
of the effect of CCT participation on their daily lives, and their relationships with family 
members, the CCT team, and others during CCT participation. The three themes are: The 
Cancer Clinical Trial Team, I’m Going Through It, and Who I Am.   The Cancer 
Clinical Team concerns the patent-participants’ recognition of the contribution of the 
individuals involved in the screening, treatment, and oversight of the Black patient-
participants during their CCT.  The patient-participants described the roles of the 
individual members (My Team) and their activities during the CCT (What They Do for 
Me).  I’m Going Through It describes the patient-participants’ experiences prior to and 
during their appointments (At My Appointment; Treatment Realities) as well as their 
varying degrees of symptom burden (How I Feel; It’s Knocking Me Down).  Who I Am 
is the patient-participants’ expressions of who they were and what was important in their 
lives.  There are three categories: (1) I Didn’t Want To Be Different Than Who I Was, (2) 
Cancer Has Changed My Life, and (3) Getting the Word Out.   Consistent with the 
dictates of RTDC, the cell phone interviews were recorded in real-time, wherever the 
participants happened to be when the cell phone call was made.  (Each matrix precedes 
its respective section and serves as s guide for the discussion of each theme.)      
Table 4-8: The Cancer Clinical Trial Team 
Theme 
 
 
The Cancer Clinical Trial Team 
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Category 
 
 
I Have a Good Team 
Sub-
category 
 
 
My Team  What They Do for Me 
Codes coordinator 
“nurse practitioner” 
“research nurse” 
 
“They call me”  
“Showed concern” 
“Normally they alternate”  
 
 
 The cancer clinical trial team.   
 I have a good team.  Albrecht’s Model highlights the significant role of the 
oncologist in the CCT process.  However, the participants indicated that the individuals 
who interacted with the patient and worked alongside the oncologist during the CCT, the 
cancer clinical trial team, were important, as well.  Regarding her CCT team, Mrs. 
Washington stated: 
 Uh, the—the team has just been wonderful.  Uh, you know, they always tell me at 
 the end of my appointment, uh, if I ever need anything just don't hesitate to call 
 and let, uh, [clears throat]—excuse me—just don't hesi—hesitate not to call if I 
 need anything.  Um, so the team has been very helpful to me.  There's no 
 unhelpful. (Mrs. Washington, Cell Phone Interview #4). 
 My team.  For most participants, other than the oncologist, the CCT team was 
composed of the clinical research nurse, and the clinical trial coordinator.  However, the 
nurse practitioner also was mentioned as a member.    
 Only the participants in the Yoga Study mentioned interacting with a clinical trial 
coordinator.  They mentioned the clinical trial coordinator by name, instead of by his 
role.  This individual individually recruited and consented all of them.   
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 S________, when he approached me, um he said how was it—yeah he—he asked 
 if I had the [inaudible 09:47], and I said yeah.  And then he got into it you know.  
 He explained it really good.  Really nice guy.  Interviewer:  Mm-hmm.  
 Interviewee: So he—after talking to him, I felt comfortable.... (Ro, Face-to-face 
 Interview). 
The clinical coordinator’s duties were focused solely on the research aspects of the CCT. 
He offered these patient-participants different CCTs in which they could enroll—all 
chose the Yoga Study.  In addition, he reviewed the CCT protocol with them, 
administered the CCT questionnaires, and collected and evaluated the data related to the 
CCT (Steed, Cell Phone Interview #1; Ro, Face-to-Face Interview).  He maintained the 
CCT paperwork and answered their questions, as needed (Steed, Cell Phone Interview 
#1).  He was their point of contact with the CCT.    
  All of the patient-participants mentioned interacting with the nurse practitioner 
during outpatient research visits alone, or in tandem with the oncologist, such as Bob, 
“So I haven’t see the doctor.  Last time I saw the, um, nurse practitioner cuz the doctor—
the last time the doctor was on vacation (Bob, Cell Phone Interview #4).”  Mrs. L 
recounted how the rapidity of her nurse practitioner’s response to her declining health 
status: 
 Well, she’s gotten better. I mean, in the beginning, I just feel like she threw me to 
 the curb cuz I had to go into the hospital the same day I met her. We met her 
 across the street, and that was it. And I was in there a full week, so I was saying, 
 ‘Wow, this is like weird. They just kicked me to the curb,’ you know. So, when I 
 saw her again, I spoke on it, and I got very upset about it. I don’t know why, and 
 she says, ‘I’m sorry.’ She said, ‘But, yes, we did keep an eye on you, but, um, 
 I’m sorry that things—you feel as though I just kicked you to the curb, but you 
 were very sick.’   (Mrs. L, Cell Phone Interview #1). 
Nurse practitioners made the participants feel secure as they progressed along in the 
CCT.  Diane reported that her nurse practitioner is the “one that looks out for me, also, 
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like Dr. _____.  She’s good.  She’s good at what she does” (Diane, Face-to-Face 
Interview).    
   The members of the sample also felt the clinical trial research nurse was 
attentive to their informational needs: 
 Interviewer:  For instance if you have questions about what comes next in your 
 clinical trial who do you talk to?  Interviewee:  There’s two people who you can 
 talk to—who I talk to that would be the nurse or [inaudible].  Interviewer:  
 When you say the nurse you mean the nurse practitioner or the research nurse?  
 Interviewee:  The research nurse, the person who I’m working with on the 
 clinical trial I think would be the person who would have that information.  That’s 
 the best person who I think who would have the information, the most 
 information.  (Lee, Face-to-Face Interview). 
Mrs. Washington depended upon her clinical trial research nurse to provide calendars of 
her extensive CCT chemotherapy treatments (Mrs. Washington, Cell Phone Interview 
#4).   Katie enjoyed meeting with her clinical trial research nurse, since she routinely 
inquired about the side effects of the CCT medication and how Katie was feeling, gave 
Katie an opportunity to ask questions, answered her questions, and discussed her 
experiences during the CCT (Katie, Cell Phone Interview #2).    
 What they do for me.    Communication between the CCT team and the patient-
participants (they call me) was common—as noted by Mrs. Washington, “Yeah, they call 
me at home (Mrs. Washington, Cell Phone Interview #4).  A member of the CCT term 
called the patient-participants following their CCT treatments, following a biopsy, or on a 
weekly basis to see how they were doing (Mrs. Washington, Cell Phone Interview #4; 
Mrs. L, Cell Phone Interview #4; and Jay, Cell Phone Interview #1). Moreover, the CCT 
Team’s show of interest or engagement in their CCT treatment (showed concern) was 
valued by the patient-participants: 
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 It—it wasn’t one of those things where, um, where the only way that I can  
 describe for where they ignored me, or as we say in Duluth, quote/unquote, 
 played me to the left. They—they absolutely, um, showed concern, continuous 
 concern.  (Steed, Cell Phone Interview #2).      
Kit was very pleased with the interest exhibited by her CCT team: 
 Um, the researchers and nurse in charge of the clinical trial have been very 
 supportive and very personal. Um, seem to be truly interested and vested in my 
 Well- being. Um, it’s just an overall positive experience. I can’t say 
 anything negative about it.  (Kit, Cell Phone Interview #1). 
 The oncologist and the nurse practitioner coordinated the clinical care of the 
patient-participants by taking turns seeing them during their research visits (normally 
they alternate), as noted by Mrs. Washington, “Yeah, they normally alternate.  So I 
either—I might see—even though they got me down for B______ [nurse practitioner], I 
might end up seeing [Dr.]_____ on Thursday.  But they had me down to see B_____ on 
Thursday” (Mrs. Washington, Cell Phone Interview#1).  Further, nurse practitioners 
fulfilled their advanced nursing role as primary healthcare providers—seeing participants 
alone or in place of the oncologist as the need arose.  Bob’s nurse practitioner saw him 
with and without his oncologist.  She fulfilled the oncologist’s requisite clinical tasks, as 
well as administrative tasks such as completing work disability forms, to Bob’s relief: 
 I had a doctor's appointment, although Dr. _____’s on vacation. So I met with the 
 nurse practitioner. So at first I was afraid. I said, “Oh, my gosh, she might not be 
 able to fill these forms out," you know, cause it says "doctor" but thank God, she 
 was able to fill out the form.  (Bob, Cell Phone Interview #3). 
Table 4-9:  I’m Going Through It 
Theme 
 
I’m Going Through It 
 
Category 
 
 At My Appointment Just Trying to Get Through It  
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Sub-
category 
 
 My 
Appointment 
Treatment 
Realities 
How I Feel It’s Knocking Me 
Down 
 
 
Codes 
 
“using some 
time” (Taking 
time for 
treatment)” 
“getting back 
and forth” 
“nice little 
wait” 
 “being 
treated 
differently” 
 
 
“they want me 
to get” (Care 
secondary to 
treatment) 
“going in the 
right direction” 
“and they told 
me” 
“withdrawal” 
“they want my 
system 
cleared” 
  
“I feel good” 
 “gettin’ myself 
together” 
“not feeling 
good day” 
“I’m miserable” 
“I’m angry” 
“I’m scared” 
“death” 
 “feeling the 
fatigue” 
“marked up pretty 
bad” 
“when the hair 
starts to come 
out” 
“pain” 
“shortness of 
breath” 
“neuropathy” 
 
 I’m going through it.  During their cell phone interviews, the patient--
participants invariably discussed a “typical” appointment day at the Cancer Center (At 
My Appointment) and the symptom burden that some experienced on a daily basis (Just 
Trying to get Through It).   
 At my appointment.  Patient-participants’ experiences encompassed activities 
prior to arriving to the Cancer Center and prior to being seen by the oncologist or 
members of the CCT (My Appointment) and information received at the appointment 
(Treatment Realities).  These experiences included mundane activities such scheduling 
time in their daily lives to attend CCT appointments (using my time) and transporting 
themselves (or being transported) to their appointment (going back and forth).  However, 
the mundane activities were interspersed with moments of gravitas. Members of the 
sample discussed feeling that they were being treated differently because of their race 
(being treated differently), waiting interminably for treatment (a nice little wait), being 
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informed their cancer had progressed or metastasized (and they told me), and being 
notified that they had responded favorably to the CCT treatment (going in the right 
direction).     
 My appointment.  Several of the participants discussed the impact of trying to 
schedule their CCT treatment around their work schedule (using some time).  These 
participants micro-managed their work and personal lives.  They actively sought 
cooperative relationships with supervisors, co-workers, and administrators in order to 
schedule and attend their CCT appointments with the modicum of disruption to their 
work responsibilities.  Katie tried to schedule her CCT appointments at 11:00 a.m. in 
order to conserve her leave time: 
 They’re usually either at 11:00. Most of the time they’re at 11:00 or 1:00. Um, so 
 I usually go to work in the morning just trying to save on using some time. Like, 
 my sick time. So, um, I usually try to schedule them, like, mostly between, like, 
 11:00 and 1:00. Usually, um, my—I don’t usually schedule it later than 1:00.  
 (Katie, Cell Phone Interview #1). 
As an administrator at a high school, Ro had accepted that stress and unexpected 
incidents would occur.  Ro attended his nine-week proton therapy appointments after 
leaving his employment for the day (Ro, Semi-structured Interview).  The two days he 
took yoga required that he leave slightly earlier.  It was a pattern that soon became known 
to his staff and the students he supervised (Ro, Cell Phone Interview #1).  However, his 
staff worked with him to make sure he was never late for his appointments.    
 Gina worked a full-time, professional salaried position, while receiving a six-hour 
CCT treatment once a week and caring for her mother who had a deteriorative cognitive 
condition.  To offset the time she used for the CCT infusions, she had arranged with her 
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employer to work extra hours on Thursdays and Fridays (Gina, Cell Phone Interview #1).  
In this way, she was able to save vacation and sick time, which she had exhausted with 
two prior autologous stem cell transplants.  She felt well-supported at work: 
 You know, they know what I’m going through.  So I really, you know, I’ve—I-I 
 don’t put any pressure on myself at work and they seem to be working with me, 
 so I’m very happy about that.  (Gina, Cell Phone Interview #2). 
 By contrast, Diane no longer felt supported.  During her first cell phone interview, 
Diane was considering working part-time in order to have time for her CCT treatment.   
As she progressed through her CCT, she began increasingly to request time off from 
work due to symptom burden and in order to attend CCT appointments (Diane, Cell 
Phone Interview #1; Diane, Cell Phone Interview #3; Diane, Cell Phone Interview #4).  
By the time of her fourth cell phone interview, Diane’s resulting symptom burden and the 
amount of work time she had lost (or had to make up at work) were taking a tremendous 
toll on her job security. Her once supportive manager was no longer supportive.  She 
shifted from considering working part-time, to retiring, and, finally, to losing her job 
(Diane, Cell Phone Interview #1, Diane, Cell Phone Interview #3; Diane, Cell Phone 
Interview #4):   
 But I was, I will actually thinking...there’s like a game changer going on around 
 here.  And I don’t know whether I need to cut my hours or just stop working 
 altogether. If I cut my hours, they can still, you know, check on my time card.  
 I’m already maxed out, and I mean way maxed out, on my vacation time.  And I  
 still have a little bit of sick time left and maybe 13 hours of personal time.  But I 
 need to think about what I really want to do.  (Diane, Cell Phone Interview #3). 
 The manner in which participants arrived at the Cancer Center varied (going back 
and forth).  The task of finding transportation, or being transported, to the Cancer Center 
varied in difficulty.  Three patient-participants used public transportation or a taxicab to 
130 
 
reach the Cancer Center.  Gina, who used public transportation, applied for funding to 
assist her in travelling from her job, to the Cancer Center, and, finally, to her home:   
 But that would help me because some of these people come there and they drive 
 and they’re there all day.  You know what I’m saying?  Then they don’t work and 
 they don’t do anything like that, you know, they’re just in this program, but I’m 
 going back and forth.  I’m coming there and I’m going to work.  I’m coming back 
 out there, you know, and I’m going home, so if I don’t have a ride, I’m dealing 
 with all of this, this public transportation that I have to pay for.   (Gina, Cell 
 Phone Interview #3). 
Participants who drove, or were driven, to their appointments generally had family 
support or were accompanied by their families at some or all of their appointments.  
Participants who walked to their appointments worked in close proximity to the Cancer 
Center and usually had advantageous arrangements in their workplaces that allowed them 
to leave for treatment.  Mrs. L was challenged repeatedly by financial concerns during 
her CCT participation.  She lived several miles from the cancer center site and was 
physically unable to walk long distances to and from public transportation.  As a result, 
she relied on taxicabs, funded by a non-profit cancer organization, to transport her to and 
from her every appointment.  Her experiences were fraught with difficulty and 
frustration, as have been described previously in Specific Aim 1.  
 Patient-participants complained of waiting for extended periods before their 
healthcare provider and CCT treatment appointments (nice little wait).  The delays 
caused the most consternation and frustration among the patient-participants.  RR related 
waiting approximately one to three hours for individual radiation treatment due to 
machine malfunctions: 
 So they had five machines to handle six machines worth of customers.  
 Interviewer:  Wow.  Okay.  Interviewee:  Patience, I guess.  [Laughter]   
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 Interviewer:  Yeah.  So how long did-did you have to wait?  Interviewee: Uh, my 
 appointment was 10:00 to get my treatment.  They finally finished it at around 
 11:53.  Interviewer: Wow.  Okay.  Interviewee:  Yeah.  Yeah.  It was a nice 
 little wait.  (RR, Cell Phone Interview #1). 
Mechanical/instrument breakdown resulted in lengthy delays for participants receiving 
radiation, such as RR and Ro who related this type of delay in two or more of their four 
cell phone interviews (Ro, Cell Phone Interview #1; Ro, RR, Cell Phone Interview #1).    
Participants reported waiting several hours to be seen and arriving home late in the 
evening: “[b]etween leaving the office, going downstairs, and then having to wait for a 
cab, and not getting home until damn near eight—eight o’clock at night.  That really, 
really got to me” (Mrs. L, Cell Phone Interview #1).  Delays in treatment were caused by 
a variety of factors.  Often, one delay contributed to subsequent delays.  For example, 
before their appointments with their oncologist/NP or for CCT treatments, patient-
participants had blood drawn to determine laboratory values.  Hence, a delay in drawing 
or in processing the blood led to additional waits.  Some long waits were due to over-
booking patient slots, which resulted in long waits for patient treatment rooms.   
  The patient-participants dealt with delays in receiving treatment in varying ways.  
Patient-participants expressed their annoyance to the nursing staff or left their 
appointments without having been seen.  Ellie came with the expectation of being seen 
late, so she brought reading materials (magazines and her Bible) and slept (Ellie, Cell 
Phone #2).  Katie accepted the long waits as a trade-off for the exemplary treatment that 
she perceived she was receiving: 
  ...you know like sometimes I feel like, okay, it’s taking too long.  But the 
 outcome is this and so it just makes me feel like you know that’s, that’s trivial.  It, 
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 it doesn’t matter how long I need to wait or anything, because I feel like I’m 
 getting great treatment.  (Katie, Cell Phone Interview #4). 
  Three patient-participants discussed the issue of being treated differently because 
of race in their cell phone interviews.  This question was never asked, directly or 
indirectly, during the face-to-face and cell phones interviews.  The intent was for it to 
arise independently from the interviews.   In her cell phone interview, Diane surmised 
that there may be fewer Blacks, because Blacks may not have insurance for oncology 
treatment (Diane, Cell Phone Interview #1).  RR raised the issue, because he expected the 
question to be asked.  He observed that he “didn’t see anything that changed differently 
because of race (RR, Cell Phone Interview #4).”  By contrast, Ellie believed that 
physicians treated black and white patients differently (Ellie, Cell Phone Interview #3). 
She posited that the doctors at the Cancer Center were like other physicians, except 
“[m]aybe they’re trained better, or something.  So, that if they do feel that way, you don’t 
feel it coming from them” (Ellie, Cell Phone Interview #3).   
 Treatment realities.  At CCT appointments, oncologists informed the patient-
participants of additional imaging, laboratory testing, or physician referrals secondary to 
CCT requirements or response assessments
13
 (they want me to get):  
 But they happened to see a nodule on my, on my lung that was the size of  a 
 pinhead—and so I supposed to go through the pulmonary doctor on Tuesday, so 
 they want me to get a CT scan tomorrow so I can take with  Tuesday to the 
 pulmonary doctor.  (Ro, Cell Phone Interview #3). 
                                                          
13
 A response assessment is an evaluation of whether the CCT treatment had stopped or 
decreased the growth of tumors and/or cancer in the body.  It occurs approximately every 
three months (or, in some protocols, at the discretion of the investigator) and are done 
with the assistance of laboratory tests, physical assessment, and radiographic imaging, 
such as computerized axial tomography (CAT) scans, magnetic resonance imaging scans 
(MRIs), ultrasounds, and/or positron emission tomography (PET) scans.    
133 
 
They were directed to imaging assessment (MRI, CT scan, PET scan, and ultrasound) 
appointments, genetics consultations to assist in receiving targeted treatment, and 
interventional radiologists for central line replacement.  CCT appointments were 
opportunities to share positive news about the outcome of CCT treatment (going in the 
right direction): 
  Interviewer: D-during your appointment with Dr. ____ , um, how, how was 
 that, how was that last meeting with him on Wednesday?  Interviewee: Um, it 
 was fine.  It was positive, I felt.  Um.  Yeah, he had some positive things to say.  I 
 had, I mean, I had already spoken with Dr. ______—Interviewer: Mm-hmm. 
 Interviewee: - um, before the meeting actually, earlier in the week.  Um.  
 Actually the end of last week, after I had my CAT scan.  Interviewer:  Mm-
 hmm.  Interviewee: And, um, so it, well, I mean, it was good to corroborate 
 with, uh, Dr. ______, you know, basically saying the same things as far as, um, 
 you know, things were looking good and going in the right direction, and—.  
 (Bob,  Cell Phone Interview, #1). 
 Receiving good news at CCT appointments meant shrinkage of cancerous masses (Katie, 
Cell Phone Interview #3).  Also, it meant laboratory values which were within normal 
ranges (Bob, Cell Phone Interview #3; Ellie, Cell Phone Interview, #2).  Moreover, for 
some participants, receiving good news meant the possibility of receiving CCT treatment 
without side effects or being told definitively when their CCT treatment would end and 
their subsequent return to their normal life would begin (Ro, Cell Phone Interview #2; 
RR, Cell Phone Interview, #4; Steed, Cell Phone Interview #2).    
  Also, at their appointments, oncologists notified patient-participants of the 
development of a new medical condition during CCT participation, or the discovery of 
metastases from a primary cancer site (and they told me), as Jay had learned at a CCT 
appointment:   
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 And they told me I—I had cancer in my back, like, three spots—on my spinal 
 cord... Well, they said, like—it, like, a tumor in my back, you know, like it—they 
 don’t wanna, like, mess with it—so it might spread and shit, so they working on 
 that, too, so.  (Jay, Cell Phone Interview #1). 
 The participants remained knowledgeable of the nature of the new medical condition or 
metastases, as well as knew with certainty the resulting treatment plan.  At a CCT, Kit 
was informed that she had developed Type 2 diabetes, secondary to steroids prescribed as 
anti-emetics for the CCT regimen (Kit, Cell Phone Interview #1).  She reported that she 
would be weaned from the steroid and referred to her primary care physician for 
management of her diabetes (Kit, Cell Phone Interview #1).  At a CCT appointment 
Gina, Diane, Mrs. L, and Willie were told that that their cancer had progressed and would 
have to be withdrawn from their CCTs. 
 Only four patient-participants discussed withdrawal from their CCT (no longer 
involved in that last trial) during the cell phone interviews, after receiving news of cancer 
progression during their CCT appointments:  Gina, Diane, Mrs. L., and Willie. Gina’s 
withdrawal was presaged by an increase in certain blood protein levels: 
 I did see—I did go in to, um, see Doctor _____today because, um, my protein 
 numbers started going up, so I’m-I’m no longer involved in that last trial.   
 Interviewer: Oh, you aren’t?  Did they propose something for you?   
 Interviewee: Um, we talked about a couple things, but, you know, I’m gonna 
 stay in prayer that, um, they took some blood today, and if my numbers aren’t—if 
 my protein numbers don’t shoot up rapidly, then he’s thinking that maybe, um, for 
 the next four weeks or so, you know, he’ll just leave me off of it and, you know, 
 everything and just see how I work, you know.  (Gina, Cell Phone Interview #3).   
Willie had begun experiencing increasing abdominal pain, which she had dismissed 
(Willie, Cell Phone Interview #1).  Approximately two weeks later, she was informed 
that there was new tumor growth, as well as metastasis of the cancer to her liver (Willie, 
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Cell Phone Interview #2).  The oncologist had assured her that she would be “on the list” 
for a new CCT opening in three to four months (Willie, Cell Phone Interview #2): 
  And-and then he said that there's a trial that will probably open up in January or 
 February.  And, um, he's put my name in for that one.  But right now, he's gonna 
 put me back on that saliparton [oxaliplatin] and I'll have to be infused there and 
 come home with that pump again, which I'm not lookin' forward to, but it is what 
 it is.  (Willie, Cell Phone Interview, #2).    
Following withdrawal from their CCT, each woman understood the need for the CCT 
medication to clear her body (they want my system cleared).  Mrs. L was hesitant to take 
any medication: 
  It’s like coming out of—out of my body.  I didn’t know that it would do that fast.  
 The only thing is, my only complaint really was—now it’s my leg and my foot.  
 It’s still—he said its neuropathy.  Interviewer:  Right.  Interviewee:  And, um, 
 [pause] and yeah, okay, is it gonna go away?  What?  You know?  But as far as 
 he couldn’t tell me—Interviewer:  Well, did he give you any medication to help 
 with it?  Interviewee: No.  No.  I don't know if I have to wait, cause they want 
 my system cleared of just about everything.  (Mrs. L., Cell Phone Interview #4).  
Gina confirmed her understanding: 
 And, um, I thought since I’m off of the um, the Dara [Daratumumab] for the last 
 three weeks because if I—you know, if I need to get—you know, if I need to go 
 on something else, I have to get the other stuff outta my system first, you know, 
 so.  (Gina, Cell Phone Interview #3).   
 Just trying to get through it.  Just Trying to get Through It describes the 
symptom burden endured by patient-participants.  During the cell phone interviews, it 
became readily apparent that patient-participants underwent symptom burden that 
affected their ability to continue working, care for their families, and care for themselves.  
Symptom burden affected emotional and physical aspects of the patient-participants’ 
lives.  They shared feelings of anger, fear, and misery and talked about good days and 
bad days (How I Feel).  They described their physical symptoms, such as nausea, hair 
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loss, pain, and fatigue.   Some of the physical symptoms were viewed as something to 
overcome, and enabled the participants to feel that they could get their “strength and 
health back together” (Mrs. Washington, Cell Phone Interview #4).  Other physical 
symptoms were debilitating and, often, non-responsive to attempts to manage them.  
Some patient-participants were prepared for the symptoms, while other participants were 
wholly unprepared for the frequency and severity of the myriad symptoms they faced 
daily.  Successful symptom management enabled many participants to achieve some 
measure of normalcy in their lives and to remain in their CCTs.   
 How I feel.  Patient-participants experienced days, when symptoms and/or side 
effects from CCT treatment did not impede their daily activities (I feel good):  
 I feel good today.  Uh, I’ve got off of the, uh, proton machine and, um, I was able 
 to, you know, go directly to my car, jump in it, and pull some out of the, uh, 
 Rapid Profile parking lot and, um—and just carry on with my—with my day.   
 Interviewer: Uh huh.  Interviewee:Um, I had to do some running around but I 
 wasn’t amiss for energy or anything like that.  (Steed, Cell Phone Interview #2). 
For Mrs. Washington, feeling good meant awakening, showering, cooking, and being 
able to eat “a nice sized portion” of food” (Mrs. Washington, Cell Phone Interview #1).   
Then, there were days when patient-participants had to attempt to gather their resolve to 
begin the day or to begin an activity (gettin’ myself together).  Ellie had difficulty starting 
her day for a few days after receiving her CCT treatment: 
 Interviewer:  - 10:00 might be a little early for you.  Interviewee: Yeah.  I think 
 so cuz I’m just really gettin’ myself together around that time, so. Especially 
 this—especially the first few days.  The first three or four days it seems like I’m 
 kinda slow getting started [Laughter].  (Ellie, Cell Phone Interview #3).   
Then, there were days the patient-participants stayed at home and barely moved from 
their beds (not feeling too good), as shared by Mrs. Washington, “Uh, I’m at home, but 
137 
 
I’m not feeling too good today” (Mrs. Washington, Cell Phone Interview #2).  In an 
earlier cell phone interview, she elaborated, “Like, I’m tired, I can’t get comfortable if 
I’m laying down.  I’ll have hot and cold flashes.  Pretty much, I may eat something, but it 
won’t be like a nice sized portion” (Mrs. Washington, Cell Phone Interview #1).  Mrs. L 
shared: 
 I’m trying.  Maybe not hard enough, you know.  I need to sit out and get some 
 sunlight in me and whatever, but it’s—I come in here and the first thing I do is 
 crawl up in my bed and go to sleep.  (Mrs. L, Cell Phone Interview #3). 
 Feeling unhappy, or uncomfortable (I’m miserable), was mentioned by some of 
the patient-participants during periods of their CCT participation, when they were 
experiencing symptom burden: 
 Now the tumor’s starting to hurt. But it’s supposed to be shrinking. And I get, 
 like, pain in my bones, like near the pelvis area. And I think I told her all of that 
 last time I saw her, so she said she would try to cut back on the chemo a little bit, 
 you know. But I’m miserable as heck.   (Mrs. L, Cell Phone Interview #3). 
The full impact of Katie’s increasing alopecia (loss of hair) had the same effect on her, 
when she was discussing with her supervisor her remaining CCT treatments: 
 Oh, we got four down, you know. Seven to go on this cycle," and I was like, 
 ‘Yeah,’ and then she was like, ‘So how are you doing?’ And I just, like, bust out 
 crying. And she was like, ‘Oh, what's going on?’ She said, you know, 'cause 
 everybody's so used to seeing a smile on my face, and I've been, you know, okay 
 and then—so I was just like, I said, ‘It's the hair.’ I said, ‘And today I just felt 
 like, you know, I, I felt like I didn’t look nice. I didn’t feel good about myself.’  
 And it's so, you know, just how I felt on Friday.  (Katie, Cell Phone Interview #3). 
Some cell phone interviews discussed anger, fear, and thoughts of death.  Gina felt anger 
for being affected by cancer, while others around her did not have cancer and were “still 
living” (I’m angry).  She described an interaction with a friend whose wife had recently 
died from pancreatic cancer:    
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 He said, ‘This is the first time I really can talk to somebody without cryin’ and 
 breakin’ down.’  And I realized—he says, ‘And I’m angry right now.’  He says, 
 “I’m going to therapy,” he said, ‘Because she was a good woman.  She wasn’t 
 drinkin’, smokin’, out there.’  He said, ‘There are people out here that are abusing 
 their bodies,” and he said, “They’re still here,’ and I realized when he said that I 
 felt the same way.  I had that same feeling sometimes.  It’s like, I’m not doin’ 
 the things that these people are doin’ but getting—still, they’re still living.  (Gina, 
 Cell Phone Interview #1). 
Fear (I’m scared) was expressed by Gina, as well, when she thought about the 
effectiveness of her CCT treatment:    
 You don’t, you know, I mean it’s-it’s supposed to just target that area, but every 
 person is different, so yeah, I’m-I’m scared because I don’t—I don’t know, um, 
 what else could develop.  I don’t—I’m scared because I want to—I want to be in 
 remission and, you know, I don’t wanna have to do—you know, anything else 
 that I might be on would be like a standard drug, and thus far standard drugs have 
 not worked for me.  (Gina, Cell Phone Interview #2). 
Ro shared the same concerns, “So you're still thinkin', you know, I've gotta get chemo 
and this treatment, are they gonna work?  And you know, is this treatment gonna be 
successful? Is this the best treatment” (Ro, Cell Phone Interview, #3)?  Last, thoughts of 
death and mortality (thinking about death) were common among the patient-
participants—although fear was not always associated with it: 
  I used to be scared.  I used to wake up in cold sweat, um, because thinking about 
 death and my dying, but now it’s like I don’t feel that way.  It’s like if I, you 
 know, I believe I’m going to heaven, so it’s—I-I-I don’t have that fear that I used 
 to have.  (Gina, Cell Phone Interview #2). 
Ro commented,  
 Uh, well, first of all, you know when you're newly diagnosed with—the first you 
 hear the word cancer, the first thing that's on your mind is how long I got, I’m 
 gonna leave here [04:25], all that you know, that start goin' through.   (Ro,  Cell  
 Phone interview, #3). 
 It’s knocking me down.   Nausea was mentioned by a few of the Black cancer 
patients who provided cell phone interviews—however, none of the participants reported 
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difficulty managing it.  Similarly, diarrhea was discussed infrequently (Bob, Cell Phone 
Interview, #4; Mrs. L Cell Phone Interview #3; Mrs. Washington, Cell Phone Interview 
#3).  Other symptoms discussed sparingly by the participants, included acid reflux, 
disequilibrium, and insomnia.  
 By contrast, many of the patient-participants discussed feeling the fatigue, or the 
subjective feeling of extreme tiredness, as expressed by Mrs. Washington, “Uh, Friday, 
Friday was good. Saturday was, Saturday was good, and then I started feelin’—it 
was Saturday night I started feeling the fatigue going on” (Mrs. Washington, Cell Phone 
Interview #2).  Generally, fatigue occurred on the day of, or within a day or two of, 
receipt of CCT treatment (Ellie, Cell Phone Interview #1; Steed, Cell Phone Interview 
#4; Mrs. Washington, Cell Phone Interview #2).   Typically, patient-participants 
described requiring several additional hours of sleep during their day (Kit, Cell Phone 
Interview #1; Mrs. L, Cell Phone Interview #1; Mrs. Washington, Cell Phone Interview 
#2; Steed, Cell Phone Interview #4). The degree to which fatigue interfered with their 
daily activities varied. Kit, who was adamant about compartmentalizing her CCT 
treatment from her daily life, stated that the fatigue “makes it hard to balance school and 
work and home” (Kit, Cell Phone Interview #1).  Other participants surrendered to the 
extreme tiredness for a period of time, then resumed with the remainder of their daily 
activities: 
 I don’t know if it was me not wanting to push it or ran out of energy. I said, ‘No, I 
 just don’t feel like doing this right now.’ I took the vacuum the cleaner and put it 
 over on the side. I went upstairs and took a nap, came back down and that was 
 it. Then I finished.  (Steed, Cell Phone Interview #4).   
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 Finally, a few, like Mrs. L and Eric were challenged severely by their fatigue.  Eric 
freely admitted that, initially, the radiation had a limited effect on his physical 
constitution (Eric, Cell Phone Interview #1).  However, at the time of his interview, he 
reported that he felt “very weak and tired” and had begun to “fall asleep all the time” 
(Eric, Cell Phone Interview, #1).  He was finding it difficult to work—although, he was 
still able to work.  Mrs. L was very challenged by fatigue.  She recognized the 
seriousness of her fatigue, but felt unable to combat it:   
 I just get tired. That’s what’s bothering me I wanna be an adult now. I want to be 
 able to do what I need to do in this apartment, and I just get, oh, like, wow. I’ll sit 
 there and try to get myself together, and the next thing, I just come right on in 
 here, crawl up on my bed and go to sleep.  (Mrs. L, Cell Phone Interview #1). 
   The male participants in the Yoga Study, Steed, Ro, and RR, had been 
randomized to receive yoga instruction as a means to reduce the effects of fatigue from 
the radiation therapy administered as part of their prostate cancer CCT (RR, Cell Phone 
Interview #4).  All the men spoke highly of the physical and meditative benefits of yoga 
instruction.  It did reduce some of their fatigue.  Yet, eventually, RR and Steed yielded to 
the effects of the radiation therapy (RR, Cell Phone Interview #1; Steed, Cell Phone 
Interview #4).    
 Symptoms tied to physical appearance, such as skin changes (marked up pretty 
bad) and hair loss (when the hair starts to come out), were very upsetting to the female 
patient-participants.  Mrs. L had a rash on her neck. She stated that the nurse practitioner 
did not know the cause of the rash and had never prescribed any medication:   
  So it’s like, are you listening?  I’m trying to tell you somethin’.  And that’s when 
 I get just tired and my skin breaking out.  She still says she doesn’t know why 
 that’s happening.  Well, okay.  All right.  Whatever.  You know.  I don’t like it.  
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 I’ve not had skin break out like this in [laughs] ever.  You know.  And it’s—it’s 
 just annoying.  But I’m marked up pretty bad, so I can just give up on the skin, 
 you know.  (Mrs. L, Cell Phone Interview #3).  
Katie had blue-black discolorations on both of her hands (Katie, Cell Phone Interview 
#2). The nurse practitioner was aware of her hand discolorations; however, Katie was not 
given medication, or any recommendations on how to care for the discolorations.   
 Hair loss, mentioned by several of the women during their face-to-face 
interviews, continued to be an enduring and painful topic during the cell phone interviews 
(Diane, Semi-structured Interview; Gina, Cell Phone Interview #1; Katie, Semi-structured 
Interview; Katie, Cell Phone Interview #1; Katie, Cell Phone Interview #2; Kit, Semi-
structured Interview; Mrs. S, Semi-structured Interview).  Hair loss was one of the 
symptoms that could not be remedied.  Katie was especially distressed and had difficulty 
adjusting to her hair loss.  Her hair had been important to her; and she recognized that she 
would have difficulty when it began to “shed”: 
 I think I mentioned that to one of my friends, and I said, ‘I know when the hair 
 starts to come out I’m gonna be, like, a mess because I’m big on getting my hair 
 done.’  I used to go to the hairdresser like every week at one time.  (Katie, Cell 
 Phone Interview #2).     
Her hair was an integral part of her self-image. Ultimately, Katie did buy a human hair 
wig and began to wear it (Katie, Cell Phone Interview #4).  However, she remained 
inconsolable about her hair loss.  Gina adjusted to hair loss by wearing wigs, while her 
hair grew naturally under her wigs as dreadlocks (locks).
14
  However, she had not come 
to terms with losing her new growth of locks which was fragile (Gina, Cell Phone 
                                                          
14
 A dreadlock, or lock, is comprised of strands of hair that have been twisted or formed 
together and allowed to grow together as a single piece of hair. 
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Interview #1).  The weight of the hair was causing the locks to break apart and fall off her 
head.  She despaired that her new growth of locks would have to be cut (Gina, Cell Phone 
Interview #1).   
 Pain (pain) and peripheral neuropathy (neuropathy) were mentioned frequently as 
extremely distressing symptom experiences.  Both symptom experiences affected the 
daily activities of the patient-participants and were not always amenable to effective 
control by the CCT team.  Willie reported that the “…only thing that I have is the pain, 
and that’s, that’s the everyday thing.  I don’t think I’m gonna ever get rid of that pain” 
(Willie, Cell Phone Interview #1).  A few patient-participants reported feeling no pain 
during their CCT (Bob, Cell Phone Interview #3; RR, Cell Phone Interview #3).  For 
those who experienced pain, the participants varied in their description of the quality and 
the duration of their pain.  The quality of the pain ranged from discomfort to feeling like 
“being hit in the back” (Ro, Cell Phone Interview, #1; Mrs. L, Cell Phone Interview #3). 
The duration of the pain varied.  Some pain was episodic.  Ro received Lupron injections 
which caused nipple and breast tenderness (Ro, Cell Phone Interview #1).  His pain 
occurred only when his chest was touched.  He described pain which nearly made him 
“drop to his knees,” when a friend playfully punched him in his chest (Ro, Cell Phone 
Interview #1).  Ellie experienced pain only when her portacath was accessed (Ellie, Cell 
Phone Interview #2). 
 For some patient-participants, the pain was continual and unremitting.  Willie and 
Mrs. L had unrelenting pain secondary to their colo-rectal cancer (Mrs. L, Cell Phone 
Interview #3; Mrs. L, Cell Phone Interview #4; Willie, Cell Phone Interview #1).  
143 
 
Abdominal pain was a regular part of their lives, since each day began and ended with 
pain for both of them (Mrs. L, Cell Phone Interview #1; Mrs. L, Cell Phone Interview #4; 
Willie, Cell Phone Interview #1). Willie assiduously kept her pain level at a pain rating of 
three to four out of ten, while Mrs. L preferred to be in pain rather than be sedated by the 
prescribed dosage of her pain medication (Mrs. L, Cell Phone Interview #3; Willie, Cell 
Phone Interview #1).   Mrs. L’s pain was a significant part of her CCT experience; she 
discussed her pain in every cell phone interview in which she participated.    
 Katie had breast pain secondary to her cancer.  She worked, cared for her sons, 
had massages, and, otherwise, continued her daily routine.  She used oxycodone to 
control her pain.  Except, she could not take her opiate pain medication in the morning, 
since she drove to work each day (Katie, Cell Phone Interview #4).  The oxycodone made 
her too drowsy to feel safe driving.  Although, there were times when the pain prompted 
her to take the opiate medication at work: 
 Now, there’s been time I taken it at work, because hoping—like if I take it when I 
 get to work, hoping that I, I’ll be okay by the time I drive home. Which I, I was, 
 but I don’t know. I just felt a little iffy about that.  (Katie, Cell Phone Interview 
 #4).  
So, she was able to relieve her pain despite putting herself at risk, when she drove home 
in the evening.  The pain severity was enough for her to risk taking the oxycodone at 
work. 
 In addition to pain caused by their disease, patient-participants related the 
occurrence of pain resulting from treatment, procedures, or evaluations secondary to the 
CCT.  Mrs. L reported feeling incredible pain while she was positioned for a MRI.     
Ellie had a portacath, or a central line in her chest which had to be accessed by inserting a 
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needle into its barrel. Because the portacath laid under the skin, accessing it necessarily 
entailed piercing the skin overlying it. The process of piercing the skin was painful for 
Ellie.  She had endured the pain until a home infusion nurse recommended that Ellie get a 
prescription for topical lidocaine from her oncologist.  Bob developed a pleural effusion 
in one of his lungs which compromised his ability to breathe effectively and without 
discomfort.  A thoracentesis
15
 was performed three times, before a pleur-x-catheter was 
inserted into the pleural effusion (Bob, Cell Phone Interview #3).  Bob’s husband was 
trained in the use of a pleur-x-catheter by a home care nurse.  The pleur-x-catheter 
allowed frequent draining of excess pleural fluid as it accumulated around Bob’s lung, 
thereby permitting Bob to breathe effectively and without discomfort.  In addition, it 
could be performed by his husband in their home, as needed.  Subsequent to drainage of 
the pleural effusion, Bob would experience pain in his lung for approximately an hour 
(Bob, Cell Phone Interview #3).  Eventually, he and his husband learned to stop draining 
the pleural effusion as soon as Bob felt the slightest discomfort.  
 Shortness of breath (shortness of breath) was mentioned by only three of the 
participants in their cell phone interviews (Bob, Cell Phone Interview #3; Diane, Cell 
Phone Interview #3; Mrs. Washington, Cell Phone Interview #4).  Mrs. Washington 
mentioned it for the first time in her last cell phone interview.  Bob mentioned it in 
relation to the pleur-x-catheter inserted secondary to his pleural effusions.  He had 
reported to his oncologist that he had experienced, “Um, extreme shortness of breath, just 
                                                          
15
 A thoracentesis is the insertion of a needle, or small tube, into a pleural effusion with 
the intent to drain the excess fluid.  It is performed in inpatient and outpatient hospital 
settings. 
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from very little activity” (Bob, Cell Phone Interview #3).  Bob’s shortness of breath 
resolved with more frequent removal of pleural fluid at home with the pleur-x-catheter 
(Bob, Cell Phone Interview #3).  By contrast, Diane’s shortness of breath was debilitating 
and affected every aspect of her life. It resulted from the disease in her lungs, abdominal 
ascites, and an abdominal tumor pressing up on her lungs (Diane, Cell Phone Interview 
#3; Diane, Cell Phone Interview #4).  She had to do everything slower (e.g., personal 
hygiene, walking, dressing), eventually could not drive, and had difficulty working her 
entire eight-hour shift (Diane, Cell Phone Interview #3; Cell Phone Interview #4). 
 Peripheral neuropathy (neuropathy) affected several members of the sample.  For 
Ellie, peripheral neuropathy was the CCT symptom which bothered her the most, “Uh, 
just that with—what bothers me—I think what bothers me the most is dealing with 
neuropathy. Mm-hmm.  It really—it-it just bothers—seems to bother me the most” (Ellie, 
Cell Phone interview #3).  It was caused by medications administered as part of the CCT.  
Peripheral neuropathy for Katie, Kit, and Mrs. Washington (all of whom who had breast 
cancer) was expressed as numbness and occasional pain in their hands and fingers (Katie, 
Cell Phone Interview #3; Kit, Cell Phone Interview #1; Mrs. Washington, Cell Phone 
Interview #3).  During their cell phone interviews, neither Kit, Katie, nor Mrs. 
Washington mentioned any situations when the peripheral neuropathy affected their daily 
activities.   They were not given medication.  However, Katie’s oncologist did lower the 
dosage of the medication causing her peripheral neuropathy (Katie, Cell Phone Interview 
#4).   
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 Mrs. L and Ellie had severe peripheral neuropathy that impeded their daily 
activities.  If Ellie touched objects with her hands during an exacerbation, her skin felt 
like it had been burned (Ellie, Cell Phone Interview #3).  She could not pick up objects, 
open containers, or button her clothes (Ellie, Cell Phone Interview #4).  She attempted to 
cope with the sensory impairment by wearing gloves.  Her oncologist prescribed 
Neurontin; however, “…it took about four weeks for it to really kick in like it’s supposed 
to” (Ellie, Cell Phone Interview #4).  Eventually, the medication causing the peripheral 
neuropathy was discontinued by the oncologist.  Mrs. L’s tactile sensory impairment 
from peripheral neuropathy resulted in her feeling like she was “being electrocuted” 
(Mrs. L, Cell Phone Interview #1).  Like Ellie, she learned to use gloves, or oven mitts, to 
touch objects in her kitchen.  She could not touch or ingest anything cold (Mrs. L, Cell 
Phone Interview #1).  All food and drink had to be room temperature, or she would 
experience a very unpleasant sensation in her throat, which was “indescribable” (Mrs. L, 
Cell Phone Interview #1).  Unlike Ellie, Mrs. L was not given any medication for her 
peripheral neuropathy. 
Table 4-10:  Who I Am 
 
Theme 
 
 
Who I Am 
 
Category 
 
I Didn’t Want to Be 
Different Than Who I 
Was 
Cancer Has Changed 
My Life 
Getting the 
Word Out 
Code 
 
 
 
 
 
“I don’t let it consume 
my whole day” 
“balance” 
“faith” 
 
“you gotta do whatever 
you have to do” 
“next thing that has to be 
worked on” 
 “insurance companies” 
“work” 
“I am very open” 
 “they’ve been 
through it” 
 “a dialogue” 
“sharing your 
story” 
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 Who I am.  Throughout their CCT treatment, patient-participants expressed a 
desire to remain “who they were” before their CCT participation (I Didn’t Want to Be 
Different Than Who I Was).  They struggled to maintain a sense of who they were and 
what was important in their lives by continuing to live despite the presence of their 
cancer in their lives (I don’t let it consume my whole day), keeping a sense of balance in 
their lives (balance), and acknowledging and sustaining their spiritual beliefs (faith).  
Ultimately, the participants did acknowledge that their cancer diagnosis and their 
participation in the CCT had changed their lives (Cancer Has Changed My Life). At 
various times during their cellphone interviews, patient-participants spoke candidly of 
finding ways to adjust to their new lives with cancer and CCT participation (you gotta do 
whatever you have to do).  They discussed their interactions with insurance companies 
(insurance companies), acknowledged the effect of CCT participation on their work lives 
(my job), and learned to manage new medical conditions which developed secondary to 
CCT participation (next thing that has to be worked on).   Finally, one common 
characteristic of many of the patient-participants was the strong desire to bring 
knowledge of cancer and CCTs to their family members and into the Black community 
(Getting the Word Out).  Patient-participants spoke of how and with whom they had 
shared information regarding their cancer diagnosis and their CCT participation (I talk 
openly).  Some were fortunate to have other individuals share their cancer and CCT 
148 
 
experiences before or during the patient-participants’ CCT participation (they’ve been 
through it)—in turn, this sharing prompted the participants to do their own sharing about 
their cancer and their CCT experiences (sharing my experience) in their church and in the 
Black community (opening the dialogue).    
  I didn’t want to be different than who I was.  During the face-to-face interviews, 
patient-participants expressed the affirmation that they were alive, present, and surviving 
their cancer and CCT treatment.  They typified this affirmation during their cell phone 
interviews.  A large part of this affirmation were their efforts to balance the demands of 
CCT treatment with the demands of their home life, work life, and/or school life (Kit was 
a doctoral student) (balance) by making a concerted decision to fit the CCT into their 
daily schedule, instead of allowing it to become the central focus of their lives. Kit stuck 
to a strict schedule to maintain normalcy in her three children’s lives, “I generally stick to 
the schedule because I have to maintain a balance” (Kit, Cell Phone Interview #1).  
Although maintaining normalcy in family life was mentioned by some of the patient-
participants, maintaining a work life balance was mentioned by more patient-
participants—especially by participants who continued to work during CCT enrollment.    
 Patient-participants balanced work and CCT treatment in various ways.  Ro 
integrated yoga into his work as a school administrator, by offering yoga as a part of the 
summer program at his school in order to calm and de-stress students with behavioral 
differences (Ro, Cell Phone Interview #1).  Katie was strategic in scheduling her CCT 
appointments as close to the late afternoon as possible, in order to preserve her sick time 
(Katie, Cell Phone Interview #4).  Diane attempted to schedule as many appointments as 
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possible on the same day (Diane, Cell Phone Interview #1).  Despite these efforts, 
participants with progressive disease began to find that CCT appointments began to 
consume more and more time out of their day (Diane, Cell Phone Interview #1).  Kit was 
the only patient-participant who was faced with integrating her work life, family life, and 
school life with her CCT enrollment.  Kit was a doctoral student, as well as a single 
mother and a full-time school administrator, who was in the midst of taking her 
comprehensive examinations and writing her dissertation proposal.  She balanced her 
CCT enrollment, work, school, and family by compartmentalizing every facet of her life: 
 I have three children.  So, um, whatever I do at work is at work.  And whatever I 
 do at home is home.  And my schoolwork.  But other than that, I don’t – I don’t 
 do work at home.  So, I generally want time so I can make sure I get home and be 
 there for my own children.  Cook dinner... I still have time for everything.  I 
 make time for everything.  Um, and it helps to ignore how you feel anyway.  It 
 kinda makes it go away.  So, um, yeah I don’t – I don’t let the cancer impede on 
 my life.  (Kit, Cell Phone Interview #1).   
 Many of the patient-participants were anchored by their belief in God, or the 
significant presence of God in their daily life (faith).  Katie’s faith allowed her to disclose 
her cancer diagnosis and CCT participation to her children: 
 These are my children. I can’t believe they have to deal with this. And I wasn’t. I 
 was just open, and candid, and okay with just talking to them, and, you know, in 
 the midst of this here just holding them, but talking to them, but I wasn’t crying or 
 anything. And I told him if I didn’t have that firm belief in that faith that I 
 wouldn’t even be able to do that. I probably would’ve been a mess.  (Katie, Cell  
 Phone Interview #1). 
Their faith sustained them, when there were indications of disease progression:  
 So, you know, I was—I was a little concerned and, you know, just a little 
 depressed, but I was like, you know what? If God worked all the rest of that out, 
 he’s gonna work this out too. One way or the other, if it’s, you know, if it’s—I-I 
 can’t do anything about this. You know, I’m part of the study and he has total 
 control. I mean I take medication and do whatever, but he has total 
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 control.  (Gina, Cell Phone Interview #2). 
 Faith enabled the patient-participants to move each day against all odds, and to 
believe that they were “not always going to be this way, feel this way, act this way” 
(Gina, Cell Phone Interview #1).  It kept them involved in activities at their church.  RR 
was a member of the trustee board at his church (RR, Cell Phone Interview #2). Diane 
was a member of a cancer support group and was spearheading a cancer prevention/CCT 
informational session at her church—even as she endured disease progression and 
increasing symptom burden (Diane, Cell Phone Interview #2).  Gina was a member of a 
telephone prayer group that met every morning at 6:30 a.m. (Gina, Cell Phone Interview, 
#2).  Katie participated in a clothing donation program at her church (Katie, Cell Phone 
Interview #1).  Also, when the time came, faith enabled Katie to step away temporarily 
from her church activities and still know that God was with her, even though she could 
no longer be active in her church: 
 And I just remember at the end [of a conversation with a friend] he said, you 
 know, he was talking  about you know praying and being faithful and whatever.  
 He said, ‘But we as church members have to know how to take a break.’  And 
 it was just so weird, and that just resonated in my head, you know, and I always 
 say, you know, do I hear this, and I’m running this, and I’m doing this.  (Katie, 
 Cell Phone Interview #4).   
 When she appreciated the enormity of her belief in God and His integral role in her life, 
she could put aside her church involvement, for a time. 
 Cancer has changed my life.  Despite attempts to manage the various aspects of 
their lives, invariably there were certain aspects of the patient-participants’ lives that 
were altered by their cancer diagnosis and CCT participation (Cancer Has Changed My 
Life).  Living with their cancer and CCT enrollment presented challenges to the 
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participants.  However, many of the patient-participants reconciled themselves to 
surmounting these challenges (you gotta do whatever you have to do), as voiced by Ro,”   
You gotta do what you gotta—if you wanna survive, if you wanna beat this, you gotta do 
whatever you have to do“(Ro, Cell Phone Interview #3).  One of the earliest challenges 
was willingness to talk about their cancer diagnoses.  Some participants still had 
difficulty talking about their cancer with others. Katie acknowledged that being 
interviewed as part of this dissertation study made her feel that it was okay to talk about 
her cancer, “And then just with you talking to me, asking me questions, just reaffirms 
that, you know, it’s okay to talk about it. It’s okay to, you know—you know, share. You 
know?” (Katie, Cell Phone Interview #1). 
 Her ability to talk about her cancer changed over the course of her cell phone 
interviews.   She made tentative, then repeated, efforts to talk to her sister, mother, and 
sons about her cancer, thereby assisting them in adjusting to her cancer and the ensuing 
side effects of the CCT medication (Katie, Cell Phone Interview #1, Katie, Cell Phone 
Interview #2; Katie, Cell Phone Interview #3; Katie, Cell Phone Interview #4).    By her 
fourth cell phone interview, Katie was talking freely about her changed life.  
Significantly, she had accepted her hair loss and her mother’s inability to accept her 
cancer diagnosis:    
 I’m so used to it now I just come in, like I wear a wig. I just come in the house 
 and take it off, and I have no hair. But I do this.  Like, she will just stare at me. 
 I don’t say anything. Used to say, like, ask questions, but I don’t say anything—I  
 just let it go. That’s how she deal, deals with it. I just leave it alone.  (Katie, Cell 
 Phone Interview #4). 
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 Initially, Jay had a more difficult time contending with his cancer diagnosis, since 
he used a mini-infuser strapped to his body to deliver chemotherapy over several days.  
He abhorred the stares and comments of others.  Jay sensed, whether correctly or 
incorrectly, that other individuals viewed him as a pariah to be avoided, because he was 
“sick” or “contagious” (Jay, Cell Phone Interview #1).  Their perceived reactions angered 
him (Jay, Cell Phone Interview #1).  The oral formulation of his CCT chemotherapeutic 
medication made it easier for Jay to accept his diagnosis and treatment: 
 They look at you like, you know, they see somebody with a bottle, and right 
 away they think that, ‘Oh, he’s sick.  He’s contagious.  Stay away from him.’  
 I’m, like, ‘Y’all are [inaudible 05:40].  Y’all don’t know what I’m going 
 through,’ you know.  They shouldn’t be talking...Yeah, so I’d—like, I really 
 didn’t like it, you know, that’s—gotta wake up with a bottle, go to bed with a  
 bottle, you gotta make sure you don’t sleep on the bottle and all that.  Make sure 
 you don’t pop the IV [inaudible 06:03] like it says.  Interviewer: Right.   
 Interviewee: But with the pill, I gotta take my little pills [inaudible 06:08] take 
 it with me and I’m good to go.  (Jay, Cell Phone Interview #1). 
 Preexisting caregiving relationships were changed by cancer and CCT 
participation.  Some patient-participants’ family members willingly assumed caregiving 
roles, such as Bob’s spouse, Ellie’s spouse and daughter, and Diane’s spouse.  Patient-
participants’ with established caregiving roles for family members instituted changes to 
these relationships, as a result of CCT appointments.  Pursuant to her interviews, Kit 
appeared to be successful in compartmentalizing her work, home, and school lives (Kit, 
Cell Phone Interview #1).  Mrs. L managed by being home with her daughter and making 
her CCT appointments contemporaneous with her daughter’s appointments (Mrs. L, Cell 
Phone Interview #3).  Katie wanted always to be present for her sons, despite juggling 
work and CCT appointments.  As a result, her sons had to accept a modicum of 
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responsibility and acknowledge the necessity for a precise schedule, from the moment 
they awakened in the morning until Katie had completed helping them with their 
homework in the evening (Katie, Cell Phone Interview #3).   
 Gina had a more demanding situation.  She was the sole caregiver for her mother 
who had dementia.  Because of lack of support and financial resources, she could only 
afford to have a neighbor “look in” on her mother periodically during the day instead of a 
full-time caregiver while Gina worked (Gina, Cell Phone Interview #1).  Despite coming 
home as late as 7PM or 8PM, she began her caregiving activities as usual:  cooked dinner 
for her and her mother, washed the dishes, washed/bathed her mother, put her mother to 
bed, and prepared herself for the next day (Gina, Cell Phone Interview #2; Gina, Cell 
Phone Interview #2).  Gina was relieved of this responsibility proximate to the second 
cell phone interview.  She had to place her mother in a nursing home, after her mother 
developed bilateral deep vein thromboses and would require lifelong anticoagulation.      
   Many of the patient-participants realized they had to adopt healthier lifestyles in 
order maintain their functional status during their CCT participation, such as Diane who 
increased your walking despite having shortness of breath,   
 And I walked more than I have in a long time last night from the-the distance that 
 they have me walking in this hospital. I started, uh, I started to go back and
 get in the car, but I went on and I pursued it and I walked all the way back. And I 
 said, now that’s huffing and puffing and deep breathing probably do a lot of that 
 stuff out of me, which I hope it did.  (Diane, Cell Phone Interview #1). 
 They increased their fluid intake of water and other liquids to combat dehydration and 
cramping secondary to electrolyte imbalances: 
 And I find that when I drink more fluids that I don’t have that—the muscle  
 spasms and the cramps and stuff that I was having. Especially now since it’s so 
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 hot, you know, I definitely have to stay hydrated. And I realize that the more that 
 I drink fluids that, um, the better it is for me, and I’m not—I’m-I’m not cramping 
 and, you know, that kinda thing.  (Gina, Cell Phone interview #2). 
Other patient-participants meditated to promote mental and psychological health, while 
the men in the Yoga CCT performed yoga for physical and mental wellness independent 
of scheduled sessions (RR, Cell Phone Interview #2; Ro, Cell Phone Interview #1; Steed, 
Cell Phone Interview # 3).  
 The lives of some of the patient-participants were changed by the development of 
additional comorbidities. They were tasked with managing not only their prior 
conditions, but also learning to manage their new comorbidities (next thing that has to be 
worked on), as noted by Kit regarding her new diabetes diagnosis.  Kit was aware of her 
borderline diabetic status, prior to her participation in I-SPY II:   
 And I found out I have diabetes yesterday now. But, uh, other than that, you 
 know, it’s good.  So, now I’m just addin’ that to the next thing that has to be 
 worked on I was borderline before, but now because of the steroids it’s pushed it 
 over.  So, I was close but I never made it to actually havin’ it.  So, now I’m fully 
 there.  (Kit, Cell Phone Interview #1).  
Kit managed her diabetes methodically, as she did every aspect of her life.  Ellie’s life 
was complicated when she developed a pulmonary embolus (blood clot in her lungs) 
towards the end of the cell phone interviews (Cell Phone Interview #4).  She adapted to 
the new medical condition and learned to self-inject lovenox (an anticoagulant) with the 
assistance of her family (Ellie, Cell Phone Interview #4).    
 All the participants had to interact with the insurance companies responsible for 
covering (or not covering) the costs of their CCT participation and the usual and 
customary care related to the CCT treatment (insurance companies).  The cost of CCT 
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participation was borne, often uneasily.  All the participants had some type of insurance 
coverage and appreciated the availability of insurance coverage (Bob, Cell Phone 
Interview #3; Mrs. L, Cell Phone Interview #3).  Having insurance also meant keeping 
insurance and managing all of the paperwork.  When asked regarding recent challenges, 
Bob mentioned, “[D]ealin’ with these, you know, insurance companies” (Bob, Cell 
Phone Interview #4).  Bob nearly lost his health insurance coverage, when his employer 
failed to pay the premiums and the insurance company failed to notify Bob of the 
nonpayment for two months (Bob, Cell Phone Interview #3):   
  Something just clicked in my mind [chuckles] one day, so I called to find out. 
 And she was like, ‘Well, yes, um, you know, your benefits haven't been paid—‘ I 
 think it was since May. At the time, that was May 16th that my payroll stopped 
 paying  for, you know, my benefits. But then they let it go. She said, ‘They don’t 
 contact you until the bill reaches—the past-due bill would reach $100’-- which 
 mine, I think, at that time had only reached, like, $24.  (Bob, Cell Phone Interview 
 #3). 
Insurance coverage for services performed frequently was an issue.  Diane faced this 
insurance reality.  Diane made a practice of requesting that her physician, radiographic, 
and other CCT-related appointments be grouped on one day, in order to avoid the $20 per 
visit copay (Diane Cell Phone Interview #1).  Before she made the request, she had two 
to three appointments a week, two to three times a month (Diane, Cell Phone Interview, 
#1).  Response assessments required frequent radiography studies.  However, insurance 
companies did not always pay for every response assessment radiography study required 
by CCTs.  So, often, the PET scans were not done:   
 And [I] was askin' about the PET scan also, and they were, like, ‘Well, you  
know,  we don’t even request PET scans anymore because the insurance 
companies they just, you know, deny, deny, deny, deny. They don’t accept—after 
you already had one they figure that’s enough.  (Bob, Cell Phone Interview #4). 
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If the PET scan was performed, the patient-participant would have to pay for it.   
  Several of the participants discussed the impact of CCT participation on their 
employment (work): 
 Well, um, people at work, you know, have been really, really, um, cooperative, 
 you know, because I’m showing up—it’s not like you’re going and you’re trying 
 to take advantage of anything. You know, they know what I’m going through. So 
 I really, you know, I’ve—I-I don’t put any pressure on myself at work and they 
 seem to be working with me, so I’m very happy about that.  (Diane, Cell Phone 
 Interview #3). 
Diane was placed in an untenable position.  She had to ascertain how to retain her job, in 
order to keep the insurance enabling her continued CCT participation—in turn, the 
increasing symptom burden and time spent at CCT appointments were resulting in her 
impending job loss: 
 ...I’m still having my manager and a couple other people have been noticing that 
 they know that I’m short of breath.  So I’m—I’m thinking in terms of now that 
 there’s something that I might have to lookin’ forward to is them puttin’ me out.   
 (Diane, Cell Phone Interview #4). 
Her position was extremely precarious during the fourth cell phone interview.  Her new 
oncologist was proposing major abdominal surgery for temporary relief of her respiratory 
distress, which would require her to recuperate at home for several weeks.  She had 
worked too few hours to qualify for leave time under the Family Medical Leave Act, had 
no vacation time left, and had 13 hours of sick time left (Diane, Cell Phone Interview #4).  
Diane chose the surgery.    
 Getting the word out.  As is evident from the interviews, the Black cancer patient-
participants had varying experiences derived from their symptom burden, the measure of 
support they received from their families and CCT teams, and the manner in which they 
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managed their cancer.  However, many were similar in their desire to share their cancer 
diagnoses and CCT experiences.  Many patient-participants, such as Kit, were willing to 
discuss candidly with others their cancer diagnosis and cancer treatment (I am very open), 
“I’m very open, so I share whatever. I feel like people should learn what’s happenin’ to 
me” (Kit, Cell Phone Interview #1).  The patient-participants were open in sharing 
information regarding their cancer diagnoses and CCT participation with church 
members, their other healthcare providers, and abject strangers: 
 Um, there were some people that walked into me yesterday and I had the IV in  
 my hand because when I left MRI and I went—okay, I had to—I didn’t have any 
 money. I had to come back and talk with the—the credit union and then come 
 back out, and a few of them say, ‘Oh, are you okay?’ And I just—I just wanted 
 to run ahead and [inaudible] and I was like, ‘I'm okay.” She was 
 like, ‘You’ve got an IV in your hand. Something’s going on.’  And I said, 
 ‘You know what? I have breast cancer.’ She said, ‘Oh my God.’ I said, 
 ‘It’s okay. I’m okay. I’m [mumbling voice 26:27]. I’m here for my 
 treatment. I’m good.’   (Katie, Cell Phone Interview #1). 
 Some patient-participants were motivated to share experiences, because someone 
had shared their on-going, and/or past, experiences with them (they’ve been through it).  
Mrs. Washington shared her on-going conversations with her co-workers: 
 ...seems like most of the ladies where I work from has started finding lumps in 
 they breasts.  So they—that has, uh, uh, and they've been through it.  So we have 
 each other's phone numbers.  And, you know, like, they'll call me up.  I'll call 
 them up.  (Mrs. Washington, Cell Phone Interview #4).   
Some patient-participants simply listened to the stories of cancer survivors who were 
patients at the Cancer Center, church members, or neighbors who lived across the street 
(Diane, Cell Phone Interview #2; Katie, Cell Phone Interview #4; Ro, Cell Phone 
Interview, #3; Steed, Cell Phone Interview #1).  Ellie spoke with a church member who 
had experienced severe peripheral neuropathy secondary to continued use of 
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oxaliplatin—the chemotherapy drug that had caused Ellie’s peripheral neuropathy and 
that had been stopped by Ellie’s oncologist (Ellie, Cell Phone Interview #4): 
 I know there’s a woman at my church who did that, and she’s so sorry because 
 things didn’t go-go well with her.  She, uh, she-she developed some other 
 problems because of the neuropathy.  Uh-huh.  She developed some other-other 
 problems...I mean, I can’t remember what all she said.  But I do remember that 
 she said neuropathy was driving her crazy, so.  (Ellie, Cell Phone Interview #3). 
This discussion affirmed Ellie’s trust in her oncologist’s individualizing her 
chemotherapy plan, rather than continuing with treatment consistent with the 
chemotherapy regimen.  Mrs. Washington’s cancer diagnosis resulted in an outpouring of 
expressions of support from the wives of her husband’s co-workers and from her 
coworkers, who were cancer survivors, or who were “going through it” at the same time 
as she (Mrs. Washington, Cell Phone Interview #4).  Male members of Steed’s church 
congregation reached out to him, when he disclosed his prostate cancer diagnosis—men, 
who heretofore, had never revealed their cancer history to Steed (Steed, Cell Phone 
Interview #1).   A few, or many, words expressing support buoyed the spirits, as well as 
the resolve of several participants to continue their CCT treatment (Kit, Cell Phone 
Interview, #1; Ro, Cell Phone Interview #3).     
 The patient-participants shared their cancer and CCT experiences (share your 
story) with members of their church, members of their community, and other individuals 
with and without cancer, as a means of opening up the discussion about cancer, cancer 
prevention, cancer treatment, and cancer clinical trials (a dialogue).
 
 A few patient-
participants did not discuss sharing their cancer and CCT experiences with others. Bob 
stated frankly that he had not talked about his pancreatic cancer and CCT with people, 
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other than his family members or individuals involved in his care (Bob, Cell Phone 
Interview, #2).  Some participants, such as Katie, spoke prospectively of what they would 
share with other individuals.  She addressed many of the issues she discussed during her 
cell phone interview.  However, paramount among her concerns was the necessity to 
listen, as well as talk, so as not to overshadow their experiences (Katie, Cell Phone 
Interview #4).  Katie stated that she would try to explain clinical trials and the reasons 
why they are done (Katie, Cell Phone Interview #4).  She sought to impart hope and 
encouragement that there is a CCT team and physicians who can provide care for them 
(Katie, Cell Phone Interview #4): 
 Interviewee: Uh, I would be supportive, but in a way that, you know, like, if 
 whatever they needed from me, I would give them.  I wouldn’t like, I wouldn’t 
 like push on like or continue—I, I would talk about uh my experience, my 
 journey, but not in a way that, you know, it overshadows what, what they’re going 
 through.  Interviewer:  Okay.  Interviewee: Um, but do let them know that, you 
 know, there, there’s always hope, the light at the end of the tunnel.  Um, and even 
 though they may not see it yet, you know, I, I feel that you know there is.  And 
 just try to just, encourage them and, you know, let them know that you know, I 
 guess all depends on if they’re diagnosed and where they are with it, but you 
 know, just let them know that um, there is, there, there, there’s, there’s a team out 
 there.  There’s some doctors out there who can you know, take care of them.  
 (Katie, Cell Phone Interview #4). 
 Several participants shared their knowledge and experience with individuals they 
did not know.  Ellie recounted one day, when she stopped at an infusion room (on her 
way to her infusion room to receive chemotherapy) and began talking to the woman 
inside, because she appeared sad (Ellie, Cell Phone Interview #4).  As they began talking, 
Ellie discovered that the woman knew nothing about her cancer and her treatment.  
Drawing from her experience, Ellie stated: 
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 I said, ‘Well, you go home, and you said you can find it [information regarding 
 the cancer clinical trial].’  She said, ‘I don’t even know where it is.’  I said, ‘If 
 you can find it, you read it because there are—there’s information in there that 
 you need to know.  So that-so that when the doctor’s treating you, you can ask 
 questions about what they’re doing.’  (Ellie, Cell Phone Interview #4). 
The woman thanked Ellie, who never saw her again.  Patient-participants spoke to 
individuals in their community and churches (a dialogue): 
 Um, about three deacons came to me and they were telling me about, um, their 
 experience.  So they came to me and they spoke to me about it, but I don’t  think 
 that there is a dialogue in the churches, the churches of ethnicity, about that 
 type of thing. And I do think that’s where the informed pastors, that’s how I’ll put 
 it—these informed pastors, I think that that’s a dialogue that they want to go on in 
 these churches.   (Steed, Cell Phone Interview #1).   
Patient-participants spoke in their church at the pulpit and among their fellow 
congregants. Encouraged by his pastor, Steed spoke candidly at the pulpit about his 
cancer experience and his CCT participation.  Steed’s sharing affected the men and the 
women in the congregation who had listened so intently: 
 He said that he wanted me to set up at the pulpit and talk about it.  And I was 
 surprised that a whole lot of other people were surprised, you could hear a pin 
 drop on the church floor.  You know, in the sanctuary, you could hear a pin drop 
 anyway.  But, you know, it was noticeable, because all of the men—I had their 
 attention.  All of them, all of the men.    
 And what was surprising was that it was the women, after I finished my piece at 
 the pulpit, I came down.  And it was during offering time when people are putting 
 their offerings in the basket, and it was the women—the men discussed it.  But it 
 was the women that came to me.  They came to me for their brother, for their 
 nephew, for their fathers... (Steed, Cell Phone Interview #1), 
After church, congregants approached him with questions—however, “[m]ost of them, 
they were the women that had questions for the men who they loved” (Steed, Cell Phone 
Interview 1).  His words had opened the dialogue among the women in the congregation.  
Ro felt strongly about dialoguing with men fin his church and the community.  He stated, 
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matter-of-factly, “...you gotta share your story because so many guys out here—us black 
guys, and I’m sorry, us black guys, we procrastinate” (Ro, Cell Phone Interview #4).  It 
became his personal mission to share his story and reach out to as many Black men as 
possible: 
 [s]ome are older than me, some are younger than me, some are much younger 
 than me, some are friends, and for me, just to be with them and let them know to 
 see that I went through it, that it’s nothin’ to be afraid of.  If you need to, and if 
 you ever come up to me and say, “Yo, Ro.  Last week I went to the doctor.  I got 
 ‘em to do my PSAs.  I got ‘em to do this.”  That makes me feel good.  (Ro, Cell 
 Phone Interview #4). 
 Ro stated frankly that he did not consider himself a “role model,” but rather he 
felt good knowing that he was assisting other Black men to take the necessary steps to 
safeguard their health and to not be afraid of CCTs (Ro, Cell Phone Interview #4).  Like 
Ro, patient-participants felt an intense need to share their experiences.  Mrs. Washington 
revealed that it made her feel strong (Mrs. Washington, Cell Phone Interview #4).  Ellie 
was motivated by the sadness she saw in a stranger’s eyes.  Steed was motivated by a 
young pastor who recognized the silence among Black men about prostate cancer and 
wanted the silence to end with Steed broaching the issue in the pulpit (Steed, Cell Phone 
Interview #1). Katie felt empowered to share because of her participation in this 
dissertation study; more specifically, after the semi-structured interview.  She had 
permitted her mother to be present.  She took the first of many steps to share her 
experience with her mother, then others subsequently: 
 I felt good, like, getting it out and just, um, feeling like she—she heard me 
 because she did kind of...well, since she came home with me last night, uh, and 
 she stayed over, and um, she was just like sitting there quiet, and um, I just felt 
 like she was listening and she heard what I was saying, because we did, you 
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 know, have a talk, like open and candidly about some of the things that I, you 
 know, said during the interview with you.  (Katie, Cell Phone Interview #1). 
Katie attempted to open the dialogue with her mother about her cancer and her CCT 
participation repeatedly throughout the dissertation study.  Despite her lack of success 
with her mother, her sharing enabled her to accept her changing body image and be at 
peace with her breast cancer diagnosis (Katie, Cell Phone Interview #3).  She and the 
other members of the sample disclosed their cancer and CCT experiences to family 
members, friends, church members, neighbors, co-workers, employers, members of the 
CCT team, and people they did not know.   They shared what brought them to The 
Cancer Center, how and why they enrolled in their CCT, how and the manner in which 
they were treated in their CCT, their relationships with their CCT teams, the support they 
received from their family members and friends, their symptom burden, and expressions 
of who they were and what was important in their lives. They shared themselves and their 
experiences in their CCTs.  
Summary 
 The two specific aims for this study were addressed through quantitative data 
from the Socio-demographic Form and the MSAS-SF, as well as the qualitative responses 
from 66 face-to-face and cell phone interviews.  The patient-participants openly and 
candidly described the factors influencing their decisions to participate and to remain in a 
CCT, as well as their experiences during their respective CCTs.  
  Patient-participants described why they sought treatment at the Cancer Center, 
why and how they decided on CCT participation and what ultimately led them to enroll 
on their CCT.  Many family members were staunch advocates for the participants, 
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caregivers as the need arose, and unflagging support at home and at the Cancer Center 
and wherever they were needed.  They were present when no one else could be present.  
Patient-participants described how oncologists and the CCT team influenced CCT 
enrollment and retention.  Also, patient-participants shared their experiences as they 
progressed through their CCTs.  The patient-participants were eloquent, poignant, and 
sincere in their depictions of their lives and the individuals with whom they daily 
interacted.  They described the details of their appointments, the symptom burdens they 
endured, their struggle to maintain balance and stability in their lives, and their efforts to 
disseminate information about cancer, cancer prevention, and CCTs.   
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CHAPTER V:  DISCUSSON 
The purposes of this study were to understand the factors that influence Black 
cancer patients to enroll and to remain in CCTs, as well as to understand the daily 
experiences of Black cancer patients during the CCT process.  This was the first study to 
seek the perspectives of Black cancer patients in determining the decisional factors 
influencing their CCT enrollment and retention, as well as to explicate their experiences 
during the CCT process.  A multimethod approach was used and included a qualitative 
descriptive design with semi-structured face-to-face and cell phone interviews with 21 
Black cancer patients involved in CCTs and a descriptive statistical analysis of the 
sample’s sociodemographics and a quantitative measure of symptom burden (the 
Memorial Symptom Assessment Scale-Short Form). The findings for the deductive 
qualitative aim suggests that all of the factors of Albrecht’s Model are important to 
patient participants in their decisions to enroll and to remain in CCTs in varying degrees.  
Albrecht’s model includes the following four factors that are important for treatment 
decisions: patient, family member, physician and protocol.  Moreover, the data provided 
some delineation of the four factors which the Albrecht Model had left relatively 
undefined.  There were several Patient Factors that motivated patient-participants to 
enroll and to remain in CCTs at the Cancer Center.    Family Member Factors were 
mentioned minimally in the data as it pertained to influences on initial CCT participation. 
By contrast, the data persuasively reflected the meaningful impact that Family Member 
Factors had on the patient-participants remaining in their CCTs. Physician Factors 
contributed to both patient-participant enrollment and retention.  A few patient-
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participants mentioned the importance of Protocol Factors in influencing their 
enrollment in CCTs.  However, there was no mention of the role Protocol Factors 
played in CCT retention. 
Elements of real-time data capture were also used to facilitate collection of four 
semi-structured cell phone participant interviews over a 2 month period, in order to 
understand patient-participants’ everyday experiences in CCTs. Patient-participants’ 
experiences centered around three areas: (1) interactions with the CCT Team during their 
CCT participation (The Cancer Clinical Trial Team), (2) experiences at patient-
participants CCT appointments and symptom burden (I’m Going Through It), and (3) 
struggles to maintain integral aspects of their lives and to share their cancer and CCT 
experiences (Who I Am).  This chapter begins with a discussion of the research findings 
as they relate to the two specific aims. Next, implications for theory, practice and health 
equity are presented.  Limitations are discussed and, finally, considerations for future 
research and inquiry are outlined.      
Discussion of Findings 
Specific Aim One 
 Patient factors.  The patient-participants in this study articulated three broad 
categories of Patient Factors that contributed to their decision to enroll and to remain in 
CCTs at the Cancer Center.  First, there was a willingness to seek additional information 
about their cancer diagnosis and treatment options (unhappy where I was; go somewhere 
else).  This willingness to obtain additional information and to understand the 
information received regarding one’s cancer and cancer treatment options is associated 
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significantly with consenting to participate in CCTs (Brandberg, Johansson, & 
Bergenmar, 2016; Miller et al., 2013).   Second, altruism motivated patient-participants to 
enroll in CCTs (To Help Others).  Several researchers have cited altruism as a motive for 
CCT participation (Harrop et al., 2016; Jenkins & Fallowfield, 2014; Ulrich et al., 2012).  
Although patient-participants offered altruistic reasons for CCT enrollment, the desire to 
help themselves was also paramount (Kaplan et al., 2015).  This finding was consistent 
with three of the four factors articulated by the Black and White cancer patients in Bryne 
et al. (2014): (1) the CCT offered optimum treatment for their cancer (give myself the best 
possible chance), (2) the CCT offered more information (learn more about my condition), 
and (3) the CCT was the sole treatment option (if one trial doesn’t work).   As 
commented by Ro, it was vital that the choice to participate in a CCT was deliberate and 
personal (go to the study for you).  These findings of personal benefit were consistent 
with work by Ulrich and colleagues (2012) who reported that cancer patients participated 
in research based on the personal benefits they might achieve.  For example, the sense of 
helping oneself was typified by patient-participants who were diagnosed with stage four 
cancer (N=8, 40%), and/or had participated in prior CCTs (N=3; 15%).  To some degree, 
participation in CCTs were a means of extending participants’ lives.  In fact, several 
patient-participants continued to seek, or had family members who continued to seek, 
available CCTs during their present CCT (if one trial doesn’t work).   
Family member factors.  The data indicated that family members, although 
important, had minimal effect on patient-participants’ CCT enrollment decisions.  A 
small number of patient-participants admitted to relying on family members in their 
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decision to enroll in their CCT.  This finding is contrary to Brown et al. (2013), where 
family members had a significant impact on CCT enrollment decision-making.  Only two 
patient-participants in this study mentioned the involvement of family members (he 
talked to all my children; my family heard).  By contrast, patient-participants spoke 
expansively of the ways in which their family members supported them during CCT 
participation. Contrary to their role in CCT enrollment, family members were integral in 
CCT retention and positively affected the daily lives of the patient-participants (Family 
and Friends Support Me).  Patient-participants spoke of the close familial ties that 
sustained them (my family is close; we support each other), the individuals who were 
their stalwart supports (my rock), and the many ways their family members supported 
them (we support each other; friends that support me; we’re like sisters; they’re in my 
world).  However, most significantly, the findings show that family member factors were 
central to patient-participants remaining in clinical research (Family and Friends 
Support).  This data supported the reconfigured Albrecht Model, wherein the physician-
patient-family member triad was visualized as influencing cancer treatment (Albrecht et 
al. 2009). 
 Family members functioned as caregivers
16
 for the patient-participants in this 
study.  Fifty-five percent (N=11) of the sample acknowledged that their caregivers were 
very important or extremely important to them during their CCT enrollment.  The four 
top caregiver types by percentage were Child (35%), Spouse (30%), Sibling (20%), and 
Friend/Parent (Friend and Parent were tied at 10% each).   Family members often 
                                                          
16
 A caregiver is a person who assists in the daily care of an individual, by satisfying 
medical and non-medical needs (Cooper, Powe, & Smith, 2013).   
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provided informational, instrumental, emotional, and spiritual support consistent with 
other research (Cooper, Powe, & Smith, 2013; Molina et al., 2016; Williams & Jeanetta, 
2015).  
Family members provided ample informational support (communication of 
information to the patient-participant) as demonstrated by their attempts to seek CCT 
information for patient-participants, offering referrals to oncologists, and information 
regarding family cancer history (Molina et al., 2016).  Also, they questioned the 
oncologist and the CCT team, which engendered information sharing with the patient-
participants (Cooper, Powe & Smith, 2013; Molina et al., 2016). Instrumental support 
(provision of material, financial, and household assistance) was exemplified by 
transportation to the Cancer Center and management of household tasks.  Emotional 
support (comprised of the conveying of love, affection and concern for the patient-
participant) was typified by being present at appointments and acting as steadfast 
advocates for patient participants (Cooper, Powe & Smith, 2013; Molina et al., 2016).   
Last, spiritual support was provided by family members who enabled patient-participants 
to remain grounded in their faith and belief in God by engaging in prayer and other 
activities with them (Cooper, Powe & Smith, 2013).  The presence of these integral 
supports enabled patient-participants to continue CCT participation and contributed to 
Family Member Factors being an important consideration on patient-participants’ 
decisions to remain in their CCTs (Cooper, Powe & Smith, 2013; Molina et al., 2016; 
Williams & Jeanetta, 2015).    
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Physician factors.  The Physician Factors underlying patient-participants’ 
decisions to enroll and to remain in their CCTs run counter to existent literature and are 
representative of the uniqueness of this sample (Albrecht et al., 2003; Corbie-Smith, 
Thomas, & St. George, 2002; Ford et al., 2013; Penberthy et al., 2012; Schmotzer, 2012; 
Sheppard et al., 2011; Simon et al., 2004; Torke, Corbie-Smith, & Branch, 2004).  
Patient-participants’ exercise of their judgment to choose the qualities they deemed 
important in their oncologists and CCT enrollment gave relevance to the Physician 
Factors.  Findings suggest that patient-participants were not passively being acted upon, 
ignored, or awaiting communication from oncologists.  The decision to enroll in a CCT 
was made by all, except one participant.  The study sample were interacting actively with 
their oncologists and the CCT Team, voicing their concerns, and seeking other avenues 
of treatment, if they perceived that the CCT was not meeting their needs.   Similarly, 
patient-participants remained at the Cancer Center, because they chose to remain. One 
individual voiced distrust of medical research—until, he interacted and chose a racially 
concordant oncologist.  Racial discordance has been cited as the basis for lack of trust 
between Black cancer patients and their White oncologists (Gordon, Street, Scharf, Kelly, 
& Souchek 2006).  For these reasons, Physician Factors were important, yet not primary 
reasons that the study sample enrolled and remained in their CCTs.   
Protocol factors.  The Face-to-Face and Cell Phone Interviews indicated that 
Protocol Factors had minimal bearing on CCT retention.  By contrast, Protocol Factors 
influenced some of the patient-participants, who were knowledgeable of their features 
and were interested in the benefits they offered, to enroll in CCTs.  Research literature 
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suggests that Blacks possess poor knowledge of CCT protocols and have little interest in 
participating in CCTs (Brown et al., 2013; Langford, Resnicow, & An., 2010; Meropol et 
al., 2007; Owen, Jackson, Thomas, Friedman, & Hebert, 2013).  However, for studies 
involving predominantly White cancer patients, knowledge of, and interest in, CCTs, 
were associated with CCT enrollment (Agarwal et al., 2006; Brandberg, Johansson, & 
Bergenmar, 2016; Lara et al., 2005). A small number patient-participants in this study 
were focused on CCT features that they perceived enhanced the likelihood of optimum 
treatment (i.e., targeted treatment, additional diagnostic tests, and randomization to 
experimental treatment).   
Most of the patient-participants’ in this dissertation study were deliberate 
consumers of oncology care, who had firm expectations of what they desired in the 
facility where they were treated, the oncologist with whom they would interact, the 
manner in which they would be treated, and, for a few, the type of CCT in which they 
would enroll.  The only factor over which they had limited control was the family 
members who supported them, advocated for them, and were present for them.  For this 
reason, as with Physician Factors, Protocol Factors were not as influential in CCT 
enrollment for the patient-participants in this dissertation study.               
Specific Aim Two     
The second aim of this dissertation chronicled the everyday experiences of the 
study sample during their CCT participation through the use cell phone interviews to 
ascertain real-time information.  Their experiences centered around three areas: (1) 
interactions with the CCT Team during patient-participants CCT participation (The 
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Cancer Clinical Trial Team), (2) experiences at CCT appointments and symptom 
burden issues (I’m Going Through It), and (3) struggles to maintain integral aspects of 
participants’ lives and to share their cancer and CCT experiences (Who I Am).   
The cancer clinical trial team.  The cancer clinical trial team was a constant 
reminder of the collaborative nature of cancer clinical research. Its members included the 
oncologist, nurse practitioner, clinical research nurse, and clinical trial coordinator (My 
Team). This configuration existed at the Cancer Center—however, Bethelmie-Bryan et 
al. (2013) have suggested expansion of the CCT Team to include a social worker, data 
manager, investigational drug pharmacist, regulatory associate, and physician assistant.  
Functioning as a coordinated unit, the members of the CCT Team at the Cancer Center 
supported and supplemented the tasks and responsibilities of the oncologist.  Oncologists 
were supported, and assisted in the care of the patient-participants, by the constituents of 
the CCT Team.  The clinical research coordinators, nurse practitioners, and clinical 
research nurses, individually and together, performed tasks typically performed by 
oncologists at the CCT appointments (What They Do for Me).  They introduced CCTs to 
patient-participants, acquired informed consent, entered laboratory and radiology orders, 
assessed the health status of patient-participants, provided detailed information about the 
CCT protocol, maintained contact with the study participants, and emergently admitted 
patient-participants to hospitals. 
 The role of the clinical research coordinator (coordinator) was mentioned only by 
patient-participants who participated in one particular clinical trial sampled in this 
dissertation study. The clinical research coordinator actively recruited subjects for this 
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particular study (as well as other studies for which he recruited subjects), administered 
questionnaires, acted as point of contact for participants, and maintained study data.  
During this dissertation study, the clinical coordinator for this particular clinical trial 
functioned as a variant of a gatekeeper by facilitating access to prospective participants.
17
    
The gatekeeper role can have both benefits and burdens for researchers. This role is often 
typified by the gatekeeper presenting the researcher’s proposed study to prospective 
participants.  Much like a clinician gatekeeper, the clinical research coordinator can 
potentially affect the ability of patient-participants to make research decisions 
autonomously (Sharkey, Savulescu, Aranda, & Schofield, 2010).  
 The patient-participants’ discussion of the CCT Team presented an invaluable 
opportunity to understand the expanding role of the nurse practitioner and the developing 
role of the clinical research nurse (Grady & Edgerly, 2009; Ulrich et al., 2013).  In this 
dissertation study, patient-participants had effective communication with their nurse 
practitioners.  Forty percent (N= 8) and 35% (N=7) of patient-participants rated their 
communication with the nurse practitioner as “Excellent” and “Very Good,” respectively.  
Nurse practitioners addressed clinically-emergent issues and provided advanced nursing 
care that enabled patient-participants to continue enrollment in their respective CCT.  As 
examples of their clinical activities, they admitted participants to the hospital for serious 
adverse events, ordered intravenous fluids and electrolyte repletions for acute 
                                                          
17
 Sharkey, Savulescu, Aranda, & Schofield (2012) define gatekeepers as healthcare providers who prevent 
access to subjects for research, who are otherwise eligible for research enrollment secondary to “factors 
such as age, gender, the type and stage of disease and previous treatment history or scheduled treatment (p. 
363).”   
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dehydration, and performed detailed and focused physical assessments to evaluate 
symptom burden. 
  From the perspective of the participants, the clinical trial research nurse oversaw 
several aspects of the CCT.   She assessed the participant’s responses to the research 
protocol, scheduled radiologic and laboratory orders, and evaluated and documented 
adverse responses to CCT medication. However, unlike the nurse practitioner and the 
oncologist who would often alternate in seeing patients, the clinical trial research nurse 
was present at all CCT research visits and was expected by the participants to be 
knowledgeable of the CCT protocol.   
 Through their coordinated efforts, the CCT Team offered continuity of care in 
tandem, and in the absence, of oncologists.  Salman, Nguyen, Lee, and Cooksey-James 
(2016) have posited that the presence of ethnic minority nurses and clinical trial 
coordinators as members of CCT Teams could facilitate communication, and assist in 
diminishing mistrust between majority researchers and the diverse populations they seek 
to recruit in their CCTs.  Arguably, the success of such an endeavor does not rest wholly 
on the ethnic and/or minority status of a CCT Team member.  The cohesiveness of the 
members of the respective CCT Team, as well as inter-staff communication and staff-
patient communication equally are important (Bethelmie-Bryan et al., 2013).  All of these 
qualities appeared to exist among the CCT Teams described by the patient-participants in 
this dissertation work. 
  I’m going through it.  The focal point of the patient-participants’ CCT 
experience was their clinical appointment (At My Appointment).  The patient-
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participants valued the exchange of information at their CCT appointments.  Eighty-five 
percent (N=17) of the sample felt that receipt of information regarding cancer diagnosis 
and treatment was extremely important.  Sixty-five percent (N=13) considered it 
extremely important to be informed of their CCT treatment.  At CCT appointments, 
health and disease status were assessed, the effectiveness and adverse effects of the CCT 
treatment were evaluated, and information regarding partial/complete response to CCT 
treatment and disease progression were shared.  
 The spectre of job loss and job insecurity secondary to CCT treatment, is a burden 
borne by CCT participants (Ulrich et al., 2012).  Fifty percent of the sample in this 
dissertation continued to work during their CCT enrollment.  The difficulty of arranging 
work schedules around appointments with oncologists and the CCT Team posed 
innumerable challenges to patient-participants (using some time).  Patient-participants in 
this dissertation study attempted to offset time lost at appointments by forging alliances 
with fellow employees and supervisors, negotiating flexible work hour arrangements, and 
judicious use of paid time off (vacation and/or sick time).  Some were successful, while 
others struggled.  Time lost at appointments was matched by transportation time and the 
inherent costs of travelling back and forth between work, the Cancer Center, and home 
(getting back and forth).  Additional time was lost waiting to be seen by the oncologist or 
the nurse practitioner or for CCT infusions or radiation (nice little wait).  Breakdown in 
operational processes, overbooking, and mechanical failure of diagnostic equipment 
contributed to the occurrence waits of one to three hours.  The patient-participants 
described these periods as the most frustrating aspects of their CCT participation. 
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    News of disease progression and eventual withdrawal from a CCT ((no longer 
involved in that last trial) occurred for 30% (N =6) of the patient-participants before 
completion of their four cell phone interviews. CCT enrollment did accord the patient-
participants a short-term survival advantage (Unger et al., 2014).  None of these patient-
participants enrolled in another CCT, either because of unavailability of a suitable trial or 
because of disease progression which prevented CCT enrollment.  Some returned to 
standard treatment options, while others did not receive any further treatment.  All of 
these patient-participants had stage 4 disease.  Research has indicated that Black cancer 
patients appear with later stage disease (stages III/IV), which has been associated with 
lower cancer survival rates among Blacks (DeSantis et al., 2016; Elfird et al., 2014; 
Parikh, Robinson, Zayfudim, Penson, & Whiteside, 2014; Phatak et al. 2013; Warner et 
al., 2012). Six of these patient-participants with stage 4 disease died within one year of 
CCT withdrawal.   More work is needed to understand the specific needs of those patients 
who are diagnosed with stage 4 disease and the palliative measures that might also be 
warranted.   
Despite the high levels of perceived communication between patient-participants 
and their CCT Team, fatigue, pain, and peripheral neuropathy were symptoms 
experienced more often by the largest number of patient-participants as reported in the 
MSAS-SF—80%, 60%, and 55% of the patient-participants reported distress from these 
symptoms, respectively.   These symptoms were described also by many participants in 
their e semi-structured cell phone interviews.  Moreover, patient-participants described 
176 
 
feelings of fear and anger.  Feelings of worry, nervousness, and irritability were reported 
in the MSAS-SF by 40%, 45%, and 50% of the sample, respectively.  These symptoms 
and emotional responses were consistent with those reported by cancer patients in 
research studies who had described the negative effects of chemotherapeutic symptoms 
on their daily tasks and responsibilities, as well as their continued participation in CCTs 
(Laugsand et al., 2010; Ulrich et al., 2012; Wootten et al. 2011).   However, these 
symptoms and emotional responses could have been managed with the assistance of 
supportive care specialists such as palliative care practitioners, social workers, physical 
therapists, and occupational therapists.  
Supportive care specialists provide services that can improve quality of life and 
survival outcomes (John, Kawachi, Lathan, & Ayanian, 2014; Temel et al., 2010; Wagner 
et al., 2010).  Only two patient-participants reported referral to healthcare providers who 
provided supportive care specialists:  Mrs. Washington (referred to a physical therapist 
for her increasing fatigue and deteriorating functional status) and RR (referred to a 
dietitian for his chronic constipation).  The remainder of the patient-participants failed to 
mention in their interviews being sent for consultations with supportive care specialists 
by the oncologists or nurse practitioners for their unmet symptom burden needs, despite 
being sent for consultations with other medical professionals during CCT participation. 
However, lack of referral to supportive care services and failure to satisfy unmet 
symptom needs among Black cancer patients is consistent with existent literature (John, 
Kawachi, Lathan, & Ayanian, 2014; Reyes-Gibby et al., 2012; Walling et al. 2016).  
Walling et al. (2016) found a significant relationship between poor physician 
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communication and unmet symptom burden needs.   The possibility of poor 
communication runs counter to the findings in this study whereas the majority of patient-
participants perceived communication as very good or excellent.  A possible explanation 
could be that the oncologists and nurse practitioners chose to manage, albeit 
inadequately, certain symptoms by prescribing medication and/or by reducing or 
eliminating CCT chemotherapeutic agents which caused the symptoms to manifest. 
 Who I am.  A finding of this dissertation study was the importance of 
participants’ self-image in CCTs.  In her work on CCT patients and self-image, Ulrich 
(2013) posited that cancer patients struggle to retain their self-image and identity, which 
become defined by their cancer diagnoses.  In navigating the changed landscapes of their 
lives, cancer patients are buffeted by the reality of their cancer diagnoses, the demands of 
their CCT procedures and requirements, and changes in social roles (Ulrich, 2013).   
Ulrich (2013) advanced that research participation could give meaning back to patient-
participants’ lives by contributing to the greater good, and benefiting future patients and 
their families.  
 The patient-participants in this dissertation study were clear that they participated 
in cancer research as a way to help others and themselves.  However, their desire to help 
themselves was also paramount as previously indicated (Kaplan et al., 2015; Truong et 
al., 2011).  For this reason, the patient-participants valued the importance of receiving 
information pertaining to their cancer diagnosis and CCT treatment.  Eighty-five percent 
of the sample felt it was extremely important to receive information about their cancer 
diagnosis, while 65% believed it was extremely important for them to receive 
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information regarding their CCT treatment.  In this data, patient-participants sought 
means to maintain their self-identity and what was important in their lives, by 
endeavoring to manage and to sustain their personal, family, work, school, and spiritual 
lives—separate and apart from their cancer diagnoses and CCT participation (I don’t let it 
consume my whole day; balance; faith). Patient-participants were strategic in accepting 
their cancer diagnoses and moving on with their lives, instead of being overwhelmed by 
the enormity of their cancer diagnosis and realities of CCT participation.  In seeking 
balance in their lives, they compartmentalized cancer as a necessary activity of their on-
going lives. Spirituality was a major component of the lives of 70% of the patient-
participants, who reported that spiritual or religious beliefs were very important or 
extremely important in their lives.  Their reliance on their spirituality supported them 
through disclosing their cancer status to their family members, accepting the reality of 
disease progression, and knowing they would not always be a person with cancer.  
Moreover, they were assisted in their efforts to retain the vestiges of their self-identity by 
their family members, especially when family members assumed supportive caregiving 
roles.  Children (35%), spouses (30%), and siblings (20%) were the primary caregivers 
for the patient-participants and ably supported them when the patient-participants 
developed medical conditions secondary to their cancer diagnosis and/or CCT 
participation.  This was consistent with Helgeson and Cohen (1996) who suggested that 
emotional, informational, and instrumental support from family members reduce feelings 
of inadequacy, loss of control, and vulnerability experienced by cancer patients.   
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 Molina et al. (2016) expanded on the power of family member support by positing 
that emotional, instrumental, informational, and appraisal support contribute to greater 
self-advocacy and community/interpersonal advocacy among Black women with breast 
cancer (I am very open; sharing your story; a dialogue).
18
  Much like the sample in the 
Molina et al. (2016), the study sample in this dissertation began as recipients of support 
from their family members.  The patient-participants transitioned from advocating for 
themselves (unhappy where I was; going somewhere else) to becoming resources for 
others, as well as advocates for CCTs.  Therefore, family member support was 
considerable in patient-participants’ willingness and desire to share their cancer and CCT 
experiences with others (Getting the Word Out) (Molina et al., 2016).  They described 
being candid with others about their cancer diagnosis (I am very open), their desire to 
educate and to assist other individuals (share your story), and their efforts to motivate 
other Blacks to participate in CCTs and to engage in cancer prevention activities (a 
dialogue).     
Implications for Theory 
  The data from this dissertation study supports the presence of the four factors in 
Albrecht’s model as important to one’s decision to participate in a CCT.  However, from 
this point, it diverges.  Albrecht’s Model presents a physician-centered approach and 
posits that physician communication is a key mediating factor on an individual’s 
treatment decision-making regarding research participation.  In fact, physicians are 
                                                          
18
 The addition of appraisal support represented efforts by family members to encourage the cancer patient 
to rely on her information-seeking facility to gather information for use in making cancer treatment-related 
decisions (Molina et al., 2016).    
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considered integral in CCT decision-making and in providing informed consent (Albrecht 
et al. 1999; Albrecht et al. 2008).  Further, Albrecht et al. (2003) does not give explicit 
definitions for the four factors that are outlined in the model. The qualitative findings 
from this dissertation work can begin to define components of these factors and other 
concepts and items that might be relevant for future qualitative and quantitative work.  
 This dissertation study does not include communication as a factor that was 
explored in the deductive qualitative analysis.  Its absence prevents a thoughtful, detailed 
consideration of the manner in which communication, specifically, motivated the patient-
participants’ interactions with their oncologists, CCT Teams, and family members.  Even 
though communication was not directly examined, communication clearly was important 
to the study sample —as indicated, previously, by the high percentage of the patient-
participants who valued the importance of receiving cancer diagnosis and CCT 
information.  Moreover, as stated previously stated, 75% of the participants rated their 
communication with their nurse practitioners and oncologists very good to excellent.  
Those seeking second opinions at the Cancer Center desired discussion of additional 
treatment options and a larger role in treatment decision-making, both of which they did 
not receive from their initial oncologists possibly due to poor communication.  Ro and 
RR described relationships with previous oncologists who failed to communicate 
treatment options. The question remains to be answered whether full testing of Albrecht’s 
Model with communication as a mediating factor would be helpful.  Further quantitative 
work to test Albrecht’s Model would be instructive.  
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 Use of Albrecht’s Model posed unanticipated challenges that will necessitate a 
secondary analysis of the semi-structured interviews.  Framing the findings of Specific 
Aim One with Albrecht’s Model compelled use of deductive content analysis, that by 
definition required the key concepts (patient, family member, physician, and protocol 
factors) to be used as initial coding categories/themes (Hsieh & Shannon, 2005).  This 
removed from consideration as organizing themes data that did not fit into the initial 
coding categories/themes, as they pertained to CCT participation and retention and that 
were not discussed in the semi-structured cell phone interviews.  For example, each 
patient-participant invariably began the semi-structured face-to-face interview with a 
discussion of the circumstances surrounding their cancer diagnosis, i.e., their cancer 
story.  The rich cancer stories of the patient-participants had no bearing on their decisions 
to enroll, or to remain, in their respective CCTs.  However, it was a story each patient-
participant wanted to tell, because it held a special meaning for them.  Cancer secrecy, or 
the failure and/or refusal of family members to share information regarding cancer 
incidence among consanguineous relatives, emerged as a theme among several of the 
participants only during the initial semi-structured face-to-face interview.  Again, cancer 
secrecy did inform, or influence, CCT participation or retention in relation to the four key 
concepts.  Finally, as worded, Specific Aim One related to patient, family member, 
physician, and protocol factors which influenced CCT participation and retention.  
Negative aspects of CCT participation that emerged frequently in the semi-structured 
face-to-face interviews, and were not repeated in the cell phone interviews, were 
precluded from analysis.  These negative aspects included lack of family support, 
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perceived discrimination, and the stress of hospitalization secondary to CCT symptom 
burden.      
Last, the CCT environment at the Cancer Center has enabled the opportunity to 
observe collaborative practice in action.  Additional research and theory-building is 
sorely needed on the expanding clinical and research roles of the CCT Team and its 
constituent nursing members, as well as their impact on CCT enrollment and retention.  
Exploring models that include interdisciplinary teams and the role of teams in improving 
communication regarding CCT participation and retention of patient-participants is now 
needed.  
Implications for Practice, Ethics, and Health Equity 
Implications for Practice 
 The findings from this dissertation study suggest several practice implications 
related to enrollment and retention of Black cancer patients in CCTs.  First, the 
contributions of the CCT Team highlight the expanding need for collaborative nursing 
practice in clinical research.  Within the realm of CCT research, expansion of nurses 
fulfilling nurse practitioner and clinical research nurse roles are sorely needed.  The nurse 
practitioner and clinical research nurse fulfill differing, yet complementary, roles that 
directly affect Black cancer patients in CCT research—the nurse practitioner oversees the 
clinical care of the CCT participant, while the clinical research nurse evaluates the CCT 
participant for the occurrence of physical and psychological adverse events resulting 
from CCT interventions (Hastings, Fisher & McCabe, 2012; Grady & Edgerly, 2009).  
Despite these role differences, both nurses are charged with insuring CCT participants’ 
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safety and advocating for CCT participants’ rights and welfare during their enrollment in 
clinical research (Hastings, Fisher & McCabe, 2012; Grady & Edgerly, 2009).  
Moreover, nurse practitioners and clinical research nurses are tasked with maintaining 
close communication and relationships with each other and with the clinical and research 
teams interacting with the CCT participants (Grady & Edgerly, 2009). In this way, nurse 
practitioners and clinical research nurses provide a continuity of care in the clinical and 
research realms that support CCT participation and influence patient health outcomes 
incident to CCT participation.  An examination of the complementary roles of nurse 
practitioners and clinical research nurses also open new avenues for research.  Little is 
known of the contribution of nurse practitioners and clinical research nurses to patient 
health outcomes, the role of nurse practitioners and clinical research nurses perform in 
ameliorating or contributing to disparate communication between oncologists and CCT 
subjects, or the ethical dilemmas faced by nurse practitioners and clinical research nurses 
as they seek to maintain the integrity of clinical research while safeguarding the rights 
and welfares of CCT participants.    
 Second, many of the oncologists administering the CCTs to which the patient-
participants’ were recruited exhibited a willingness to share information which was 
valued by and generated trust among the patient-participants.  In describing their reasons 
for choosing the oncologists who would ultimately enroll them in CCTs, patient-
participants shared how they valued the oncologists’ evaluative meticulousness and 
willingness to provide information regarding their cancer and CCT.  These characteristics 
were dependent upon effective communication and engendered trust.  The trust the 
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oncologists created was contrary to much of the literature concerning Blacks and cancer 
clinical research, wherein distrust of clinical research and of physicians colored the 
participation decision-making of Blacks (Corbie-Smith, Thomas, & St. George, 2002; 
Ford et al., 2013; Schmotzer, 2012; Torke, Corbie-Smith, & Branch, 2004).  However, 
the oncologists exhibited all of the characteristics deemed necessary to build trust:  
competence, honesty, caring, and effective communication (Hillen et al., 2014).  This 
same competence of the oncologists resulted in their successful referral of the patient-
participants to other healthcare providers, when necessary.   
Penner et al. (2013) indicates that the time spent by the oncologists providing 
information may have engendered the trust felt by the patient-participants.  In Penner et 
al. (2013), researchers found that greater trust was created between Black cancer patients 
and their White oncologists at an oncology clinic encounter, when the White oncologists 
answered the Black cancer patient questions as completely as possible, made certain that 
the Black cancer patients understood the content of the discussion, and listened carefully 
to the Black cancer patient.  The willingness and thoroughness of the oncologists to 
discuss cancer diagnosis and CCT information ran counter to the existent literature, 
where investigators stated that oncologists spent less time and had less effective 
communication with Black cancer patients during discussion of CCTs (Eggly, Barton, 
Winckles, Penner & Albrecht, 2013; Kehl et al., 2014). This manner of information-
sharing was not evident among all of the oncologists encountered by the patient-
participants; however, it should be incorporated into the research practice of oncologists 
recruiting Black cancer patients into CCTs.  However, much could be learned with 
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further research into the communication patterns that evoked trust in the patient-
participants and ran counter to the disparate communication shared between Black cancer 
patients and their oncologists in the existing literature.  
 Last, there was a difference in symptom burden, as measured by the MSAS-SF 
and as reported by the patient-participants during the face-to-face and cell phone 
interviews.  The MSAS-SF means for the sample for psychological and physical distress 
ranged from no symptom distress to mild symptom distress, respectively. The mean 
psychological and physical symptom burden values at baseline do not reflect the intense, 
life-altering symptom burden experienced by some of the patient-participants as they 
progressed through their trials.  More importantly, the mean symptom burden scores self-
reported by patient-participants in the MSAS-SF did not accurately reflect the range and 
severity of symptom burden experienced by the patient-participants.  The members of the 
sample with the youngest mean age and the highest mean PHYS distress value were the 
Breast cancer group.  Three of its members also were single parents who had school-age 
children.  The patient-participants with the oldest mean age and the highest PHYS 
distress value were the Colo-rectal group who reported pain and peripheral neuropathy 
frequently during their cell phone semi-structured interviews.   
 As reported, the mean global distress index was 1.09.  The median, range, 
minimum, and maximum for the global distress index were 1.06, 2.90, 0.00, and 2.90, 
respectively.  For the PHYS scale, the mean value was 1.09; the median, range, 
minimum, and maximum were 1.07, 2.93, 0.00, and 2.93 respectively.   Finally, for the 
PSYCH scale, the mean value was .77; the median, range, minimum, and maximum were 
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0.67, 2.43, 0.00, and 2.43.  For all of the MSAS-SF distress sub-scales, the maximum 
distress values (all of which were higher than 2.40) were indicative of high moderate 
symptom distress and were offset by minimum distress values of 0.00.  The cancer group 
with the highest PSYCH distress value was Breast with a maximum of 2.43 (and a mean 
of 1.15), whose members had a mean age of 47 years.  The cancer group with the highest 
PHYS distress value was Colo-rectal with a maximum value of 2.93 (and a mean of 
1.52), whose members had a mean age of 62.8.    
 The difference in the mean quantitative measure and the qualitative self-reported 
values may reflect unmet symptom burden needs that should be addressed by the CCT 
Team.  Failure of the CCT Team to capture these unmet needs endangers the scientific 
integrity of the respective CCTs, if the symptom profile and adverse event data are 
deficient and incomplete.  Moreover, patient-participants’ quality of life during the CCT 
is adversely impacted.  Explanations may include the ineffectiveness of written 
instruments to capture the degree and the intensity of the patient-participants’ symptom 
experience over a particular point in time (Stone et al., 2007).  There is the possibility 
that patient-participants minimized the extent of their symptom burden in order to 
continue to receive the perceived benefit of CCT enrollment and also be perceived by the 
CCT Team as a “good patient” (Joseph & Dohan, 2009).  It is not known whether this 
was the case in the dissertation study. Understating symptom burden permits continued 
CCT participation, barring occurrence of disease progression.  Incorporating elements of 
real-time data capture of symptom burden, via telephonic interview or text messaging, 
may enable a more complete capture of the symptom and toxicity profiles of 
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investigational agents.  Moreover, it provides valuable data necessary for the CCT Team 
to evaluate cancer patients’ true symptom burden needs.  This may lead to more timely 
treatment, or referral to appropriate support services.   The moderate to severe symptom 
burden self-reported by participants in the cell phone interviews also suggests the need 
for expansion of the CCT Team to include a palliative specialist, such as a palliative care 
nurse.  Palliative care seeks to improve the quality of life of individuals with life-
threatening disease, such as cancer, through relief and prevention of psychological and 
physical suffering (Bauman & Temel, 2014).  Introduction of palliative care services 
early in CCT participation permits identification of potentially debilitating symptoms 
which can diminish a CCT participant’s quality of life and avert unnecessary suffering 
(Bauman & Temel, 2014).  The need for early referral is especially true for CCT 
participants with late stage cancer, since 40% (N = 8) of the patient-participants in the 
dissertation study were diagnosed with stage four cancer.  Early integration of palliative 
care with late stage cancer patients maximizes their quality of life, increases their 
satisfaction with their clinical care and CCT treatment, and lessens symptom burden 
(Bakitas et al., 2009; Zimmerman et al., 2014). 
 Implications for Ethics 
 There are several ethical implications which can be drawn from the data.   First, a 
therapeutic misconception can occur in research when participants mistakenly believe 
that they will receive medical benefit from their research participation.  Often there is a 
failure to understand that the true purpose of CCTs is to produce generalizable 
knowledge (Appelbaum, Lidz, & Grssio, 2004; Pentz et al., 2012).  CCTs are not 
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intended for curative purposes, although remission could occur as a result of the use of 
investigational medication and it might also provide participants with time to discuss 
their goals and preferences. The majority of patient-participants in this dissertation work 
perceived their CCTs to be medical care for their cancer; hence, their use of the term “my 
treatment” to refer to the CCT intervention.  There were also a few patient-participants 
who actively sought CCTs to prolong their life.  The potential for a therapeutic 
misconception was potentially high in this study sample, although questions surrounding 
this issue were not directly asked of participants. This could have been facilitated by 
several factors. All the patient-participants were enrolled in their CCTs by oncologists, 
who were both the principal investigators of the CCTs and the primary oncologists of the 
patient-participants.  In addition, many of the patient-participants (N = 11; 52%) received 
their initial cancer treatment via CCTs—so it was possible that patient-participants could 
confuse the clinical trials with medical treatment.  This confusion was typified by Bob’s 
belief that randomization in a CCT meant that he was receiving better treatment, and 
Kit’s decision to enroll in I-SPY II—more diagnostic testing meant better treatment for 
her breast cancer. 
 Two recommendations can be made.  Oncologists who administer CCTs as initial 
treatment for cancer should state clearly the experimental nature of the CCT.  Although 
there was not a question that directly asked the purpose of CCTs, the only patient-
participants who understood that CCTs were for research purposes were those who had 
enrolled in prior CCTs (Diane, Gina, Niecy) and those who understood the life-limiting 
nature of their cancer (Bob and Reecy).  An argument can be made that, perhaps, 
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oncologists who administer CCTs should relinquish primary “ownership” of their patients 
who are enrolled on their CCTs to other oncologists.  Otherwise, there is a blurring of the 
line between clinical care and medical care.   Also, oncologists should explain thoroughly 
the purpose of CCTs, especially when CCTs serve as front-line cancer treatment along 
with recognized standard treatment.   
 Second, there is also the possibility of unrealistic optimism in CCT participation. 
Unrealistic optimism is the belief held by a research participant that he is more likely to 
receive a benefit from a clinical trial than a similarly-situated person (Crites & Kodish, 
2013).  For example, a participant may not make a reasoned assessment of the risks and 
benefits of CCT participation, since he unrealistically believes that the CCT will impart a 
positive outcome.  The possibility of attributing unrealistic optimism to any of the 
patient-participants flows from the blurred distinction between it and the strong 
spirituality characterizing many of the patient-participants.  However, none expressed the 
tenets of unrealistic optimism as a basis for participating in their respective CCT.  But, a 
formal question on optimism was not asked of participants. During the course of their 
enrollment, many discussed a belief that a spiritual force would assist them through the 
rigors of the CCT. More research on the role of spirituality and optimism is needed.  
 Third, medical paternalism is the failure of physicians to provide understandable 
information regarding a medical procedure or intervention and to allow sufficient time for 
a patient to make a reasoned decision.  The inherent peril of medical paternalism is its 
stripping away of patients’, or CCT participants’, ability to act autonomously.  Medical 
paternalism drove some of the patient-participants to leave their initial oncologists and 
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seek second opinions at the Cancer Center (Stirrat & Gill, 2005).  Examples of imposition 
of such medical paternalism on the patient-participants included RR’s oncologist who 
insisted on robotic prostate surgery and Ro’s oncologist who did not discuss treatment 
options.  However, a potential measure of medical paternalism resulted in Mrs. S’s and 
Mrs. L’s eventual CCT enrollments.  It could be argued that their CCT participation was 
colored by the absence of self-determination—especially, Mrs. L who was given a CCT 
Informed Consent to sign without being given proper time to make a reasoned decision.  
Yet, the vast majority of the patient-participants exercised autonomy in the choice of their 
oncologists, the CCTs in which they ultimately enrolled, the management of their 
symptom burden, and the choice to withdraw from CCTs—as was done by Niecy and 
Diane.  However, the troubling implication is that medical paternalism continues to occur 
and prompted two patient-participants to make a choice that potentially limited their 
autonomy. This study did not ask whether these particular participants perceived their 
autonomy to be affected in any way.  
Implications for Health Equity 
 Despite possessing the attributes of high educational attainment and 100% insured 
status, the patient-participants in this dissertation were members of a racial/ethnic group 
with documented cancer health disparity and exhibited some of the characteristics 
indicative of cancer health disparity (Flowers et al., 2007; Halpern & Holden, 2012; 
Howerton et al., 2007; Kauh, Brawley, & Berger, 2007).  The presence of discrimination 
was shared by a few of the patient-participants in terms of feeling that they were being 
treated differently because of race.  Research has indicated that perceived discrimination 
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in healthcare is experienced most commonly among Blacks and affects the quality of life 
of Black cancer patients (Benjamins, 2012;  Merluzzi, Philip, Zhang, & Sullivan 2015).  
Researchers have found that perceived discrimination is experienced when individuals 
are subject to curt responses, dismissive behavior, and limited eye contact (Tajeu et al., 
2015).  Cuevas, O’Brien, and Saha (2016) identified perceived discrimination when 
Black patients encountered discourteous and disrespectful treatment by office staff and 
physicians, failures by physicians to communicate concern or acknowledge symptoms 
and health issues, and feelings of being treated unfairly because of their racial 
background.  Discussion of discrimination by the patient-participants was not stimulated 
by any one question of any of the face-to-face and cell phone interviews.  The issue arose 
independently from the individuals based upon their healthcare experiences at the Cancer 
Center.  The three patient-participants, who mentioned discrimination in their cell phone 
interviews sounded hesitant to address the topic.
19
  None of them stated that they had 
experienced any difference in treatment.  Moreover, all of them in other portions of their 
cell phone and face-to-face interviews had espoused trust and satisfaction with their 
oncologists and/or CCT Team.  It is unclear from the patient-participants’ statements 
whether they perceived, or witnessed, discrimination at the Cancer Center, who exhibited 
the discriminatory behavior, and what behavior or actions were deemed discriminatory.  
These participants did not elaborate on their experiences or perceptions.    
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 Interestingly, the issues of racial bias and discrimination in healthcare arose more frequently in the face-
to-face interviews, where the patient participants explained in detail their experiences at the Cancer Center, 
in other healthcare venues, and during visits from health professionals to their homes.  However, because 
the dictates of Specific Aim Two limit data only to cell phone interviews, a discussion regarding the 
patient-participants’ experience of perceived racial bias and discrimination during their CCT participation 
cannot be addressed here. 
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 Cancer health disparity among Blacks also has been characterized by initial 
presentation for oncology care with late stage disease, increased cancer mortality, and 
inability to access healthcare (DeSantis et al., 2016; Elfird et al., 2014).   Forty percent (N 
= 8) of the patient-participants presented for treatment with late stage cancer—stage four 
cancer.  Lack of access to health care pursuant to lack of insurance was not an issue for 
the members of this sample.  One hundred percent of the patient-participants had 
insurance coverage.  Insurance status did not insulate the patient-participants from 
additional costs related to CCT participation.  However, the financial toxicity of 
conventional and CCT cancer care is not relegated only to Black cancer patients (Nipp et 
al., 2016; Zafar et al., 2013).  It is a burden borne by countless cancer patients who, in 
their efforts to assuage the financial burden of cancer care, adopt strategies to reduce out-
of-pocket costs such as selling personal possessions, missing appointments to avoid 
expenditures on co-payments, or partially filling (or not filling at all) medication 
prescriptions (Zafar et al., 2013).    
 Despite participating in a CCT at a NCI-Designated comprehensive cancer center, 
the patient-participants lacked access to resources that could have assisted them in 
managing the myriad of out-of-pocket expenses related to their CCT participation, i.e., 
cost of supportive medication related to CCT interventions (e.g., anti-emetics and 
opioids), co-pays for clinic visits and CCT medications, and co-pays and/or out-of-pocket 
expenses for imaging.    Unlike the cancer patients in Zafar et al. (2013) who benefitted 
from a non-profit organization providing financial assistance for payment of cancer care-
related costs, the oppressive burden of financial toxicity was identified by several 
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participants who lacked access to resources that could reliably have relieved the financial 
burden of cancer care.   It was felt by Jill who could not pay her Medicare co-pays, by 
Mrs. L who relied on a sponsored taxicab service to take her to her appointments until the 
service stopped operating, and by Diane who attempted to arrange all of her CCT-related 
appointments on one day in order to avoid paying multiple insurance co-pays.  
 DeSantis et al. (2016) reported that, since the 1990s, cancer death rates have been 
decreasing for Black cancer patients.  However, Black cancer patients continue to have 
lower survival rates than White cancer patients for most cancers at all cancer stages. 
Except for lung cancer in Black women, Black men and women have lower relative five-
year survival rates than White men and women for the cancer types recruited for this 
dissertation study (DeSantis et al., 2016).  The low survival rates are attributed to such 
factors as presentation to treatment with late stage disease (which has limited treatment 
options) and socioeconomic factors—both of which are related to concerns for health 
equity.  DeSantis proposed that, if Black cancer patients receive cancer treatment similar 
to White cancer patients, they would likely have similar survival outcomes to White 
cancer patients.  However, as has been stated, cancer disparity has claimed the lives of 
nearly one-half (10 of the 21) of the patient-participants since this dissertation study 
began in 2013, due to disease progression or related morbidity.  Only one of the patient-
participants had lived with cancer for more than four years.      
Limitations and Methodological Considerations 
  There are limitations to this dissertation study.  Every attempt was made to recruit 
new patient-participants in order to achieve 30 completed quantitative measures of 
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symptom burden. However, saturation was achieved with the data that was obtained and 
provided rich findings from which to address future research needs to understand the 
perspectives of Blacks enrolled in CCTs.  The small sample size of this dissertation does, 
however, limit applicability to other Black cancer patients.   
The choice of the Cancer Center (a NCI-Designated comprehensive cancer center 
in a large, northeastern city) introduced some level of sample selection bias   Choice of a 
comprehensive cancer center increased the likelihood of recruiting a sample of Black 
cancer patients willing to participate in CCTs.  NCI-Designated comprehensive cancer 
centers are recognized for providing innovative cancer interventional, clinical, laboratory, 
and population-based research, as well being a central situs for cancer-related resources 
and programs, translational research, and public education and outreach programs (“NCI-
Designated Cancer Centers,” n.d.).  As a result, it was not surprising that the patient-
participants shared similar sociodemographic characteristics, such as high levels of 
educational attainment (75% of the study sample attended at least some college and 35% 
of the study sample had completed college) and insured status.  All of the patient-
participants had insurance coverage (and some had more than one type of insurance).    
High educational attainment significantly correlates with enrollment in CCTs (Unger et 
al., 2013).
20
    Moreover, lack of insurance is a barrier to CCT participation (Byrne et al., 
2014; Du et al., 2005).    The patient-participants’ educational attainment and insurance 
status heightened access to informational resources and to healthcare.  However, these 
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 In a survey of 5499 cancer patients from 2007 to 2011 via an internet survey, Unger et al. (2013) used 
income and education as components of socioeconomic status and found that cancer patients with lower 
education (p = .02) were less likely to participate in CCTs. 
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attributes did not decrease the likelihood of their experiencing cancer disparity.  The 
attributes did not improve their survival outcomes
21
, their ability to pay cancer-related 
costs, or their symptom burden.     .      
Methodologically, the choice to limit analysis to cell phone interviews for the 
second aim of this dissertation study highlights the differences between real-time 
collection of symptom burden and symptom burden data collected via questionnaire and 
grounds the patient-participants’ cancer experiential data in the moment of the interview.  
Communication was not included as a factor for deductive analysis in this dissertation 
study, given the extensive research on physician and patient communication by Albrecht 
and her research team with Black cancer patients (Albrecht et al., 2003; Albrecht et al, 
2008; Albrecht, Penner, & Cline, 2009; Cline et al., 2007; Eggly et al., 2006; Penner et 
al., 2013)   By contrast, Albrecht and her research team have done little in substantively 
defining the patient, family member, physician, and protocol factors that potentially 
influence CCT participation.  The role of communication was, however, evident in all of 
the interviews.  In the future, understanding the types of communication that are 
important to patient-participants and their families would be important to explore.  Using 
cell phone interviews as a means to address real-time data capture of was limited by 
concerns for reducing respondent burden (i.e., the patient-participants’ perception of 
physical, psychological, and economic privations experienced as a result of research 
participation) (Ulrich, Wallen, Fiester, & Grady, 2005).  By limiting calls to 24-48 hours 
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 DeSantis et al. (2016) found that the relative survival rates for Blacks continued to be lower than Whites 
for most cancer at every stage of cancer diagnosis.  Of the ten patient-participants who died during the 
period October 2013 to November 2015, only one had had cancer for more than four years.   
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proximate to patient-participants’ clinic appointments, it was hoped that patient-
participants would not be unduly fatigued.  Sometimes, however, it was difficult to 
contact some participants in the 24-48 designated period. Cell phone calls were made 
beyond the 24 to 48 hour period in order to reach some participants.  There was also 
some concern about the spontaneous and authentic nature of the real-time responses 
because patient-participants came to expect calls from the doctoral candidate. Despite this 
limitation and the other limitations discussed as well as the methodological 
considerations, the information gathered from this dissertation study remains useful for 
subsequent study and hypothesis generation.  
Last, despite the steps taken by the doctoral candidate to ensure trustworthiness, 
there was always the possibility that she may have misconstrued or misinterpreted the 
patient-participants’ meaning and intent they wished to convey during analysis of the cell 
phone interviews.  The absence of close physical proximity negated consideration of such 
physical nuances as facial expression, gestures, and posture, all of which could have 
resulted in differing interpretations of the data.  Further, as with all quantitative and 
qualitative research, the doctoral candidate acknowledges that interjection of researcher 
bias was a possibility in such areas as the choice of research site, selection of participants, 
and analysis of the data (especially, here, where the doctoral candidate principally was 
responsible for collection and analysis of  the data).       
Benefits and Challenges of Using a Multimethod Approach 
This dissertation study used a multimethod approach to describe the experiences 
of a sample of 21 Black cancer patients as they participated in CCTs.  It was comprised 
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of differing types of qualitative analyses (inductive and deductive) used in independent 
aims as well as a quantitative measure.  By using different data collection methods, it  
added descriptive richness and detail to the overall research question on why Black 
patient-participants’ enroll and remain in their CCTs (Cheek, Lipschitz, Abrams, Vago, 
& Nakamura, 2015; Morse & Cheek, 2014).   
 Albrecht’s Model provided the theoretical base to begin exploring and explicating 
the various elements of patient-participants’ experiences (Morse & Cheek, 2014).  A 
disadvantage of this deductive approach, however, was the necessity to solely focus on 
the model and its four factors.  Thus, negative experiences such as perceived 
discrimination, cancer secrecy, conflict with the CCT Team, and instances where there 
was a lack of family member support were not included in the analysis for the first aim.  
Moreover, if these experiences did not emerge from the cell phone interviews, they were 
not included in the analysis for the second aim. Nevertheless, the use of inductive content 
analysis for the second aim provided several distinct advantages.   
The cell phone interviews elucidated how symptom burden was a central aspect of 
patient-participants’ CCT participation experiences.  Patient-participants discussed the 
physical and emotional aspects of their symptom experiences on nearly every part of their 
lives (How I Feel; It’s Knocking Me Down).  A significant finding of this dissertation 
study was the differences in symptom burden experience as described by the qualitative 
cell phones interviews and reported by the self-report quantitative measure of the MSAS-
SF.  The cell phone interviews portrayed symptom burden experiences which were more 
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frequent and more intense than the mild to moderate physical and psychological symptom 
burden scores reported in the initial MSAS-SF completed by 20 study participants.   
 Despite being a reliable and valid symptom burden measure, there are always 
limitations with self-report questionnaires. Consistent with its instructions, the MSAS-SF 
measured the frequency and severity of a finite list of symptoms experienced by each 
patient-participant during the last seven days.  Participants in this study recalled 
aggregated experiences and events that had occurred within the seven days preceding the 
moment the MSAS-SF was completed (Palmier-Claus et al., 2010; Shiffman, Stone & 
Hufford, 2008; Stone et al., 2007).   EMA literature suggests that recall data are likely 
biased, imperfect, and outside the situational and environmental contexts of patient-
participants’ lives (Shiffman, Stone, & Hufford, 2008; Stone et al., 2007).    More 
significantly, discrete moments of symptom burden could not be collected, nor described 
by the patient-participants.  Using a multimethod approach with four cell phone 
interviews over a period of time showcased the advantages of real-time collection of 
patient-participants’ experiences.  They captured the richly textured features of the 
symptom burden experience at different time points in the study sample.  With this 
method, patient-participants described more fully in their own words their attitudes, 
feelings, and impressions of their symptom burden experience.   Ellie was able to share 
more fully the physical sensation of her peripheral neuropathy and her frustration with 
experiencing peripheral neuropathy as outlined below:     
 I go to pick up something, and I forget to put my gloves on.  And then I end up 
 feeling a slight—I don’t know if you’ve ever had your hands in dry ice, but I 
 remember as a kid one time— I didn’t know what it was.  And I put my hand in 
 dry [ice], and it kind of, like, burned my skin.  And-and that’s the way it feels.... 
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 I think what bothers me the most is dealing with...neuropathy. Mm-hmm.  It 
 really—it-it just bothers—seems to bother me the most... it.  (Ellie, Cell Phone 
 Interview #3). 
Her description and frustration were clear and concrete.  It was easily 
understandable, why she felt enduring peripheral neuropathy was worse than managing 
her colostomy, the fatigue she felt during the first few days following her CCT 
chemotherapy, and the pain she experienced when her portacath was accessed.  
Completing the quantitative items on the MSAS-SF would not have provided the richness 
of information collected during this cell phone interview.  The cell phone interviews 
suggested the existence of unmet symptom burden needs, despite the exemplary 
communication between the patient-participants and their oncologist and nurse 
practitioner.  Seventy-five percent of patient-participants rated their communication with 
the oncologist as well as the nurse practitioner as “Very Good” or “Excellent.”  More 
work is now needed on the use of real-time data capture and understanding the benefits 
and challenges of using this method with seriously ill populations with different types of 
data collection, such as text messaging or other approaches.       
Future Research 
  In line with the findings of this dissertation and by the totality of the data gleaned 
from the face-to-face and cell phone interviews, several recommendations for future 
research are proposed. Qualitative and mixed-method research on larger samples of Black 
cancer patients enrolling in CCTs in NCI-designated comprehensive cancer centers, 
safety-net hospitals, and community settings is needed to determine differences in CCT 
experiences and perceived symptom burden.  It would be helpful to know whether this 
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dissertation’s study participants were indicative of all Black cancer patients, or Black 
cancer patients who sought cancer treatment at a NCI-designated comprehensive cancer 
center.  Because this study did not study Black individuals who decided not to participate 
in CCTs, it is not known whether there would be a difference in perceptions and 
experiences between those who participate and those who do not.  Future research should 
examine this inquiry.  Because there were differences in the degree of symptom burden 
experienced by patient-participants, particularly when measured by a quantitative 
symptom burden tool (the MSAS-SF) and also by qualitative cell phone interviews, a 
larger mixed methods study comparing quantitative and qualitative assessments of 
symptom burden is now needed.  More qualitative research on the role and influence of 
the CCT Team on the participation and retention of Black cancer patient in CCTs would 
also be instructive    
 The face-to-face semi-structured interviews for the first aim of this dissertation 
were analyzed deductively with a focus on Albrecht’s model.  Data that did not describe 
the specified factors within this model were not a focus of this dissertation.  For this 
reason, a secondary data analysis is now warranted to identify the themes and categories 
that did not fit the constraints of Albrecht’s model (e.g., communication, cancer secrecy, 
and perceived discrimination), but may add to a more expansive understanding of the 
factors influencing CCT participation and retention.   
Last, this dissertation study was concerned with the patient, family member, 
physician, and protocol factors that were considered important to CCT participation.  
However, only a small percentage of Black cancer patients participate in therapeutic 
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CCTs.  It would be interesting to expand the focus of inquiry to include Black cancer 
patients enrolled in various other types of clinical trials, including supportive care trials 
as well as those who are receiving outpatient conventional clinical treatment at a 
designated Cancer Center.  We don’t know whether the four factors that are considered in 
CCT participation based on Albrecht’s Model would be the same for those who seek 
conventional clinical treatment. Nor do we know whether there are differences in 
symptom burden for those in conventional cancer treatment versus those participating in 
research.   
Conclusion 
 Enrollment and retention continue to be issues of concern for the cancer research 
community.  This study sought to understand the day-to-day experiences of Black cancer 
patients participating in CCTs and the patient, family member, physician, and protocol 
factors that contribute to Black cancer patient CCT enrollment and retention. Notably, the 
study data indicates that patient and physician factors were both important in enrollment 
and retention of patient-participants in their CCTs.   Patient-participants had definite 
expectations of the characteristics they desired in their oncologists, how they wanted to 
be approached by healthcare providers, and how they wanted to manage cancer treatment.  
When their expectations were not met, they addressed the problem at hand and 
considered other available courses of action.  Moreover, the patient-participants in this 
dissertation study were not passively being acted upon, ignored, or awaiting 
communication from oncologists.  Many participants exercised their judgment and chose 
the qualities they deemed important in their oncologists and CCT enrollment.  Arguably, 
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these actions gave relevance to the physician factors.  Although protocol factors attracted 
some patient-participants to their CCTs, family member support kept them in their CCTs.  
Examination of family member factors revealed the informational, instrumental, 
emotional, and spiritual support which enabled the patient-participants to endure 
symptom burden, persevere through the uncertainties of their cancer diagnosis and CCT 
regimens, and become advocates for cancer prevention and CCT participation. 
The study data indicates that, during their CCT enrollment, the patient-
participants experienced physical and emotional stresses, work and financial challenges, 
and threats to their self-identity.  Several patient-participants struggled with symptom 
burden throughout their participation in the trial. The physical changes in their bodies, as 
well as the rigors of CCT participation and their initial cancer diagnoses, drove them to 
attempt to retain some vestiges of themselves.  They compartmentalized their daily lives 
so that their CCT and CCT-related appointments did not overwhelm them.   Insurance 
and work issues were constant reminders of the economic toll of cancer and CCT 
participation.   
Many of the patient-participants did not consider themselves “guinea pigs.”  They 
were pioneers and trailblazers who sought to benefit themselves, other Black cancer 
patients, their churches, and their communities.  They were consumers of cancer clinical 
research, who actively scoured the Internet seeking CCT opportunities—alone and with 
the assistance of their family members.   Far from laboring under the paternalistic control 
of oncologists, the patient-participants sought second opinions, addressed symptom 
burden issues, and personally withdrew (Diane and Niecy) from CCTs which they felt 
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were not benefitting them.   In sum, the study data contributed to nursing knowledge by 
revealing the heterogeneity of Black cancer patients beyond the narrow confines of 
existing research inquiry.  The question which must be answered by additional research is 
whether the heterogeneity of this sample reflects Black cancer patients who seek cancer 
care at the Cancer Center, or Black cancer patients whose personal perspectives are not 
represented in the research literature.  For these reasons, it is critical to test the 
generalizability of this study’s findings on a larger sample, as a first step to developing 
interventions targeted at reducing the crippling cancer disparities affecting Black cancer 
patients.   
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APPENDIX A 
Semi-Structured Face-to-Face Interview Guide 
Type of Clinical Trial __________ (i.e., prostate, breast, lung, or colo-rectal) 
Clinical Trial Phase □ Phase I   □ Phase II   □ Phase III 
Interviewee ID:  ________ 
Interview Subject Pseudonym: ____________           
Audiotaped: Yes____ No____   
Date Administered:  ____/___/____  
 
Interview with Participants
 
"Good morning/afternoon/evening. I am ________ (introduce self).   I have received 
funding from the National Institutes of Nursing Research to better understand the cancer 
clinical trial experiences of Black adults with cancer enrolled in cancer clinical trials.  I 
have received permission from the Cancer Center to call you to discuss your interest in 
talking about these issues.  I am not part of your specific cancer clinical trial nor do I 
have any relationship with any cancer clinical trial research team at the Cancer Center.  
Everything you share with me will be kept confidential and will not be shared with any 
member of the cancer clinical trial team.  So, it will be very important that you contact 
and share the following information with the nurse/physician on the cancer clinical trial 
team: (1) any symptom information that you describe to me, and (2) any issues or 
concerns about your experiences during the cancer clinical trial. All information you 
provide will be grouped together with other interviewees’ information and analyzed 
together as a group.  No one will be able to identify your individual information.      
This interview is being done to determine your individual perceptions, feelings, and 
opinions of being involved in a cancer clinical trial.  I will be asking you to describe to 
me your feelings and perceptions about participating in a cancer clinical, the factors in 
your decision to participate in a cancer clinical trial, and the symptoms you may be 
experiencing as part of participation in a cancer clinical trial.   I am very interested in 
learning more about the experience of Black patients and their views on cancer clinical 
trials.       
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 Discuss prior acquisition of Informed Consent with subject (purpose, risks/benefits, 
confidentiality, audio taping of information, aggregate of data, and other essential 
elements).  
"If it is okay with you, I will be tape recording our conversation. By recording our 
conversation, I can get all the details of our discussion and concentrate on your thoughts 
on this subject. All your comments will remain confidential and no results will reference 
any specific individual. My proceeding with this interview indicates your agreement to 
this interview and to the tape-recording.”   
 INDIVIDUAL-RELATED FACTORS 
1. “Can you share with me some of your personal reasons for wanting to participate in 
your clinical trial?” 
2. “What are your expectations for the clinical trial?”   (Probes:  What do you want to 
happen?  What has happened so far?)  
3. “In your own words, describe for me how things in your everyday life affected your 
decision to enroll in the clinical trial?  (Probes:  Does the clinical trial affect your ability 
to work? Does participation in the clinical trial take away time from time spent with your 
family or friends? Time for hobbies?  Postponement of vacation?)     
FAMILY/CAREGIVER SUPPORT FACTORS 
1. “Can you share with me your support, if any?”  (Probes:  Do you have someone who 
takes care of you, runs errands for you, provides childcare, takes care of you when you 
are sick, etc.) 
 If so, who are they (relationally)?  Probe:  How would you describe them?  
(brother? sister? friend? son? daughter? church member? spouse?) 
 What do they do for you? 
 How often do they help you or provide care for you? 
2. “Can you describe in your own words how having cancer has affected the people who 
help you?” 
3. “Describe how you feel about the help you receive?   
4. “How do members of your family feel about your participation in a cancer clinical 
trial?” 
 SYMPTOM MANAGEMENT/SUPPORTIVE CARE 
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1. “In your own words, can you describe your health right now?  How would you 
describe your health before you joined the clinical trial?”  
2. “Have you told anyone at your oncologist’s (cancer doctor) office about how you are 
feeling?”  If so, whom?  If not, why not?  
3. “Can you share with me if you are receiving any treatment for any symptoms?”  
(Please describe the symptoms and the treatment that you are receiving.) 
 Can you describe the symptoms that you feel are being treated well?   
 Can you describe symptoms that you feel are not being treated well? 
 Can you describe any symptoms that you feel are not being treated at all?” 
4. “Can you describe any symptoms that you are having that you did not have before 
starting the cancer clinical trial?”  (Probes:  Are any of them worse than others?  How 
long have you had the symptoms?) 
HEALTHCARE PROVIDER FACTORS 
1.  Describe in your own words what the research team has meant to you as part of 
participating in the cancer clinical trial. 
2.  Can you share with me your thoughts about the contributions of the oncologist (cancer 
doctor) and other members of the clinical trial team such as the clinical research nurse 
and the nurse practitioner to your experience in the clinical trial? 
 How have they been helpful or not so helpful to you? 
 When you have questions about the clinical trial, who is most helpful to you? 
(Probes:  Who gives you information about “what comes next” in the clinical trial 
and your cancer care and treatment?)  Can you share with me your experiences or 
give an example? 
PROTOCOL-RELATED FACTORS 
1. “In your own words, can you tell me about your cancer clinical trial?”  (Probes:  How 
often per month do you visit the Cancer Center for appointments?   How often do you 
receive chemo?  How often do you go to the Cancer Center to have blood drawn or to 
have blood products? Can you describe for me what they are studying in your specific 
cancer clinical trial? ) 
2.  Can you share with me anything that might make you drop out of the trial? (Probe: 
Side effects? Symptom burden?  Financial concerns?) 
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3. “Can you describe anything that you do not or did not understand about the cancer 
clinical trial?” 
 “If there is anything that you do not understand, have you shared that with any 
member of the cancer clinical trial team?” 
4.  Can you share with me your travel arrangements and appointment scheduling? (I ask 
this question because some patients report that it is difficult to come to the Cancer 
Center)  (Probes:  How easy is it for you to get to the Cancer Center? Has it interrupted 
your work schedule or child care needs in any way (if needed)?  Has it interrupted your 
ability to provide care for an adult?) 
5.  Have you experienced any financial concerns related to participating in the clinical 
trial?  If so, would you be willing to share this information with me or give me examples? 
Is there anything you could share with me from your perspective as a Black adult with 
cancer who is participating in cancer research?  I ask this question because very few 
Black adults with cancer participate in clinical trials, but they often suffer from higher 
rates of cancer.  So, I would be interested in your thoughts and what you think might help 
other Black adults with and without cancer understand about participation in a cancer 
clinical trial. 
Thank you.     
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APPENDIX B 
Semi-structured Cell Phone Interview Guide 
Type of Clinical Trial __________ (i.e., prostate, breast, lung, or colo-rectal) 
Clinical Trial Phase □ Phase I   □ Phase II   □ Phase III 
Interviewee ID:  ________ 
Interview Subject Pseudonym: ____________           
Audiotaped: Yes____  No____   
Date Administered:  ____/___/____  
 
Cell Phone Interview with Participants
 
"Good morning/afternoon/evening. I am ________ (introduce self).  I am a doctoral 
nursing student at the University of Pennsylvania School of Nursing.  I have received 
funding from the National Institutes of Nursing Research to better understand the cancer 
clinical trial experiences of Black adults with cancer enrolled in cancer clinical trials.  I 
have received permission from the Cancer Center to call you to discuss your interest in 
talking about these issues.  I am not part of your specific cancer clinical trial nor do I 
have any relationship with any cancer clinical trial research team at the Cancer Center.    
This cell phone interview is being done to gather your real-time life issues associated 
with your participation in a cancer clinical trial.  I will be asking you to answer questions 
from your perspective as a Black adult living with cancer.  These questions will concern 
your participation and experiences in the cancer clinical trial and any challenges that you 
are facing currently.  
Everything you share with me will be kept confidential.  All information you provide will 
be grouped together with other interviewees’ information and analyzed together as a 
group.  No one will be able to identify your individual information.  I want to remind you 
that I am not involved with the cancer clinical trial team and will not be sharing this 
information with the cancer clinical trial team.  So, it is very important that you contact 
and share the following information with the nurse/physician on the cancer clinical trial 
team:  (1) any symptom information that you describe to me, and (2) any issues or 
concerns about your experiences during the cancer clinical trial.   
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This short interview will be audio-recorded.  My continuing with this interview indicates 
your agreement to this interview and to the audio-recording.”   
ASSESSMENT OF PRIVACY AND SAFETY 
Let me begin by asking you a few short questions about you and your surroundings: 
1.  “Right now, do you feel safe and secure where you are located.” 
2.  “Where are you located right now?  Is there another telephone nearby that would 
allow me to contact you (e.g., if your cell phone lost power or stopped working, and I 
was unable to continue our interview using your cell phone)?” 
3.  “Are you comfortable talking to me at this point?”  (Probes:  Are you by yourself or 
are there other individuals present? Is this okay with you? Would you like me to call you 
back at another time to protect your privacy?) 
4.  “Do you feel comfortable discussing the cancer clinical trial, right now?”  (Probes:  
“Is someone close enough to you to hear your conversation with me?  If someone is close 
enough to hear our conversation, are you comfortable with that person listening to our 
conversation?  If no, would you like to move to a place where you can answer my 
questions without anyone listening nearby? Would you like me to call back at another 
time.”?) 
5.  “If you experience any severe symptoms during your interview, 
 Do you have any medications or equipment nearby? 
 Is there someone nearby who you know will help you?  Who I can call? 
 In case you have a medical emergency and are unable to talk to me during 
your interview, can I call 911 for you?” 
 
BRIEF TELEPHONE INTERVIEW QUESTIONS FOR REAL-TIME DATA 
CAPTURE 
1.” How are you today?  Can you briefly describe how you are doing today?  How long 
have you been in the trial at this point?” 
2. “Would you briefly describe (in your own words) ONE EXERIENCE today that stands 
out in your mind related to your participation in the cancer clinical trial?  The experience 
you describe can be positive, negative, or neutral.” 
3. “In your own words, briefly describe your most recent experience with the cancer 
clinical trial research team.  What has been helpful or not so helpful in your care and 
treatment?” 
4. “Can you share and describe any symptoms that you have been experiencing.  This can 
be of any type that is important to you. ” (Prompt:  Remind subject that any symptom 
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information described should be shared also with nurse/physician of cancer clinical trial 
team) 
5. “What are the challenges that you have been facing as you continue to participate in 
the cancer clinical trial? Can you share a few of these that are most important to you?”   
 
Thank you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
211 
 
APPENDIX C 
Telephone Recruitment Script 
Type of Clinical Trial __________ (i.e., prostate, breast, lung, or colo-rectal) 
Clinical Trial Phase □ Phase I   □ Phase II   □ Phase III 
Subject Assent:  ________ 
Date Available for Informed Consent/HIPAA Authorization: ____________           
Date Administered:  ____/___/____  
 
Telephone Recruitment Script 
 
"Good morning/afternoon/evening. I am ________ (introduce self).  I am a Black 
doctoral nursing student at the University of Pennsylvania School of Nursing.  I have 
received funding from the National Institutes of Nursing Research to better understand 
the cancer clinical trial experiences of Black adults with cancer enrolled in cancer clinical 
trials.  I have received permission from the Cancer Center to call you to discuss your 
interest in talking about these issues.   
I am not part of your specific cancer clinical trial nor do I have any relationship with any 
cancer clinical trial research team at the Cancer Center.  Everything you share with me 
will be kept confidential.  I am not involved with the cancer clinical trial team and will 
not be sharing this information with any member of the cancer clinical trial team.  So, it 
will be very important that you contact and share the following information with the 
nurse/physician on the cancer clinical trial team:  (1) any symptom information that you 
describe to me, and (2) any issues or concerns about your experiences during the cancer 
clinical trial. All information you provide will be grouped together with other 
interviewees’ information and analyzed together as a group.  No one will be able to 
identify your individual information.   At no time will your information be able to be 
connected to you. 
I have permission from your oncologist, Dr.______________ , to call you. I am very 
interested in learning more about the experience of Black patients and their views on 
cancer clinical trials.  I am calling you to see if you would be interested in sharing with 
me your feelings, opinions, and experiences about participating in a cancer clinical trial.  
I will be asking you to describe to me your feelings and perceptions about participating in 
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a cancer clinical trial, the factors in your decision to participate in a cancer clinical trial, 
and any symptoms you may be experiencing as part of participation in a cancer clinical 
trial.  Your total time commitment will be about four hours spread over three months.  As 
a token of my appreciation for your participation, you will be reimbursed a total of 
$35.00 for your time.  
Are you interested?  Would you be willing to meet me at the Perelman Center and talk 
about it further?”   
 (a)  Yes: “Thank you very much.  Before I go any further, I want to explain very 
briefly what you will be doing.  The study has three parts: 
 First, I want to meet with you for about one and one-half hours during one of the 
days that you have an appointment with your oncologist at the Perelman Center.  
During this appointment, you will fill out four forms.  Two of the forms provide 
more information about what you will be doing and the information you will be 
providing.  Next, you will complete a form which provides information about you 
and another form asks you to describe any of the symptoms you may be 
experiencing during the cancer clinical trial in which you are participating.  Last, I 
would like to interview you about your experiences and feelings as a Black cancer 
patient involved in a cancer clinical trial.  The interview should take about one 
hour.  We can also do the interview over the telephone.   
 You will be asked to complete four (4), 20-30 minute cell phone interviews over 
the course of two months; during these interviews you will be asked questions 
about your experiences and perceptions about participating in a cancer clinical 
trial and any symptoms you may be experiencing; 
 At a final meeting, you will be asked to complete a form which describes some of 
the symptoms you may be experiencing during the course of the cancer clinical 
trial in which you are participating and review a few of your interviews to make 
sure the statements you made express how you felt. 
 Do you have any questions?  (Arrange first meeting).  If at any time you have any 
questions, please feel free to call me at ____________.   Thank you for your time.” 
 (b) No:   “Thank you for your time.  If you change your mind and decide that you 
want to participate please do not hesitate to contact me at _____________.” 
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APPENDIX D 
SOCIO-DEMOGRAPHIC INFORMATION FORM 
1.   What is your race or ethnic background? 
 _____ Black/African     _____Black/Biracial  
 _____ Black/African American   _____Black/Multi-racial  
 _____ Black/Caribbean American   _____ Black/Other  
2.  Are you Hispanic or Latino? 
 _____ Yes  
 _____ No  
3.   What is your gender:   
 _____ Female     ______ Other: ________________  
 _____ Male                      
4.   What is your age? _____ 
5.   Check the highest level of education completed? 
 _____ 8
th
 Grade or Less     _____ Some College  
 _____ Some High School     _____ College Graduate 
 _____ High School Graduate     _____ Graduate/Postgraduate 
    
6.   What is your marital status? 
 _____ Never Married    _____ Separated  
 _____ Married     _____ Widowed  
 _____ Divorced      _____ Partnered 
7.   What type of cancer do you have? 
 _____ Breast     _____ Uterine  
 _____ Lung      _____ Cervical  
 _____ Prostate    _____ Stomach (Gastric) 
214 
 
 _____ Colo-rectal    _____ Pancreatic 
 _____ Leukemia    _____ Head & Neck 
 _____ Multiple Myeloma       _____ Liver 
8.   How long have you had cancer? 
 _____ 0-1 Years      _____11-15 Years   
 _____ 2-5 Years      _____16-20 Years   
 _____ 6-10 Years      _____ More than 20 Years   
9.  What medical treatment are you receiving for your cancer (check all that apply)? 
 _____ None        _____ Immunotherapy    
 _____ Chemotherapy     _____ Surgery   
 _____Radiation   
10.  Do you know what stage of cancer that you have?  
 _____ Don’t Know       _____ Stage 3    
 _____ Stage 1      _____ Stage 4    
 _____ Stage 2   
11.   Do you have any other type of health problem (for example: high blood pressure, 
diabetes, high cholesterol, etc.)? 
 _____ Yes  
 _____ No  
12.  If you have another type of health problem, please write it below: 
 _______________   _______________ 
 _______________   _______________ 
13.  How would you describe the area where you live? 
 _____ Urban 
 _____ Suburban 
 _____ Rural 
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14.  Do you have insurance? 
 _____ Yes  
 _____ No  
15.  If you have insurance, what type of insurance do you have? 
 _____ Private health insurance (Aetna, Blue Cross, etc.) 
 _____ Out-of-pocket/Self Pay 
 _____ Medicare   
 _____ Medicaid  
 _____ Veterans Benefits  
 _____ Other (please specify:  ____________________________________)  
16.  How important are your spiritual and/or religious beliefs? 
 _____ Not Important   _____ Important  
 _____ A Little Important   _____ Very Important  
 _____ Somewhat Important   _____ Extremely Important  
17.  Are you currently employed?          
 _____ Yes  
 _____ No   
18.  If employed, what are your hours?         
 _____ Full-time   
 _____ Part-time   
19.  If not employed, what below applies to you: 
 _____ Unemployed      _____ Student   
 _____ Retired      _____ Stay-at-home parent    
 _____ Disabled     _____ Other (please specify: 
       _________________________)  
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20.  Do you have a caregiver (someone who takes care of you, runs errands for you, 
provides childcare, takes care of you when you are sick, etc.)? 
 _____ Yes  
 _____ No   
21.  If you have a caregiver, how important is having a caregiver to you? 
 _____ Not Important     _____ Important   
 _____ A Little Important     _____ Very Important    
 _____ Somewhat Important     _____ Extremely Important   
22.  If you have a caregiver, who is your caregiver (check all that apply)? 
 _____ Spouse (husband or wife)    _____ Parent   
 _____ Partner      _____ Child   
 _____ Sibling (sister or brother)    _____ Friend   
 _____Grandparent   
 23.  How important is it for you to get information about your cancer diagnosis and 
treatment? 
 _____ Not Important     _____ Important   
 _____ A little Important     _____ Very Important    
 _____ Somewhat Important     _____ Extremely Important   
24.  How would you rate your ability to get information about your cancer diagnosis and 
treatment from your oncologist?  
 _____ Poor       _____ Very Good   
 _____ Fair       _____ Excellent   
 _____ Good   
25.  How would you rate your communication with your oncologist?  
 _____ Poor       _____ Very Good   
 _____ Fair       _____ Excellent   
 _____ Good   
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26.  How would you rate your communication with your oncology nurse practitioner (if 
you have one)? 
 _____ Poor       _____ Very Good   
 _____ Fair       _____ Excellent   
 _____ Good   
27.  How important is it for you to get information about your clinical trial treatment? 
 _____ Not Important     _____ Important   
 _____ A little Important     _____ Very Important    
 _____ Somewhat Important     _____ Extremely Important   
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APPENDIX E 
Memorial Symptom Assessment Scale-Short Form
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